Download PDF

Clinical Trial Results:
A Phase I/II, randomized, controlled, observer-blind, multi-center study to assess the reactogenicity, safety and immunogenicity of three GlaxoSmithKline (GSK) Biologicals’ investigational supra-seasonal universal influenza vaccines (SUIVs) (unadjuvanted or adjuvanted with AS03 or AS01) administered as a 1 or 2-dose priming schedule followed by a booster dose 12 months post-primary vaccination in 18 to 39 year-old healthy subjects

Summary
EudraCT number	2017-001584-20
Trial protocol	BE
Global end of trial date	26 Mar 2020

Results information
Results version number	v2(current)
This version publication date	01 May 2021
First version publication date	01 Apr 2021
Other versions	v1
Version creation reason	Correction of full data set Results have been amended to account for consistency with other registries.

Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information

Collapse all Expand all

Trial information

Top of page

Sponsor protocol code

207543

ISRCTN number

US NCT number

NCT03275389

WHO universal trial number (UTN)

Sponsor organisation name

GlaxoSmithKline Biologicals

Sponsor organisation address

Rue de l’Institut 89, Rixensart, Belgium, B-1330

Public contact

Clinical Trials Call Center, GlaxoSmithKline Biologicals, 044 2089-904466, GSKClinicalSupportHD@gsk.com

Scientific contact

Clinical Trials Call Center, GlaxoSmithKline Biologicals, 044 2089-904466, GSKClinicalSupportHD@gsk.com

Is trial part of an agreed paediatric investigation plan (PIP)

Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?

Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?

Analysis stage

Final

Date of interim/final analysis

10 Dec 2020

Is this the analysis of the primary completion data?

Yes

Primary completion date

26 Mar 2020

Global end of trial reached?

Yes

Global end of trial date

26 Mar 2020

Was the trial ended prematurely?

Main objective of the trial

To assess the reactogenicity and safety of each vaccine dose throughout the entire study period, in all study groups. To describe the anti-H1 stalk humoral immune response 28 days after each priming dose (1 or 2 dose(s)) in all study groups.

Protection of trial subjects

The subjects were observed closely for at least 60 minutes (Phase I subjects) or 30 minutes (Phase II subjects) following the administration of the vaccines/products, with appropriate medical treatment readily available in case of anaphylaxis.

Background therapy

Evidence for comparator

Actual start date of recruitment

08 Sep 2017

Long term follow-up planned

Independent data monitoring committee (IDMC) involvement?

Yes

Number of subjects enrolled per country

Country: Number of subjects enrolled

Belgium: 101

Country: Number of subjects enrolled

United States: 369

Worldwide total number of subjects

470

EEA total number of subjects

101

Number of subjects enrolled per age group

In utero

Preterm newborn - gestational age < 37 wk

Newborns (0-27 days)

Infants and toddlers (28 days-23 months)

Children (2-11 years)

Adolescents (12-17 years)

Adults (18-64 years)

470

From 65 to 84 years

85 years and over

Subject disposition

Top of page

Recruitment details

Screening details

470 subjects were enrolled and randomized in the study, however, while 2 subjects were allocated subjects numbers, they did not receive any vaccine dose.

Period 1 title

Overall Study (overall period)

Is this the baseline period?

Yes

Allocation method

Randomised - controlled

Blinding used

Double blind

Roles blinded

Subject, Investigator, Monitor, Assessor

Blinding implementation details

The site staff worked in an observer-blind manner. As the vaccines appearance and preparation were different, two teams of study personnel were set up: • A team of unblinded personnel (responsible for the reception, preparation and administration of the vaccines). • A team of blinded personnel (responsible for the clinical safety evaluation of the subjects).

Are arms mutually exclusive

Yes

D-SUIV Adjuvanted Group 1

Arm description

Subjects received one dose of D-SUIV cH8/1N1+AS03 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH5/1N1+AS03 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.

Arm type

Experimental

Investigational medicinal product name

D-SUIV cH8/1N1+AS03 Placebo D-SUIV cH5/1N1+AS03

Investigational medicinal product code

Other name

Pharmaceutical forms

Powder and solvent for emulsion for injection

Routes of administration

Intramuscular use

Dosage and administration details

1 dose at Day 1 (D-SUIV cH8/1N1+AS03) 1 dose at Day 57 (Placebo); 1 dose at Month 14 (D-SUIV cH5/1N1+AS03)

D-SUIV Adjuvanted Group 2

Arm description

Subjects received one dose of D-SUIV cH5/1N1+AS03 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH8/1N1+AS03 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.

Arm type

Experimental

Investigational medicinal product name

D-SUIV cH5/1N1+AS03 Placebo D-SUIV cH8/1N1+AS03

Investigational medicinal product code

Other name

Pharmaceutical forms

Powder and solvent for emulsion for injection

Routes of administration

Intramuscular use

Dosage and administration details

1 dose at Day 1 (D-SUIV cH5/1N1+AS03); 1 dose at Day 57 (Placebo); 1 dose at Month 14 (D-SUIV cH8/1N1+AS03)

D-SUIV Adjuvanted Group 3

Arm description

Subjects received one dose of D-SUIV cH8/1N1+AS03 vaccine at Day 1, one dose D-SUIV cH5/1N1+AS03 vaccine at Day 57 and one booster dose of D-SUIV cH11/1N1+AS03 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.

Arm type

Experimental

Investigational medicinal product name

D-SUIV cH8/1N1+AS03 D-SUIV cH5/1N1+AS03 D-SUIV cH11/1N1+AS03

Investigational medicinal product code

Other name

Pharmaceutical forms

Powder and solvent for emulsion for injection

Routes of administration

Intramuscular use

Dosage and administration details

1 dose at Day 1 (D-SUIV cH8/1N1+AS03); 1 dose at Day 57 (D-SUIV cH5/1N1+AS03); 1 dose at Month 14 (D-SUIV cH11/1N1+AS03)

D-SUIV Adjuvanted Group 4

Arm description

Subjects received one dose of D-SUIV cH8/1N1+AS01 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH5/1N1+AS01 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.

Arm type

Experimental

Investigational medicinal product name

D-SUIV cH8/1N1+AS01 Placebo D-SUIV cH5/1N1+AS01

Investigational medicinal product code

Other name

Pharmaceutical forms

Powder and solvent for emulsion for injection

Routes of administration

Intramuscular use

Dosage and administration details

1 dose at Day 1 (D-SUIV cH8/1N1+AS01); 1 dose at Day 57 (Placebo); 1 dose at Month 14 (D-SUIV cH5/1N1+AS01)

D-SUIV Adjuvanted Group 5

Arm description

Subjects received one dose of D-SUIV cH5/1N1+AS01 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH8/1N1+AS01 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.

Arm type

Experimental

Investigational medicinal product name

D-SUIV cH5/1N1+AS01 Placebo D-SUIV cH8/1N1+AS01

Investigational medicinal product code

Other name

Pharmaceutical forms

Powder and solvent for suspension for injection

Routes of administration

Intramuscular use

Dosage and administration details

1 dose at Day 1 (D-SUIV cH5/1N1+AS01); 1 dose at Day 57 (Placebo); 1 dose at Month 14 (D-SUIV cH8/1N1+AS01)

D-SUIV Adjuvanted Group 6

Arm description

Subjects received one dose of D-SUIV cH8/1N1+AS01 vaccine at Day 1, one dose of D-SUIV cH5/1N1+AS01 vaccine at Day 57 and one booster dose of D-SUIV cH11/1N1+AS01 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.

Arm type

Experimental

Investigational medicinal product name

D-SUIV cH8/1N1+AS01 D-SUIV cH5/1N1+AS01 D-SUIV cH11/1N1+AS01

Investigational medicinal product code

Other name

Pharmaceutical forms

Powder and solvent for suspension for injection

Routes of administration

Intramuscular use

Dosage and administration details

1 dose at Day 1 (D-SUIV cH8/1N1+AS01); 1 dose at Day 57 (D-SUIV cH5/1N1+AS01); 1 dose at Month 14 (D-SUIV cH11/1N1+AS01)

D-SUIV Unadjuvanted Group 1

Arm description

Subjects received one dose of D-SUIV cH8/1N1 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH5/1N1 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.

Arm type

Experimental

Investigational medicinal product name

D-SUIV cH8/1N1 Placebo D-SUIV cH5/1N1

Investigational medicinal product code

Other name

Pharmaceutical forms

Powder and solvent for suspension for injection

Routes of administration

Intramuscular use

Dosage and administration details

1 dose at Day 1 (D-SUIV cH8/1N1); 1 dose at Day 57 (Placebo); 1 dose at Month 14 (D-SUIV cH5/1N1)

D-SUIV Unadjuvanted Group 2

Arm description

Subjects received one dose of D-SUIV cH5/1N1 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH8/1N1 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.

Arm type

Experimental

Investigational medicinal product name

D-SUIV cH5/1N1 Placebo D-SUIV cH8/1N1

Investigational medicinal product code

Other name

Pharmaceutical forms

Powder and solvent for suspension for injection

Routes of administration

Intramuscular use

Dosage and administration details

1 dose at Day 1 (D-SUIV cH5/1N1); 1 dose at Day 57 (Placebo); 1 dose at Month 14 (D-SUIV cH8/1N1)

D-SUIV Unadjuvanted Group 3

Arm description

Subjects received one dose of D-SUIV cH8/1N1 vaccine at Day 1, one dose of D-SUIV cH5/1N1 vaccine at Day 57 and one booster dose of D-SUIV cH11/1N1 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.

Arm type

Experimental

Investigational medicinal product name

D-SUIV cH8/1N1 D-SUIV cH5/1N1 D-SUIV cH11/1N1

Investigational medicinal product code

Other name

Pharmaceutical forms

Powder and solvent for suspension for injection

Routes of administration

Intramuscular use

Dosage and administration details

1 dose at Day 1 (D-SUIV cH8/1N1); 1 dose at Day 57 (D-SUIV cH5/1N1); 1 dose at Month 14 (D-SUIV cH11/1N1)

IIV4 Group

Arm description

Subjects received one dose of Fluarix Quadrivalent (IIV4) vaccine at Day 1, one dose of Placebo at Day 57 and one dose of Fluarix Quadrivalent vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.

Arm type

Active comparator

Investigational medicinal product name

Fluarix Quadrivalent (IIV4); Placebo

Investigational medicinal product code

Other name

Pharmaceutical forms

Suspension for injection in pre-filled syringe

Routes of administration

Intramuscular use

Dosage and administration details

1 dose at Day 1 (Fluarix Quadrivalent (IIV4)) 1 dose at Day 57 (Placebo) 1 dose at Month 14 (Fluarix Quadrivalent)

Number of subjects in period 1 ^[1]	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Started	45	46	47	47	48	47	47	48	46	47
Completed	34	30	24	25	32	29	22	30	31	29
Not completed	11	16	23	22	16	18	25	18	15	18
NOT WILLING TO PARTICIPATE THIS VISIT	-	-	1	-	-	-	-	-	-	1
Unknown	-	4	3	2	2	2	-	-	1	-
MIGRATED / MOVED FROM THE STUDY AREA	-	2	-	3	-	-	1	-	-	-
Lost to follow-up	10	10	19	12	11	12	21	15	12	14
SERIOUS ADVERSE EVENT AND/OR PIMD	-	-	-	-	-	1	-	-	-	1
CONSENT WITHDRAWAL NOT DUE TO ADV. EVENT	1	-	-	5	3	3	3	3	2	2

Notes
[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.
Justification: 470 subjects were enrolled and randomized in the study, however, while 2 subjects were allocated subjects numbers, they did not receive any vaccine dose.

Baseline characteristics

Top of page

Reporting group title

D-SUIV Adjuvanted Group 1

Reporting group description

Reporting group title

D-SUIV Adjuvanted Group 2

Reporting group description

Reporting group title

D-SUIV Adjuvanted Group 3

Reporting group description

Reporting group title

D-SUIV Adjuvanted Group 4

Reporting group description

Reporting group title

D-SUIV Adjuvanted Group 5

Reporting group description

Reporting group title

D-SUIV Adjuvanted Group 6

Reporting group description

Reporting group title

D-SUIV Unadjuvanted Group 1

Reporting group description

Reporting group title

D-SUIV Unadjuvanted Group 2

Reporting group description

Reporting group title

D-SUIV Unadjuvanted Group 3

Reporting group description

Reporting group title

IIV4 Group

Reporting group description

Reporting group values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group	Total
Number of subjects	45	46	47	47	48	47	47	48	46	47	468
Age categorical
Units: Subjects
In utero	0	0	0	0	0	0	0	0	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0	0	0	0	0	0	0	0	0
Newborns (0-27 days)	0	0	0	0	0	0	0	0	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0	0	0	0	0	0	0	0	0
Children (2-11 years)	0	0	0	0	0	0	0	0	0	0	0
Adolescents (12-17 years)	0	0	0	0	0	0	0	0	0	0	0
Adults (18-64 years)	45	46	47	47	48	47	47	48	46	47	468
From 65-84 years	0	0	0	0	0	0	0	0	0	0	0
85 years and over	0	0	0	0	0	0	0	0	0	0	0
Age continuous
Units: years
arithmetic mean (standard deviation)	29.0 ( 6.6 )	29.3 ( 5.7 )	28.6 ( 6.0 )	28.7 ( 6.4 )	29.1 ( 6.2 )	28.8 ( 6.1 )	29.6 ( 5.8 )	28.5 ( 5.9 )	28.8 ( 5.9 )	29.3 ( 5.8 )	-
Sex: Female, Male
Units: Participants
Female	26	27	28	28	27	27	27	26	25	27	268
Male	19	19	19	19	21	20	20	22	21	20	200
Race/Ethnicity, Customized
Units: Subjects
American indian or alaska native	0	0	0	0	1	0	0	0	0	0	1
Asian - central / south asian heritage	0	0	0	0	0	0	0	0	1	0	1
Asian - east asian heritage	0	1	0	0	0	0	0	0	0	0	1
Asian - south east asian heritage	0	1	0	1	0	0	0	0	0	0	2
Black or african american	11	9	10	8	5	7	10	13	6	9	88
Native hawaiian or other pacific islander	0	0	0	0	0	0	1	0	0	0	1
Other, Not specified	0	0	0	2	2	1	1	1	2	1	10
White - arabic / north african heritage	0	1	0	0	0	1	0	1	0	2	5
White - caucasian / european heritage	34	34	37	36	40	38	35	33	37	35	359

End points

Top of page

Reporting group title

D-SUIV Adjuvanted Group 1

Reporting group description

Reporting group title

D-SUIV Adjuvanted Group 2

Reporting group description

Reporting group title

D-SUIV Adjuvanted Group 3

Reporting group description

Reporting group title

D-SUIV Adjuvanted Group 4

Reporting group description

Reporting group title

D-SUIV Adjuvanted Group 5

Reporting group description

Reporting group title

D-SUIV Adjuvanted Group 6

Reporting group description

Reporting group title

D-SUIV Unadjuvanted Group 1

Reporting group description

Reporting group title

D-SUIV Unadjuvanted Group 2

Reporting group description

Reporting group title

D-SUIV Unadjuvanted Group 3

Reporting group description

Reporting group title

IIV4 Group

Reporting group description

Primary: Number of subjects with solicited local adverse events (AEs) after first dose administration

Top of page

End point title

Number of subjects with solicited local adverse events (AEs) after first dose administration ^[1]

End point description

Assessed solicited local symptoms are pain, erythema and swelling. Any = occurrence of the symptom regardless of intensity grade. Any erythema/swelling = erythema/swelling spreading beyond 20 millimeters (mm) of injection site.

End point type

Primary

End point timeframe

During the 7-day (Days 1-7) follow-up period after first vaccine dose

Notes
[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: This outcome was descriptive; hence no statistical analyses were required.

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	44	46	45	46	46	46	45	47	46	45
Units: Participants
Erythema	1	3	2	2	1	3	1	0	1	0
Pain	34	42	37	39	40	42	16	13	15	35
Swelling	4	2	2	4	3	2	0	0	1	0

No statistical analyses for this end point

Primary: Number of subjects with solicited local AEs after second dose administration

Top of page

End point title

Number of subjects with solicited local AEs after second dose administration ^[2]

End point description

End point type

Primary

End point timeframe

During the 7-day (Days 1-7) follow-up period after second vaccine dose

Notes
[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: This outcome was descriptive; hence no statistical analyses were required.

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	40	37	36	41	41	37	38	39	40	39
Units: Participants
Erythema	0	0	1	0	0	0	0	0	0	0
Pain	5	2	29	2	8	32	4	5	12	10
Swelling	0	0	4	0	0	2	0	0	0	0

No statistical analyses for this end point

Primary: Number of subjects with solicited local AEs after booster dose administration

Top of page

End point title

Number of subjects with solicited local AEs after booster dose administration ^[3]

End point description

End point type

Primary

End point timeframe

During the 7-day (Days 1-7) follow-up period after booster vaccine dose

Notes
[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: This outcome was descriptive; hence no statistical analyses were required.

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	33	32	27	30	31	30	24	32	33	31
Units: Participants
Erythema	1	1	0	0	1	1	0	0	0	0
Pain	27	31	26	29	28	25	4	10	13	21
Swelling	2	2	0	1	1	1	0	0	0	0

No statistical analyses for this end point

Primary: Number of subjects with solicited general AEs after first dose administration

Top of page

End point title

Number of subjects with solicited general AEs after first dose administration ^[4]

End point description

Assessed solicited general symptoms are arthralgia, fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever [defined as oral temperature equal to or above 38.0 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade

End point type

Primary

End point timeframe

During the 7-day (Days 1-7) follow-up period after first vaccine dose

Notes
[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: This outcome was descriptive; hence no statistical analyses were required.

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	44	46	45	46	46	46	45	47	46	46
Units: Participants
Arthralgia	4	6	9	2	3	8	6	5	2	5
Fatigue	17	18	22	18	21	18	17	19	12	12
Gastrointestinal symptoms	6	7	10	6	8	8	6	8	10	8
Headache	18	18	19	23	16	26	16	19	15	14
Myalgia	16	13	19	17	19	20	9	9	6	11
Shivering	6	3	10	10	8	9	2	2	2	3
Temperature	1	1	0	2	2	1	1	1	0	0

No statistical analyses for this end point

Primary: Number of subjects with solicited general AEs after second dose administration

Top of page

End point title

Number of subjects with solicited general AEs after second dose administration ^[5]

End point description

End point type

Primary

End point timeframe

During the 7-day (Days 1-7) follow-up period after second vaccine dose

Notes
[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: This outcome was descriptive; hence no statistical analyses were required.

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	40	37	36	41	41	39	38	39	40	40
Units: Participants
Arthralgia	3	4	4	0	4	4	0	0	2	2
Fatigue	7	7	10	6	7	8	5	5	10	5
Gastrointestinal symptoms	3	4	4	3	3	6	1	4	2	2
Headache	8	12	13	7	9	12	5	12	8	7
Myalgia	5	6	12	1	4	16	3	2	6	3
Shivering	2	4	4	0	3	5	1	0	2	1
Temperature	1	2	0	0	1	2	0	0	0	0

No statistical analyses for this end point

Primary: Number of subjects with solicited general AEs after booster dose administration

Top of page

End point title

Number of subjects with solicited general AEs after booster dose administration ^[6]

End point description

End point type

Primary

End point timeframe

During the 7-day (Days 1-7) follow-up period after booster vaccine dose

Notes
[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: This outcome was descriptive; hence no statistical analyses were required.

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	33	32	27	30	31	30	24	32	33	31
Units: Participants
Arthralgia	6	8	4	4	9	4	1	1	2	1
Fatigue	15	19	17	16	20	9	2	6	6	3
Gastrointestinal symptoms	3	8	8	5	6	5	1	2	4	0
Headache	9	13	14	15	16	15	3	7	6	4
Myalgia	15	17	15	15	13	10	0	4	5	3
Shivering	5	13	6	6	14	9	0	1	2	1
Temperature	2	3	1	4	2	1	0	0	0	0

No statistical analyses for this end point

Primary: Number of subjects with any unsolicited AEs post-vaccination period

Top of page

End point title

Number of subjects with any unsolicited AEs post-vaccination period ^[7]

End point description

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any is defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination

End point type

Primary

End point timeframe

During the 28-day (Days 1-28) follow-up period accross doses

Notes
[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: This outcome was descriptive; hence no statistical analyses were required.

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	45	46	47	47	48	47	47	48	46	47
Units: Participants	27	23	23	24	24	17	22	23	22	21

No statistical analyses for this end point

Primary: Number of subjects with change from baseline in hematological and biochemical laboratory results at Day 8 by toxicity grading

Top of page

End point title

Number of subjects with change from baseline in hematological and biochemical laboratory results at Day 8 by toxicity grading ^[8]

End point description

Hematological parameters assessed are: Eosinophils increase [EOSi], hemoglobin decrease [HEMd] , lymphocytes decrease [LYMd], Neutrophils decrease [NEUd], platelets decrease [PLTCd], white blood cells decrease [WBCd], WBC increase [WBCi]. Biochemical parameters assessed are: alanine aminotransferase increase [ALTi], aspartate aminotransferase increase [ASTi], blood urea nitrogen [BUN], creatinine [CRE].Toxicity grading is according to the Food and Drug Administration (FDA) guidance for industry: Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical Trials (September 2007). The grading scale is defined as follows: mild (Grade 1), moderate (Grade 2), severe (Grade 3) and potentially life threatening (Grade 4). Category naming has been defined as follows: Parameter- grading at Baseline- grading at Timing: e.g.: "ALTi-G0-G1" (with G=Grade and UNK= Unknown).

End point type

Primary

End point timeframe

At Day 8

Notes
[8] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: This outcome was descriptive; hence no statistical analyses were required.

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	44	46	45	46	46	46	44	47	45	46
Units: Participants
ALTi, UNK, G0 (N=0;0;0;0;0;0;1;0;1;0)	0	0	0	0	0	0	0	0	1	0
ALTi, UNK, G1 (N=0;0;0;0;0;0;1;0;1;0)	0	0	0	0	0	0	1	0	0	0
ALTi,G0,UNK (N=40;46;43;45;45;45;44;44;43;46)	0	0	0	3	0	0	1	0	0	1
ALTi, G0, G0 (N=40;46;43;45;45;45;44;44;43;46)	40	45	42	41	45	45	43	44	41	44
ALTi, G0, G1 (N=40;46;43;45;45;45;44;44;43;46)	0	1	1	0	0	0	0	0	2	1
ALTi, G0, G3 (N=40;46;43;45;45;45;44;44;43;46)	0	0	0	1	0	0	0	0	0	0
ALTi, G1, G0 (N=4;0;2;1;1;1;0;3;2;0)	3	0	1	1	1	0	0	2	2	0
ALTi, G1, G1 (N=4;0;2;1;1;1;0;3;2;0)	1	0	1	0	0	1	0	1	0	0
ASTi, UNK, G0 (N=0;0;0;0;0;0;1;0;1;0)	0	0	0	0	0	0	1	0	1	0
ASTi, G0, UNK (N=44;46;45;46;46;45;43;46;45;46)	0	0	0	3	0	0	1	0	0	1
ASTi, G0, G0 (N=44;46;45;46;46;45;43;46;45;46)	44	46	44	42	46	45	42	44	44	44
ASTi, G0, G1 (N=44;46;45;46;46;45;43;46;45;46)	0	0	1	0	0	0	0	2	0	0
ASTi, G0, G2 (N=44;46;45;46;46;45;43;46;45;46)	0	0	0	0	0	0	0	0	1	1
ASTi, G0, G4 (N=44;46;45;46;46;45;43;46;45;46)	0	0	0	1	0	0	0	0	0	0
ASTi, G1, G0 (N=0;0;0;0;0;1;1;0;0;0)	0	0	0	0	0	1	1	0	0	0
ASTi, G2, G0 (N=0;0;0;0;0;0;0;1;0;0)	0	0	0	0	0	0	0	1	0	0
BUN, UNK, G0 (N=0;0;0;0;0;0;1;0;1;0)	0	0	0	0	0	0	1	0	1	0
BUN, G0, UNK (N=43;46;45;46;46;46;44;47;43;46)	0	0	0	3	0	0	1	0	0	1
BUN, G0, G0 (N=43;46;45;46;46;46;44;47;43;46)	43	46	45	43	46	46	43	47	43	45
BUN, G1, G0 (N=1;0;0;0;0;0;0;0;1;0)	1	0	0	0	0	0	0	0	1	0
BUN, G2, G0 (N=0;0;0;0;0;0;0;0;1;0)	0	0	0	0	0	0	0	0	1	0
CRE, UNK, G0 (N=0;0;0;0;0;0;1;0;1;0)	0	0	0	0	0	0	1	0	1	0
CRE, G0, UNK (N=44;46;45;46;46;46;44;47;45;46)	0	0	0	3	0	0	1	0	0	1
CRE, G0, G0 (N=44;46;45;46;46;46;44;47;45;46)	44	46	45	43	46	46	43	47	45	45
EOSi, UNK, G0 (N=1;1;3;1;1;1;1;2;5;2)	1	1	3	1	1	1	1	2	5	2
EOSi, G0, UNK (N=43;44;41;44;45;45;44;45;40;43)	2	0	2	1	0	0	2	2	1	2
EOSi, G0, G0 (N=43;44;41;44;45;45;44;45;40;43)	41	43	38	43	45	44	40	43	38	41
EOSi, G0, G1 (N=43;44;41;44;45;45;44;45;40;43)	0	1	1	0	0	1	2	0	1	0
EOSi, G1, G0 (N=0;1;1;1;0;0;0;0;1;1)	0	1	1	1	0	0	0	0	0	0
EOSi, G1, G1 (N=0;1;1;1;0;0;0;0;1;1)	0	0	0	0	0	0	0	0	1	1
HEMd, UNK, G0 (N=0;1;0;0;0;0;1;0;0;1)	0	1	0	0	0	0	1	0	0	1
HEMd, G0, UNK (N=39;41;42;42;44;43;39;42;43;43)	1	0	1	1	0	0	1	1	1	2
HEMd, G0, G0 (N=39;41;42;42;44;43;39;42;43;43)	37	37	40	39	43	40	37	40	40	40
HEMd, G0, G1 (N=39;41;42;42;44;43;39;42;43;43)	1	4	1	1	1	3	1	1	2	1
HEMd, G0, G2 (N=39;41;42;42;44;43;39;42;43;43)	0	0	0	1	0	0	0	0	0	0
HEMd, G1, UNK (N=3;3;2;4;0;2;4;2;1;2)	0	0	0	0	0	0	1	0	0	0
HEMd, G1, G0 (N=3;3;2;4;0;2;4;2;1;2)	0	0	0	0	0	0	1	2	0	1
HEMd, G1, G1 (N=3;3;2;4;0;2;4;2;1;2)	3	1	2	4	0	1	2	0	0	0
HEMd, G1, G2 (N=3;3;2;4;0;2;4;2;1;2)	0	2	0	0	0	1	0	0	1	1
HEMd, G2, G1 (N=2;0;1;0;2;1;1;2;2;0)	0	0	0	0	0	0	1	0	0	0
HEMd, G2, G2 (N=2;0;1;0;2;1;1;2;2;0)	2	0	1	0	2	1	0	0	2	0
HEMd, G2, G3 (N=2;0;1;0;2;1;1;2;2;0)	0	0	0	0	0	0	0	2	0	0
HEMd, G3, UNK (N=0;1;0;0;0;0;0;1;0;0)	0	0	0	0	0	0	0	1	0	0
HEMd, G3, G3 (N=0;1;0;0;0;0;0;1;0;0)	0	1	0	0	0	0	0	0	0	0
LYMd, UNK, G0 (N=1;1;3;1;1;1;1;2;5;2)	1	1	3	1	1	1	1	2	5	2
LYMd, G0, UNK (N=43;45;39;45;44;45;44;45;39;44)	2	0	2	1	0	0	2	2	1	2
LYMd, G0, G0 (N=43;45;39;45;44;45;44;45;39;44)	39	45	37	44	43	45	42	42	38	41
LYMd, G0, G1 (N=43;45;39;45;44;45;44;45;39;44)	2	0	0	0	1	0	0	1	0	1
LYMd, G1, G0 (N=0;0;3;0;0;0;0;0;2;0)	0	0	2	0	0	0	0	0	2	0
LYMd, G1, G2 (N=0;0;3;0;0;0;0;0;2;0)	0	0	1	0	0	0	0	0	0	0
LYMd, G2, G0 (N=0;0;0;0;1;0;0;0;0;0)	0	0	0	0	1	0	0	0	0	0
NEUd, UNK, G0 (N=1;1;3;1;1;1;1;2;5;2)	1	1	3	1	1	1	1	2	2	1
NEUd, UNK, G1 (N=1;1;3;1;1;1;1;2;5;2)	0	0	0	0	0	0	0	0	2	1
NEUd, UNK, G2 (N=1;1;3;1;1;1;1;2;5;2)	0	0	0	0	0	0	0	0	1	0
NEUd, G0, UNK (N=41;41;41;44;41;44;43;41;39;41)	2	0	2	1	0	0	2	2	1	2
NEUd, G0, G0 (N=41;41;41;44;41;44;43;41;39;41)	37	40	39	41	41	43	39	38	37	37
NEUd, G0, G1 (N=41;41;41;44;41;44;43;41;39;41)	2	1	0	1	0	0	1	1	0	2
NEUd, G0, G2 (N=41;41;41;44;41;44;43;41;39;41)	0	0	0	1	0	1	1	0	1	0
NEUd, G1, G0 (N=2;4;0;1;2;1;1;2;1;1)	1	4	0	0	0	1	0	0	1	1
NEUd, G1, G1 (N=2;4;0;1;2;1;1;2;1;1)	1	0	0	0	2	0	1	2	0	0
NEUd, G1, G2 (N=2;4;0;1;2;1;1;2;1;1)	0	0	0	1	0	0	0	0	0	0
NEUd, G2, G0 (N=0;0;1;0;1;0;0;2;1;2)	0	0	1	0	1	0	0	2	1	2
NEUd, G3, G0 (N=0;0;0;0;1;0;0;0;0;0)	0	0	0	0	1	0	0	0	0	0
PLTCd, UNK, G0 (N=0;1;0;0;0;0;1;0;1;1)	0	1	0	0	0	0	1	0	1	1
PLTCd, G0, UNK (N=44;45;45;44;46;46;44;46;44;45)	1	0	2	1	0	0	2	2	1	2
PLTCd, G0, G0 (N=44;45;45;44;46;46;44;46;44;45)	43	45	42	43	46	45	42	44	43	43
PLTCd, G0, G1 (N=44;45;45;44;46;46;44;46;44;45)	0	0	0	0	0	1	0	0	0	0
PLTCd, G0, G2 (N=44;45;45;44;46;46;44;46;44;45)	0	0	1	0	0	0	0	0	0	0
PLTCd, G1, G0 (N=0;0;0;2;0;0;0;1;0;0)	0	0	0	1	0	0	0	1	0	0
PLTCd, G1, G1 (N=0;0;0;2;0;0;0;1;0;0)	0	0	0	1	0	0	0	0	0	0
PLTCd, G2, G1 (N=0;0;0;0;0;0;0;0;1;0)	0	0	0	0	0	0	0	0	1	0
WBCd, UNK, G0 (N=0;1;0;0;0;0;1;0;2;1)	0	1	0	0	0	0	1	0	2	1
WBCd, G0, UNK (N=43;45;44;46;44;46;44;44;42;45)	1	0	2	1	0	0	2	2	1	2
WBCd, G0, G0 (N=43;45;44;46;44;46;44;44;42;45)	41	45	42	44	44	46	41	42	41	43
WBCd, G0, G1 (N=43;45;44;46;44;46;44;44;42;45)	1	0	0	1	0	0	1	0	0	0
WBCd, G1, G0 (N=1;0;1;0;1;0;0;3;2;0)	1	0	1	0	1	0	0	3	2	0
WBCd, G2, G0 (N=0;0;0;0;1;0;0;0;0;0)	0	0	0	0	1	0	0	0	0	0
WBCi, UNK, G0 (N=0;1;0;0;0;0;1;0;2;1)	0	1	0	0	0	0	1	0	2	1
WBCi, G0, UNK (N=42;43;44;44;45;46;42;44;40;44)	1	0	2	1	0	0	2	2	1	2
WBCi, G0, G0 (N=42;43;44;44;45;46;42;44;40;44)	41	43	42	42	45	45	39	39	38	39
WBCi, G0, G1 (N=42;43;44;44;45;46;42;44;40;44)	0	0	0	1	0	1	1	3	1	3
WBCi, G1, G0 (N=2;2;1;2;1;0;2;3;3;1)	1	2	0	1	1	0	1	1	2	0
WBCi, G1, G1 (N=2;2;1;2;1;0;2;3;3;1)	1	0	1	1	0	0	1	2	1	1
WBCi, G2, G1 (N=0;0;0;0;0;0;0;0;1;0)	0	0	0	0	0	0	0	0	1	0

No statistical analyses for this end point

Primary: Number of subjects with change in hematological and biochemical laboratory results from Day 8 to Day 29 versus baseline by toxicity grading

Top of page

End point title

Number of subjects with change in hematological and biochemical laboratory results from Day 8 to Day 29 versus baseline by toxicity grading ^[9]

End point description

Hematological parameters assessed are: EOSi, HEMd, LYMd, NEUd, PLTCd, WBCd, WBCi. Biochemical parameters assessed are: ALTi, ASTi, BUN, CRE. Toxicity grading is according to the FDA guidance for industry: Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical Trials (September 2007). The grading scale is defined as following: mild (Grade 1), moderate (Grade 2), severe (Grade 3) and potentially life threatening (Grade 4). Category naming has been defined as: Parameter-grading at Baseline-grading at Timing: e.g.: "ALTi-G0-G1" (with G=Grade and UNK=Unknown). The reported results consider any change that occurred during the defined time frame: i.e. any abnormality occurring at an intermediate visit leading to a maximum change from baseline, during the period covered, is the reported result for the outcome.

End point type

Primary

End point timeframe

From Day 8 to Day 29

Notes
[9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: This outcome was descriptive; hence no statistical analyses were required.

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	44	46	45	46	46	46	44	47	45	46
Units: Participants
ALTi, UNK, G0 (N=0;0;0;0;0;0;1;0;1;0)	0	0	0	0	0	0	0	0	1	0
ALTi, UNK, G1 (N=0;0;0;0;0;0;1;0;1;0)	0	0	0	0	0	0	1	0	0	0
ALTi, G0, UNK (N=40;46;43;45;45;45;44;44;43;46)	0	0	0	0	0	0	1	0	0	0
ALTi, G0, G0 (N=40;46;43;45;45;45;44;44;43;46)	40	45	41	44	45	44	41	43	40	44
ALTi, G0, G1 (N=40;46;43;45;45;45;44;44;43;46)	0	1	2	0	0	1	2	0	3	2
ALTi, G0, G2 (N=40;46;43;45;45;45;44;44;43;46)	0	0	0	0	0	0	0	1	0	0
ALTi, G0, G3 (N=40;46;43;45;45;45;44;44;43;46)	0	0	0	1	0	0	0	0	0	0
ALTi, G1, G0 (N=4;0;2;1;1;1;0;3;2;0)	3	0	1	1	1	0	0	2	2	0
ALTi, G1, G1 (N=4;0;2;1;1;1;0;3;2;0)	1	0	1	0	0	1	0	1	0	0
ASTi, UNK, G0 (N=0;0;0;0;0;0;1;0;1;0)	0	0	0	0	0	0	1	0	1	0
ASTi, G0, UNK (N=44;46;45;46;46;45;43;46;45;46)	0	0	0	0	0	0	1	0	0	0
ASTi, G0, G0 (N=44;46;45;46;46;45;43;46;45;46)	44	46	44	45	46	44	42	43	42	45
ASTi, G0, G1 (N=44;46;45;46;46;45;43;46;45;46)	0	0	1	0	0	1	0	3	2	0
ASTi, G0, G2 (N=44;46;45;46;46;45;43;46;45;46)	0	0	0	0	0	0	0	0	1	1
ASTi, G0, G4 (N=44;46;45;46;46;45;43;46;45;46)	0	0	0	1	0	0	0	0	0	0
ASTi, G1, G0 (N=0;0;0;0;0;1;1;0;0;0)	0	0	0	0	0	0	1	0	0	0
ASTi, G1, G1 (N=0;0;0;0;0;1;1;0;0;0)	0	0	0	0	0	1	0	0	0	0
ASTi, G2, G0 (N=0;0;0;0;0;0;0;1;0;0)	0	0	0	0	0	0	0	1	0	0
BUN, UNK, G0 (N=0;0;0;0;0;0;1;0;1;0)	0	0	0	0	0	0	1	0	1	0
BUN, G0, UNK (N=43;46;45;46;46;46;44;47;43;46)	0	0	0	0	0	0	1	0	0	0
BUN, G0, G0 (N=43;46;45;46;46;46;44;47;43;46)	43	45	45	46	46	46	43	47	43	46
BUN, G0, G1 (N=43;46;45;46;46;46;44;47;43;46)	0	1	0	0	0	0	0	0	0	0
BUN, G1, G0 (N=1;0;0;0;0;0;0;0;1;0)	1	0	0	0	0	0	0	0	1	0
BUN, G2, G0 (N=0;0;0;0;0;0;0;0;1;0)	0	0	0	0	0	0	0	0	1	0
CRE, UNK, G0 (N=0;0;0;0;0;0;1;0;1;0)	0	0	0	0	0	0	1	0	1	0
CRE, G0, UNK (N=44;46;45;46;46;46;44;47;45;46)	0	0	0	0	0	0	1	0	0	0
CRE, G0, G0 (N=44;46;45;46;46;46;44;47;45;46)	44	46	45	46	46	46	43	47	45	46
EOSi, UNK, G0 (N=1;1;3;1;1;1;1;2;5;2)	1	1	3	1	1	1	0	2	5	2
EOSi, UNK, G1 (N=1;1;3;1;1;1;1;2;5;2)	0	0	0	0	0	0	1	0	0	0
EOSi, G0, UNK (N=43;44;41;44;45;45;44;45;40;43)	0	0	0	0	0	0	1	0	0	0
EOSi, G0, G0 (N=43;44;41;44;45;45;44;45;40;43)	43	43	40	44	45	44	40	45	39	43
EOSi, G0, G1 (N=43;44;41;44;45;45;44;45;40;43)	0	1	1	0	0	1	3	0	1	0
EOSi, G1, G0 (N=0;1;1;1;0;0;0;0;1;1)	0	0	1	1	0	0	0	0	0	0
EOSi, G1, G1 (N=0;1;1;1;0;0;0;0;1;1)	0	1	0	0	0	0	0	0	1	1
HEMd, UNK, G0 (N=0;1;0;0;0;0;1;0;0;1)	0	1	0	0	0	0	1	0	0	1
HEMd, G0, G0 (N=39;41;42;42;44;43;39;42;43;43)	37	37	41	38	43	40	37	39	39	42
HEMd, G0, G1 (N=39;41;42;42;44;43;39;42;43;43)	2	4	1	3	1	3	2	3	4	1
HEMd, G0, G2 (N=39;41;42;42;44;43;39;42;43;43)	0	0	0	1	0	0	0	0	0	0
HEMd, G1, UNK (N=3;3;2;4;0;2;4;2;1;2)	0	0	0	0	0	0	1	0	0	0
HEMd, G1, G0 (N=3;3;2;4;0;2;4;2;1;2)	0	0	0	0	0	0	1	2	0	1
HEMd, G1, G1 (N=3;3;2;4;0;2;4;2;1;2)	3	1	2	4	0	1	2	0	0	0
HEMd, G1, G2 (N=3;3;2;4;0;2;4;2;1;2)	0	2	0	0	0	1	0	0	1	1
HEMd, G2, G2 (N=2;0;1;0;2;1;1;2;2;0)	2	0	1	0	2	1	1	0	2	0
HEMd, G2, G3 (N=2;0;1;0;2;1;1;2;2;0)	0	0	0	0	0	0	0	2	0	0
HEMd, G3, G3 (N=0;1;0;0;0;0;0;1;0;0)	0	1	0	0	0	0	0	1	0	0
LYMd, UNK, G0 (N=1;1;3;1;1;1;1;2;5;2)	0	1	3	1	1	1	1	2	5	2
LYMd, UNK, G1 (N=1;1;3;1;1;1;1;2;5;2)	1	0	0	0	0	0	0	0	0	0
LYMd, G0, UNK (N=43;45;39;45;44;45;44;45;39;44)	0	0	0	0	0	0	1	0	0	0
LYMd, G0, G0 (N=43;45;39;45;44;45;44;45;39;44)	41	45	39	45	42	45	43	43	39	41
LYMd, G0, G1 (N=43;45;39;45;44;45;44;45;39;44)	2	0	0	0	1	0	0	2	0	3
LYMd, G0, G2 (N=43;45;39;45;44;45;44;45;39;44)	0	0	0	0	1	0	0	0	0	0
LYMd, G1, G0 (N=0;0;3;0;0;0;0;0;2;0)	0	0	1	0	0	0	0	0	0	0
LYMd, G1, G1 (N=0;0;3;0;0;0;0;0;2;0)	0	0	1	0	0	0	0	0	2	0
LYMd, G1, G2 (N=0;0;3;0;0;0;0;0;2;0)	0	0	1	0	0	0	0	0	0	0
LYMd, G2, G0 (N=0;0;0;0;1;0;0;0;0;0)	0	0	0	0	1	0	0	0	0	0
NEUd, UNK, G0 (N=1;1;3;1;1;1;1;2;5;2)	0	1	3	1	1	1	1	2	2	1
NEUd, UNK, G1 (N=1;1;3;1;1;1;1;2;5;2)	1	0	0	0	0	0	0	0	2	0
NEUd, UNK, G2 (N=1;1;3;1;1;1;1;2;5;2)	0	0	0	0	0	0	0	0	1	1
NEUd, G0, UNK (N=41;41;41;44;41;44;43;41;39;41)	0	0	0	0	0	0	1	0	0	0
NEUd, G0, G0 (N=41;41;41;44;41;44;43;41;39;41)	38	39	40	40	40	42	37	38	38	38
NEUd, G0, G1 (N=41;41;41;44;41;44;43;41;39;41)	3	2	1	2	1	1	2	3	0	2
NEUd, G0, G2 (N=41;41;41;44;41;44;43;41;39;41)	0	0	0	1	0	1	3	0	1	1
NEUd, G0, G3 (N=41;41;41;44;41;44;43;41;39;41)	0	0	0	1	0	0	0	0	0	0
NEUd, G1, G0 (N=2;4;0;1;2;1;1;2;1;1)	1	3	0	0	0	1	0	0	0	0
NEUd, G1, G1 (N=2;4;0;1;2;1;1;2;1;1)	1	1	0	0	1	0	1	1	1	1
NEUd, G1, G2 (N=2;4;0;1;2;1;1;2;1;1)	0	0	0	1	1	0	0	1	0	0
NEUd, G2, G0 (N=0;0;1;0;1;0;0;2;1;2)	0	0	1	0	0	0	0	1	1	1
NEUd, G2, G1 (N=0;0;1;0;1;0;0;2;1;2)	0	0	0	0	1	0	0	1	0	0
NEUd, G2, G2 (N=0;0;1;0;1;0;0;2;1;2)	0	0	0	0	0	0	0	0	0	1
NEUd, G3, G0 (N=0;0;0;0;1;0;0;0;0;0)	0	0	0	0	1	0	0	0	0	0
PLTCd, UNK, G0 (N=0;1;0;0;0;0;1;0;1;1)	0	1	0	0	0	0	1	0	1	1
PLTCd, G0, UNK (N=44;45;45;44;46;46;44;46;44;45)	0	0	0	0	0	0	1	0	0	0
PLTCd, G0, G0 (N=44;45;45;44;46;46;44;46;44;45)	43	45	44	44	46	45	43	46	44	45
PLTCd, G0, G1 (N=44;45;45;44;46;46;44;46;44;45)	1	0	0	0	0	1	0	0	0	0
PLTCd, G0, G2 (N=44;45;45;44;46;46;44;46;44;45)	0	0	1	0	0	0	0	0	0	0
PLTCd, G1, G0 (N=0;0;0;2;0;0;0;1;0;0)	0	0	0	1	0	0	0	1	0	0
PLTCd, G1, G2 (N=0;0;0;2;0;0;0;1;0;0)	0	0	0	1	0	0	0	0	0	0
PLTCd, G2, G1 (N=0;0;0;0;0;0;0;0;1;0)	0	0	0	0	0	0	0	0	1	0
WBCd, UNK, G0 (N=0;1;0;0;0;0;1;0;2;1)	0	1	0	0	0	0	1	0	1	0
WBCd, UNK, G1 (N=0;1;0;0;0;0;1;0;2;1)	0	0	0	0	0	0	0	0	1	1
WBCd, G0, UNK (N=43;45;44;46;44;46;44;44;42;45)	0	0	0	0	0	0	1	0	0	0
WBCd, G0, G0 (N=43;45;44;46;44;46;44;44;42;45)	41	44	44	43	43	46	42	44	41	42
WBCd, G0, G1 (N=43;45;44;46;44;46;44;44;42;45)	2	1	0	3	1	0	1	0	1	3
WBCd, G1, G0 (N=1;0;1;0;1;0;0;3;2;0)	1	0	1	0	1	0	0	3	2	0
WBCd, G2, G0 (N=0;0;0;0;1;0;0;0;0;0)	0	0	0	0	1	0	0	0	0	0
WBCi, UNK, G0 (N=0;1;0;0;0;0;1;0;2;1)	0	1	0	0	0	0	1	0	2	1
WBCi, G0, UNK (N=42;43;44;44;45;46;42;44;40;44)	0	0	0	0	0	0	1	0	0	0
WBCi, G0, G0 (N=42;43;44;44;45;46;42;44;40;44)	42	40	43	42	45	45	38	39	39	41
WBCi, G0, G1 (N=42;43;44;44;45;46;42;44;40;44)	0	3	1	2	0	1	3	5	1	3
WBCi, G1, G0 (N=2;2;1;2;1;0;2;3;3;1)	0	0	0	1	1	0	1	1	2	0
WBCi, G1, G1 (N=2;2;1;2;1;0;2;3;3;1)	1	2	1	1	0	0	1	2	1	1
WBCi, G1, G2 (N=2;2;1;2;1;0;2;3;3;1)	1	0	0	0	0	0	0	0	0	0
WBCi, G2, G1 (N=0;0;0;0;0;0;0;0;1;0)	0	0	0	0	0	0	0	0	1	0

No statistical analyses for this end point

Primary: Number of subjects with change in hematological and biochemical laboratory results from Day 8 to Day 85 versus baseline by toxicity grading

Top of page

End point title

Number of subjects with change in hematological and biochemical laboratory results from Day 8 to Day 85 versus baseline by toxicity grading ^[10]

End point description

Hematological parameters assessed are: EOSi, HEMd, LYMd, NEUd, PLTCd, WBCd, WBCi. Biochemical parameters assessed are: ALTi, ASTi, BUN, CRE. Toxicity grading is according to the FDA guidance for industry: Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical Trials (September 2007). The grading scale is defined as following: mild (Grade 1), moderate (Grade 2), severe (Grade 3) and potentially life threatening (Grade 4). Category naming has been defined as: Parameter-grading at Baseline-grading at Timing: e.g.: "ALTi-G0-G1" (with G=Grade and UNK= Unknown). The reported results consider any change that occurred during the defined time frame: i.e. any abnormality occurring at an intermediate visit leading to a maximum change from baseline, during the period covered, is the reported result for the outcome.

End point type

Primary

End point timeframe

From Day 8 to Day 85

Notes
[10] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: This outcome was descriptive; hence no statistical analyses were required.

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	44	46	45	46	46	46	44	47	45	46
Units: Participants
ALTi, UNK, G0 (N=0;0;0;0;0;0;1;0;1;0)	0	0	0	0	0	0	0	0	1	0
ALTi, UNK, G1 (N=0;0;0;0;0;0;1;0;1;0)	0	0	0	0	0	0	1	0	0	0
ALTi, G0, UNK (N=40;46;43;45;45;45;44;44;43;46)	0	0	0	0	0	0	1	0	0	0
ALTi, G0, G0 (N=40;46;43;45;45;45;44;44;43;46)	39	42	39	42	44	42	39	39	35	43
ALTi, G0, G1 (N=40;46;43;45;45;45;44;44;43;46)	0	4	4	2	0	3	4	4	8	3
ALTi, G0, G2 (N=40;46;43;45;45;45;44;44;43;46)	0	0	0	0	1	0	0	1	0	0
ALTi, G0, G3 (N=40;46;43;45;45;45;44;44;43;46)	1	0	0	1	0	0	0	0	0	0
ALTi, G1, G0 (N=4;0;2;1;1;1;0;3;2;0)	3	0	1	1	1	0	0	2	2	0
ALTi, G1, G1 (N=4;0;2;1;1;1;0;3;2;0)	1	0	1	0	0	1	0	1	0	0
ASTi, UNK, G0 (N=0;0;0;0;0;0;1;0;1;0)	0	0	0	0	0	0	1	0	1	0
ASTi, G0, UNK (N=44;46;45;46;46;45;43;46;45;46)	0	0	0	0	0	0	1	0	0	0
ASTi, G0, G0 (N=44;46;45;46;46;45;43;46;45;46)	43	44	43	45	43	43	39	43	40	45
ASTi, G0, G1 (N=44;46;45;46;46;45;43;46;45;46)	0	2	2	0	2	2	3	3	4	0
ASTi, G0, G2 (N=44;46;45;46;46;45;43;46;45;46)	0	0	0	0	1	0	0	0	1	1
ASTi, G0, G4 (N=44;46;45;46;46;45;43;46;45;46)	1	0	0	1	0	0	0	0	0	0
ASTi, G1, G1 (N=0;0;0;0;0;1;1;0;0;0)	0	0	0	0	0	1	1	0	0	0
ASTi, G2, G0 (N=0;0;0;0;0;0;0;1;0;0)	0	0	0	0	0	0	0	1	0	0
BUN, UNK, G0 (N=0;0;0;0;0;0;1;0;1;0)	0	0	0	0	0	0	1	0	1	0
BUN, G0, UNK (N=43;46;45;46;46;46;44;47;43;46)	0	0	0	0	0	0	1	0	0	0
BUN, G0, G0 (N=43;46;45;46;46;46;44;47;43;46)	42	45	45	44	45	45	43	46	42	45
BUN, G0, G1 (N=43;46;45;46;46;46;44;47;43;46)	1	1	0	1	1	1	0	1	1	1
BUN, G0, G2 (N=43;46;45;46;46;46;44;47;43;46)	0	0	0	1	0	0	0	0	0	0
BUN, G1, G0 (N=1;0;0;0;0;0;0;0;1;0)	1	0	0	0	0	0	0	0	1	0
BUN, G2, G0 (N=0;0;0;0;0;0;0;0;1;0)	0	0	0	0	0	0	0	0	1	0
CRE, UNK, G0 (N=0;0;0;0;0;0;1;0;1;0)	0	0	0	0	0	0	1	0	1	0
CRE, G0, UNK (N=44;46;45;46;46;46;44;47;45;46)	0	0	0	0	0	0	1	0	0	0
CRE, G0, G0 (N=44;46;45;46;46;46;44;47;45;46)	44	46	45	46	46	46	43	47	45	46
EOSi, UNK, G0 (N=1;1;3;1;1;1;1;2;5;2)	1	1	3	1	1	1	0	2	5	2
EOSi, UNK, G1 (N=1;1;3;1;1;1;1;2;5;2)	0	0	0	0	0	0	1	0	0	0
EOSi, G0, UNK (N=43;44;41;44;45;45;44;45;40;43)	0	0	0	0	0	0	1	0	0	0
EOSi, G0, G0 (N=43;44;41;44;45;45;44;45;40;43)	43	40	39	44	45	44	40	43	36	43
EOSi, G0, G1 (N=43;44;41;44;45;45;44;45;40;43)	0	4	2	0	0	1	3	2	4	0
EOSi, G1, G0 (N=0;1;1;1;0;0;0;0;1;1)	0	0	1	1	0	0	0	0	0	0
EOSi, G1, G1 (N=0;1;1;1;0;0;0;0;1;1)	0	1	0	0	0	0	0	0	1	1
HEMd, UNK, G0 (N=0;1;0;0;0;0;1;0;0;1)	0	1	0	0	0	0	1	0	0	1
HEMd, G0, G0 (N=39;41;42;42;44;43;39;42;43;43)	37	34	41	35	42	37	37	39	39	40
HEMd, G0, G1 (N=39;41;42;42;44;43;39;42;43;43)	2	7	1	6	2	6	2	3	4	3
HEMd, G0, G2 (N=39;41;42;42;44;43;39;42;43;43)	0	0	0	1	0	0	0	0	0	0
HEMd, G1, UNK (N=3;3;2;4;0;2;4;2;1;2)	0	0	0	0	0	0	1	0	0	0
HEMd, G1, G0 (N=3;3;2;4;0;2;4;2;1;2)	0	0	0	0	0	0	0	2	0	1
HEMd, G1, G1 (N=3;3;2;4;0;2;4;2;1;2)	2	1	1	3	0	1	2	0	0	0
HEMd, G1, G2 (N=3;3;2;4;0;2;4;2;1;2)	1	2	1	1	0	1	1	0	1	1
HEMd, G2, G2 (N=2;0;1;0;2;1;1;2;2;0)	1	0	1	0	2	1	1	0	1	0
HEMd, G2, G3 (N=2;0;1;0;2;1;1;2;2;0)	1	0	0	0	0	0	0	2	1	0
HEMd, G3, G3 (N=0;1;0;0;0;0;0;1;0;0)	0	1	0	0	0	0	0	1	0	0
LYMd, UNK, G0 (N=1;1;3;1;1;1;1;2;5;2)	0	1	3	1	1	1	1	2	5	2
LYMd, UNK, G1 (N=1;1;3;1;1;1;1;2;5;2)	1	0	0	0	0	0	0	0	0	0
LYMd, G0, UNK (N=43;45;39;45;44;45;44;45;39;44)	0	0	0	0	0	0	1	0	0	0
LYMd, G0, G0 (N=43;45;39;45;44;45;44;45;39;44)	41	41	39	44	40	44	43	41	38	40
LYMd, G0, G1 (N=43;45;39;45;44;45;44;45;39;44)	2	1	0	1	3	1	0	4	1	4
LYMd, G0, G2 (N=43;45;39;45;44;45;44;45;39;44)	0	2	0	0	1	0	0	0	0	0
LYMd, G0, G3 (N=43;45;39;45;44;45;44;45;39;44)	0	1	0	0	0	0	0	0	0	0
LYMd, G1, G0 (N=0;0;3;0;0;0;0;0;2;0)	0	0	1	0	0	0	0	0	0	0
LYMd, G1, G1 (N=0;0;3;0;0;0;0;0;2;0)	0	0	1	0	0	0	0	0	2	0
LYMd, G1, G2 (N=0;0;3;0;0;0;0;0;2;0)	0	0	1	0	0	0	0	0	0	0
LYMd, G2, G0 (N=0;0;0;0;1;0;0;0;0;0)	0	0	0	0	1	0	0	0	0	0
NEUd, UNK, G0 (N=1;1;3;1;1;1;1;2;5;2)	0	1	2	0	1	0	1	1	2	1
NEUd, UNK, G1 (N=1;1;3;1;1;1;1;2;5;2)	1	0	1	1	0	1	0	0	1	0
NEUd, UNK, G2 (N=1;1;3;1;1;1;1;2;5;2)	0	0	0	0	0	0	0	1	1	1
NEUd, UNK, G3 (N=1;1;3;1;1;1;1;2;5;2)	0	0	0	0	0	0	0	0	1	0
NEUd, G0, UNK (N=41;41;41;44;41;44;43;41;39;41)	0	0	0	0	0	0	1	0	0	0
NEUd, G0, G0 (N=41;41;41;44;41;44;43;41;39;41)	37	35	40	36	37	39	37	35	36	37
NEUd, G0, G1 (N=41;41;41;44;41;44;43;41;39;41)	4	4	1	4	2	4	2	4	2	3
NEUd, G0, G2 (N=41;41;41;44;41;44;43;41;39;41)	0	1	0	2	1	1	3	1	1	1
NEUd, G0, G3 (N=41;41;41;44;41;44;43;41;39;41)	0	1	0	2	1	0	0	1	0	0
NEUd, G1, G0 (N=2;4;0;1;2;1;1;2;1;1)	1	2	0	0	0	1	0	0	0	0
NEUd, G1, G1 (N=2;4;0;1;2;1;1;2;1;1)	1	2	0	0	1	0	0	1	1	1
NEUd, G1, G2 (N=2;4;0;1;2;1;1;2;1;1)	0	0	0	1	1	0	1	1	0	0
NEUd, G2, G0 (N=0;0;1;0;1;0;0;2;1;2)	0	0	1	0	0	0	0	0	0	1
NEUd, G2, G1 (N=0;0;1;0;1;0;0;2;1;2)	0	0	0	0	0	0	0	2	0	0
NEUd, G2, G2 (N=0;0;1;0;1;0;0;2;1;2)	0	0	0	0	1	0	0	0	1	1
NEUd, G3, G1 (N=0;0;0;0;1;0;0;0;0;0)	0	0	0	0	1	0	0	0	0	0
PLTCd, UNK, G0 (N=0;1;0;0;0;0;1;0;1;1)	0	1	0	0	0	0	1	0	1	1
PLTCd, G0, UNK (N=44;45;45;44;46;46;44;46;44;45)	0	0	0	0	0	0	1	0	0	0
PLTCd, G0, G0 (N=44;45;45;44;46;46;44;46;44;45)	42	45	44	43	46	45	43	45	44	45
PLTCd, G0, G1 (N=44;45;45;44;46;46;44;46;44;45)	2	0	0	0	0	1	0	1	0	0
PLTCd, G0, G2 (N=44;45;45;44;46;46;44;46;44;45)	0	0	1	1	0	0	0	0	0	0
PLTCd, G1, G0 (N=0;0;0;2;0;0;0;1;0;0)	0	0	0	1	0	0	0	1	0	0
PLTCd, G1, G3 (N=0;0;0;2;0;0;0;1;0;0)	0	0	0	1	0	0	0	0	0	0
PLTCd, G2, G1 (N=0;0;0;0;0;0;0;0;1;0)	0	0	0	0	0	0	0	0	1	0
WBCd, UNK, G0 (N=0;1;0;0;0;0;1;0;2;1)	0	1	0	0	0	0	1	0	1	0
WBCd, UNK, G1 (N=0;1;0;0;0;0;1;0;2;1)	0	0	0	0	0	0	0	0	1	1
WBCd, G0, UNK (N=43;45;44;46;44;46;44;44;42;45)	0	0	0	0	0	0	1	0	0	0
WBCd, G0, G0 (N=43;45;44;46;44;46;44;44;42;45)	41	43	44	41	41	46	42	42	40	41
WBCd, G0, G1 (N=43;45;44;46;44;46;44;44;42;45)	2	2	0	5	2	0	1	2	2	4
WBCd, G0, G2 (N=43;45;44;46;44;46;44;44;42;45)	0	0	0	0	1	0	0	0	0	0
WBCd, G1, G0 (N=1;0;1;0;1;0;0;3;2;0)	1	0	1	0	1	0	0	2	2	0
WBCd, G1, G1 (N=1;0;1;0;1;0;0;3;2;0)	0	0	0	0	0	0	0	1	0	0
WBCd, G2, G1 (N=0;0;0;0;1;0;0;0;0;0)	0	0	0	0	1	0	0	0	0	0
WBCi, UNK, G0 (N=0;1;0;0;0;0;1;0;2;1)	0	1	0	0	0	0	1	0	2	1
WBCi, G0, UNK (N=42;43;44;44;45;46;42;44;40;44)	0	0	0	0	0	0	1	0	0	0
WBCi, G0, G0 (N=42;43;44;44;45;46;42;44;40;44)	41	39	42	39	45	44	36	39	38	39
WBCi, G0, G1 (N=42;43;44;44;45;46;42;44;40;44)	1	4	2	5	0	2	5	5	1	5
WBCi, G0, G3 (N=42;43;44;44;45;46;42;44;40;44)	0	0	0	0	0	0	0	0	1	0
WBCi, G1, G0 (N=2;2;1;2;1;0;2;3;3;1)	0	0	0	1	1	0	0	1	1	0
WBCi, G1, G1 (N=2;2;1;2;1;0;2;3;3;1)	1	2	1	1	0	0	2	2	2	1
WBCi, G1, G2 (N=2;2;1;2;1;0;2;3;3;1)	1	0	0	0	0	0	0	0	0	0
WBCi, G2, G1 (N=0;0;0;0;0;0;0;0;1;0)	0	0	0	0	0	0	0	0	1	0

No statistical analyses for this end point

Primary: Number of subjects with change in hematological and biochemical laboratory results from Day 8 to Month 14+28 days versus baseline by toxicity grading

Top of page

End point title

Number of subjects with change in hematological and biochemical laboratory results from Day 8 to Month 14+28 days versus baseline by toxicity grading ^[11]

End point description

Hematological parameters assessed are: EOSi, HEMd, LYMd, NEUd, PLTCd, WBCd, WBCi. Biochemical parameters assessed are: ALTi, ASTi, BUN, CRE. Toxicity grading is according to the FDA guidance for industry: Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical Trials (September 2007). The grading scale is defined as following: mild (Grade 1), moderate (Grade 2), severe (Grade 3) and potentially life threatening (Grade 4). Category naming has been defined as: Parameter-grading at Baseline-grading at Timing: e.g.: "ALTi-G0-G1" (with G=Grade and UNK= Unknown). The reported results consider any change that occurred during the defined time frame: i.e. any abnormality occurring at an intermediate visit leading to a maximum change from baseline, during the period covered, is the reported result for the outcome.

End point type

Primary

End point timeframe

From Day 8 to Month 14 + 28 days

Notes
[11] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: This outcome was descriptive; hence no statistical analyses were required.

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	44	46	45	46	46	46	44	47	45	46
Units: Participants
ALTi, UNK, G0 (N=0;0;0;0;0;0;1;0;1;0)	0	0	0	0	0	0	0	0	1	0
ALTi, UNK, G1 (N=0;0;0;0;0;0;1;0;1;0)	0	0	0	0	0	0	1	0	0	0
ALTi, G0, UNK (N=40;46;43;45;45;45;44;44;43;46)	0	0	0	0	0	0	1	0	0	0
ALTi, G0, G0 (N=40;46;43;45;45;45;44;44;43;46)	38	38	39	42	40	41	38	39	30	40
ALTi, G0, G1 (N=40;46;43;45;45;45;44;44;43;46)	1	8	3	2	4	3	5	4	13	6
ALTi, G0, G2 (N=40;46;43;45;45;45;44;44;43;46)	0	0	1	0	1	1	0	1	0	0
ALTi, G0, G3 (N=40;46;43;45;45;45;44;44;43;46)	1	0	0	1	0	0	0	0	0	0
ALTi, G1, G0 (N=4;0;2;1;1;1;0;3;2;0)	3	0	1	1	1	0	0	2	2	0
ALTi, G1, G1 (N=4;0;2;1;1;1;0;3;2;0)	1	0	1	0	0	1	0	1	0	0
ASTi, UNK, G0 (N=0;0;0;0;0;0;1;0;1;0)	0	0	0	0	0	0	0	0	1	0
ASTi, UNK, G1 (N=0;0;0;0;0;0;1;0;1;0)	0	0	0	0	0	0	1	0	0	0
ASTi, G0, UNK (N=44;46;45;46;46;45;43;46;45;46)	0	0	0	0	0	0	1	0	0	0
ASTi, G0, G0 (N=44;46;45;46;46;45;43;46;45;46)	42	43	41	44	42	43	37	42	37	43
ASTi, G0, G1 (N=44;46;45;46;46;45;43;46;45;46)	1	3	3	1	3	2	5	4	7	2
ASTi, G0, G2 (N=44;46;45;46;46;45;43;46;45;46)	0	0	1	0	1	0	0	0	1	1
ASTi, G0, G4 (N=44;46;45;46;46;45;43;46;45;46)	1	0	0	1	0	0	0	0	0	0
ASTi, G1, G1 (N=0;0;0;0;0;1;1;0;0;0)	0	0	0	0	0	1	1	0	0	0
ASTi, G2, G0 (N=0;0;0;0;0;0;0;1;0;0)	0	0	0	0	0	0	0	1	0	0
BUN, UNK, G0 (N=0;0;0;0;0;0;1;0;1;0)	0	0	0	0	0	0	1	0	1	0
BUN, G0, UNK (N=43;46;45;46;46;46;44;47;43;46)	0	0	0	0	0	0	1	0	0	0
BUN, G0, G0 (N=43;46;45;46;46;46;44;47;43;46)	41	45	45	44	45	45	42	46	41	45
BUN, G0, G1 (N=43;46;45;46;46;46;44;47;43;46)	1	1	0	0	1	1	1	1	2	1
BUN, G0, G2 (N=43;46;45;46;46;46;44;47;43;46)	1	0	0	1	0	0	0	0	0	0
BUN, G0, G3 (N=43;46;45;46;46;46;44;47;43;46)	0	0	0	1	0	0	0	0	0	0
BUN, G1, G0 (N=1;0;0;0;0;0;0;0;1;0)	1	0	0	0	0	0	0	0	1	0
BUN, G2, G0 (N=0;0;0;0;0;0;0;0;1;0)	0	0	0	0	0	0	0	0	1	0
CRE, UNK, G0 (N=0;0;0;0;0;0;1;0;1;0)	0	0	0	0	0	0	1	0	1	0
CRE, G0, UNK (N=44;46;45;46;46;46;44;47;45;46)	0	0	0	0	0	0	1	0	0	0
CRE, G0, G0 (N=44;46;45;46;46;46;44;47;45;46)	44	46	45	46	46	46	43	47	45	46
EOSi, UNK, G0 (N=1;1;3;1;1;1;1;2;5;2)	1	1	3	1	1	1	0	2	5	2
EOSi, UNK, G1 (N=1;1;3;1;1;1;1;2;5;2)	0	0	0	0	0	0	1	0	0	0
EOSi, G0, UNK (N=43;44;41;44;45;45;44;45;40;43)	0	0	0	0	0	0	1	0	0	0
EOSi, G0, G0 (N=43;44;41;44;45;45;44;45;40;43)	42	40	39	43	45	44	39	42	34	43
EOSi, G0, G1 (N=43;44;41;44;45;45;44;45;40;43)	1	4	2	1	0	1	4	3	6	0
EOSi, G1, G0 (N=0;1;1;1;0;0;0;0;1;1)	0	0	1	1	0	0	0	0	0	0
EOSi, G1, G1 (N=0;1;1;1;0;0;0;0;1;1)	0	1	0	0	0	0	0	0	1	1
HEMd, UNK, G0 (N=0;1;0;0;0;0;1;0;0;1)	0	1	0	0	0	0	1	0	0	1
HEMd, G0, G0 (N=39;41;42;42;44;43;39;42;43;43)	35	33	39	33	39	37	35	36	39	39
HEMd, G0, G1 (N=39;41;42;42;44;43;39;42;43;43)	4	8	3	8	5	5	3	6	4	4
HEMd, G0, G2 (N=39;41;42;42;44;43;39;42;43;43)	0	0	0	1	0	1	1	0	0	0
HEMd, G1, UNK (N=3;3;2;4;0;2;4;2;1;2)	0	0	0	0	0	0	1	0	0	0
HEMd, G1, G0 (N=3;3;2;4;0;2;4;2;1;2)	0	0	0	0	0	0	0	2	0	1
HEMd, G1, G1 (N=3;3;2;4;0;2;4;2;1;2)	2	1	1	3	0	1	2	0	0	0
HEMd, G1, G2 (N=3;3;2;4;0;2;4;2;1;2)	0	2	1	1	0	1	1	0	1	1
HEMd, G1, G3 (N=3;3;2;4;0;2;4;2;1;2)	1	0	0	0	0	0	0	0	0	0
HEMd, G2, G2 (N=2;0;1;0;2;1;1;2;2;0)	1	0	1	0	1	1	1	0	1	0
HEMd, G2, G3 (N=2;0;1;0;2;1;1;2;2;0)	0	0	0	0	1	0	0	2	1	0
HEMd, G2, G4 (N=2;0;1;0;2;1;1;2;2;0)	1	0	0	0	0	0	0	0	0	0
HEMd, G3, G3 (N=0;1;0;0;0;0;0;1;0;0)	0	1	0	0	0	0	0	1	0	0
LYMd, UNK, G0 (N=1;1;3;1;1;1;1;2;5;2)	0	0	3	1	1	1	1	2	4	2
LYMd, UNK, G1 (N=1;1;3;1;1;1;1;2;5;2)	1	1	0	0	0	0	0	0	1	0
LYMd, G0, UNK (N=43;45;39;45;44;45;44;45;39;44)	0	0	0	0	0	0	1	0	0	0
LYMd, G0, G0 (N=43;45;39;45;44;45;44;45;39;44)	40	41	39	44	40	44	43	38	38	40
LYMd, G0, G1 (N=43;45;39;45;44;45;44;45;39;44)	3	1	0	1	3	1	0	7	1	4
LYMd, G0, G2 (N=43;45;39;45;44;45;44;45;39;44)	0	2	0	0	1	0	0	0	0	0
LYMd, G0, G3 (N=43;45;39;45;44;45;44;45;39;44)	0	1	0	0	0	0	0	0	0	0
LYMd, G1, G0 (N=0;0;3;0;0;0;0;0;2;0)	0	0	1	0	0	0	0	0	0	0
LYMd, G1, G1 (N=0;0;3;0;0;0;0;0;2;0)	0	0	1	0	0	0	0	0	2	0
LYMd, G1, G2 (N=0;0;3;0;0;0;0;0;2;0)	0	0	1	0	0	0	0	0	0	0
LYMd, G2, G1 (N=0;0;0;0;1;0;0;0;0;0)	0	0	0	0	1	0	0	0	0	0
NEUd, UNK, G0 (N=1;1;3;1;1;1;1;2;5;2)	0	1	2	0	1	0	1	1	2	1
NEUd, UNK, G1 (N=1;1;3;1;1;1;1;2;5;2)	1	0	1	1	0	1	0	0	1	0
NEUd, UNK, G2 (N=1;1;3;1;1;1;1;2;5;2)	0	0	0	0	0	0	0	1	1	1
NEUd, UNK, G3 (N=1;1;3;1;1;1;1;2;5;2)	0	0	0	0	0	0	0	0	1	0
NEUd, G0, UNK (N=41;41;41;44;41;44;43;41;39;41)	0	0	0	0	0	0	1	0	0	0
NEUd, G0, G0 (N=41;41;41;44;41;44;43;41;39;41)	36	34	37	35	36	38	34	35	34	34
NEUd, G0, G1 (N=41;41;41;44;41;44;43;41;39;41)	5	4	2	5	3	5	5	4	4	6
NEUd, G0, G2 (N=41;41;41;44;41;44;43;41;39;41)	0	2	2	2	1	1	3	1	1	1
NEUd, G0, G3 (N=41;41;41;44;41;44;43;41;39;41)	0	1	0	2	1	0	0	1	0	0
NEUd, G1, G0 (N=2;4;0;1;2;1;1;2;1;1)	1	2	0	0	0	1	0	0	0	0
NEUd, G1, G1 (N=2;4;0;1;2;1;1;2;1;1)	0	2	0	0	1	0	0	1	0	1
NEUd, G1, G2 (N=2;4;0;1;2;1;1;2;1;1)	1	0	0	1	1	0	1	1	1	0
NEUd, G2, G0 (N=0;0;1;0;1;0;0;2;1;2)	0	0	1	0	0	0	0	0	0	1
NEUd, G2, G1 (N=0;0;1;0;1;0;0;2;1;2)	0	0	0	0	0	0	0	2	0	0
NEUd, G2, G2 (N=0;0;1;0;1;0;0;2;1;2)	0	0	0	0	1	0	0	0	1	1
NEUd, G3, G1 (N=0;0;0;0;1;0;0;0;0;0)	0	0	0	0	1	0	0	0	0	0
PLTCd, UNK, G0 (N=0;1;0;0;0;0;1;0;1;1)	0	1	0	0	0	0	1	0	1	1
PLTCd, G0, UNK (N=44;45;45;44;46;46;44;46;44;45)	0	0	0	0	0	0	1	0	0	0
PLTCd, G0, G0 (N=44;45;45;44;46;46;44;46;44;45)	42	45	44	43	46	45	43	45	44	45
PLTCd, G0, G1 (N=44;45;45;44;46;46;44;46;44;45)	2	0	0	0	0	1	0	1	0	0
PLTCd, G0, G2 (N=44;45;45;44;46;46;44;46;44;45)	0	0	1	1	0	0	0	0	0	0
PLTCd, G1, G0 (N=0;0;0;2;0;0;0;1;0;0)	0	0	0	1	0	0	0	1	0	0
PLTCd, G1, G3 (N=0;0;0;2;0;0;0;1;0;0)	0	0	0	1	0	0	0	0	0	0
PLTCd, G2, G2 (N=0;0;0;0;0;0;0;0;1;0)	0	0	0	0	0	0	0	0	1	0
WBCd, UNK, G0 (N=0;1;0;0;0;0;1;0;2;1)	0	1	0	0	0	0	1	0	1	0
WBCd, UNK, G1 (N=0;1;0;0;0;0;1;0;2;1)	0	0	0	0	0	0	0	0	1	1
WBCd, G0, UNK (N=43;45;44;46;44;46;44;44;42;45)	0	0	0	0	0	0	1	0	0	0
WBCd, G0, G0 (N=43;45;44;46;44;46;44;44;42;45)	41	42	41	40	41	46	42	41	38	41
WBCd, G0, G1 (N=43;45;44;46;44;46;44;44;42;45)	2	3	3	6	2	0	1	3	4	4
WBCd, G0, G2 (N=43;45;44;46;44;46;44;44;42;45)	0	0	0	0	1	0	0	0	0	0
WBCd, G1, G0 (N=1;0;1;0;1;0;0;3;2;0)	0	0	1	0	1	0	0	2	2	0
WBCd, G1, G1 (N=1;0;1;0;1;0;0;3;2;0)	1	0	0	0	0	0	0	1	0	0
WBCd, G2, G1 (N=0;0;0;0;1;0;0;0;0;0)	0	0	0	0	1	0	0	0	0	0
WBCi, UNK, G0 (N=0;1;0;0;0;0;1;0;2;1)	0	1	0	0	0	0	1	0	2	1
WBCi, G0, UNK (N=42;43;44;44;45;46;42;44;40;44)	0	0	0	0	0	0	1	0	0	0
WBCi, G0, G0 (N=42;43;44;44;45;46;42;44;40;44)	39	39	40	37	43	43	35	37	36	36
WBCi, G0, G1 (N=42;43;44;44;45;46;42;44;40;44)	3	4	4	6	2	3	5	6	3	7
WBCi, G0, G2 (N=42;43;44;44;45;46;42;44;40;44)	0	0	0	1	0	0	1	1	0	1
WBCi, G0, G3 (N=42;43;44;44;45;46;42;44;40;44)	0	0	0	0	0	0	0	0	1	0
WBCi, G1, G0 (N=2;2;1;2;1;0;2;3;3;1)	0	0	0	1	1	0	0	1	1	0
WBCi, G1, G1 (N=2;2;1;2;1;0;2;3;3;1)	1	2	1	1	0	0	2	2	1	1
WBCi, G1, G2 (N=2;2;1;2;1;0;2;3;3;1)	1	0	0	0	0	0	0	0	1	0
WBCi, G2, G1 (N=0;0;0;0;0;0;0;0;1;0)	0	0	0	0	0	0	0	0	1	0

No statistical analyses for this end point

Primary: Number of subjects with change in hematological and biochemical laboratory results from Day 8 to Month 26 versus baseline by toxicity grading

Top of page

End point title

Number of subjects with change in hematological and biochemical laboratory results from Day 8 to Month 26 versus baseline by toxicity grading ^[12]

End point description

Hematological parameters assessed are: EOSi, HEMd, LYMd, NEUd, PLTCd, WBCd, WBCi. Biochemical parameters assessed are: ALTi, ASTi, BUN, CRE. Toxicity grading is according to the FDA guidance for industry: Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical Trials (September 2007). The grading scale is defined as following: mild (Grade 1), moderate (Grade 2), severe (Grade 3) and potentially life threatening (Grade 4). Category naming has been defined as: Parameter-grading at Baseline-grading at Timing: e.g.: "ALTi-G0-G1" (with G=Grade and UNK= Unknown). The reported results consider any change that occurred during the defined time frame: i.e. any abnormality occurring at an intermediate visit leading to a maximum change from baseline, during the period covered, is the reported result for the outcome.

End point type

Primary

End point timeframe

From Day 8 to Month 26

Notes
[12] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: This outcome was descriptive; hence no statistical analyses were required.

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	44	46	45	46	46	46	44	47	45	46
Units: Participants
ALTi, UNK, G0 (N=0;0;0;0;0;0;1;0;1;0)	0	0	0	0	0	0	0	0	1	0
ALTi, UNK, G1 (N=0;0;0;0;0;0;1;0;1;0)	0	0	0	0	0	0	1	0	0	0
ALTi, G0, UNK (N=40;46;43;45;45;45;44;44;43;46)	0	0	0	0	0	0	1	0	0	0
ALTi, G0, G0 (N=40;46;43;45;45;45;44;44;43;46)	38	38	39	42	40	39	37	38	29	40
ALTi, G0, G1 (N=40;46;43;45;45;45;44;44;43;46)	1	8	3	2	4	5	6	5	14	6
ALTi, G0, G2 (N=40;46;43;45;45;45;44;44;43;46)	0	0	1	0	1	1	0	1	0	0
ALTi, G0, G3 (N=40;46;43;45;45;45;44;44;43;46)	1	0	0	1	0	0	0	0	0	0
ALTi, G1, G0 (N=4;0;2;1;1;1;0;3;2;0)	2	0	1	1	1	0	0	2	1	0
ALTi, G1, G1 (N=4;0;2;1;1;1;0;3;2;0)	2	0	1	0	0	1	0	1	1	0
ASTi, UNK, G0 (N=0;0;0;0;0;0;1;0;1;0)	0	0	0	0	0	0	0	0	1	0
ASTi, UNK, G1 (N=0;0;0;0;0;0;1;0;1;0)	0	0	0	0	0	0	1	0	0	0
ASTi, G0, UNK (N=44;46;45;46;46;45;43;46;45;46)	0	0	0	0	0	0	1	0	0	0
ASTi, G0, G0 (N=44;46;45;46;46;45;43;46;45;46)	42	42	41	44	42	42	36	42	37	43
ASTi, G0, G1 (N=44;46;45;46;46;45;43;46;45;46)	1	4	3	1	3	1	6	4	7	2
ASTi, G0, G2 (N=44;46;45;46;46;45;43;46;45;46)	0	0	1	0	1	2	0	0	1	1
ASTi, G0, G4 (N=44;46;45;46;46;45;43;46;45;46)	1	0	0	1	0	0	0	0	0	0
ASTi, G1, G1 (N=0;0;0;0;0;1;1;0;0;0)	0	0	0	0	0	1	1	0	0	0
ASTi, G2, G0 (N=0;0;0;0;0;0;0;1;0;0)	0	0	0	0	0	0	0	1	0	0
BUN, UNK, G0 (N=0;0;0;0;0;0;1;0;1;0)	0	0	0	0	0	0	1	0	1	0
BUN, G0, UNK (N=43;46;45;46;46;46;44;47;43;46)	0	0	0	0	0	0	1	0	0	0
BUN, G0, G0 (N=43;46;45;46;46;46;44;47;43;46)	40	45	45	44	45	45	42	46	41	45
BUN, G0, G1 (N=43;46;45;46;46;46;44;47;43;46)	2	1	0	0	1	1	1	1	2	1
BUN, G0, G2 (N=43;46;45;46;46;46;44;47;43;46)	1	0	0	1	0	0	0	0	0	0
BUN, G0, G3 (N=43;46;45;46;46;46;44;47;43;46)	0	0	0	1	0	0	0	0	0	0
BUN, G1, G0 (N=1; 0;0;0;0;0;0;0;1;0)	1	0	0	0	0	0	0	0	0	0
BUN, G1, G1 (N=1;0;0;0;0;0;0;0;1;0)	0	0	0	0	0	0	0	0	1	0
BUN, G2, G0 (N=0;0;0;0;0;0;0;0;1;0)	0	0	0	0	0	0	0	0	1	0
CRE, UNK, G0 (N=0;0;0;0;0;0;1;0;1;0)	0	0	0	0	0	0	1	0	1	0
CRE, G0, UNK (N=44;46;45;46;46;46;44;47;45;46)	0	0	0	0	0	0	1	0	0	0
CRE, G0, G0 (N=44;46;45;46;46;46;44;47;45;46)	44	46	45	46	46	46	43	47	45	46
EOSi, UNK, G0 (N=1;1;3;1;1;1;1;2;5;2)	1	1	3	1	1	1	0	2	5	2
EOSi, UNK, G1 (N=1;1;3;1;1;1;1;2;5;2)	0	0	0	0	0	0	1	0	0	0
EOSi, G0, UNK (N=43;44;41;44;45;45;44;45;40;43)	0	0	0	0	0	0	1	0	0	0
EOSi, G0, G0 (N=43;44;41;44;45;45;44;45;40;43)	42	40	39	43	45	44	38	41	34	42
EOSi, G0, G1 (N=43;44;41;44;45;45;44;45;40;43)	1	4	2	1	0	1	5	4	6	1
EOSi, G1, G0 (N=0;1;1;1;0;0;0;0;1;1)	0	0	1	1	0	0	0	0	0	0
EOSi, G1, G1 (N=0;1;1;1;0;0;0;0;1;1)	0	1	0	0	0	0	0	0	1	1
HEMd, UNK, G0 (N=0;1;0;0;0;0;1;0;0;1)	0	1	0	0	0	0	1	0	0	1
HEMd, G0, G0 (N=39;41;42;42;44;43;39;42;43;43)	33	32	37	31	38	36	35	35	37	39
HEMd, G0, G1 (N=39;41;42;42;44;43;39;42;43;43)	5	9	5	7	6	6	3	6	5	4
HEMd, G0, G2 (N=39;41;42;42;44;43;39;42;43;43)	1	0	0	4	0	1	1	1	0	0
HEMd, G0, G3 (N=39;41;42;42;44;43;39;42;43;43)	0	0	0	0	0	0	0	0	1	0
HEMd, G1, UNK (N=3;3;2;4;0;2;4;2;1;2)	0	0	0	0	0	0	1	0	0	0
HEMd, G1, G0 (N=3;3;2;4;0;2;4;2;1;2)	0	0	0	0	0	0	0	2	0	1
HEMd, G1, G1 (N=3;3;2;4;0;2;4;2;1;2)	2	1	1	3	0	1	2	0	0	0
HEMd, G1, G2 (N=3;3;2;4;0;2;4;2;1;2)	0	2	1	1	0	1	1	0	1	1
HEMd, G1, G3 (N=3;3;2;4;0;2;4;2;1;2)	1	0	0	0	0	0	0	0	0	0
HEMd, G2, G2 (N=2;0;1;0;2;1;1;2;2;0)	1	0	1	0	1	1	1	0	1	0
HEMd, G2, G3 (N=2;0;1;0;2;1;1;2;2;0)	0	0	0	0	1	0	0	2	1	0
HEMd, G2, G4 (N=2;0;1;0;2;1;1;2;2;0)	1	0	0	0	0	0	0	0	0	0
HEMd, G3, G3 (N=0;1;0;0;0;0;0;1;0;0)	0	1	0	0	0	0	0	1	0	0
LYMd, UNK, G0 (N=1;1;3;1;1;1;1;2;5;2)	0	0	3	1	1	1	1	2	4	2
LYMd, UNK, G1 (N=1;1;3;1;1;1;1;2;5;2)	1	1	0	0	0	0	0	0	1	0
LYMd, G0, UNK (N=43;45;39;45;44;45;44;45;39;44)	0	0	0	0	0	0	1	0	0	0
LYMd, G0, G0 (N=43;45;39;45;44;45;44;45;39;44)	39	40	39	44	40	44	43	37	38	40
LYMd, G0, G1 (N=43;45;39;45;44;45;44;45;39;44)	4	1	0	1	3	1	0	8	1	4
LYMd, G0, G2 (N=43;45;39;45;44;45;44;45;39;44)	0	3	0	0	1	0	0	0	0	0
LYMd, G0, G3 (N=43;45;39;45;44;45;44;45;39;44)	0	1	0	0	0	0	0	0	0	0
LYMd, G1, G0 (N=0;0;3;0;0;0;0;0;2;0)	0	0	1	0	0	0	0	0	0	0
LYMd, G1, G1 (N=0;0;3;0;0;0;0;0;2;0)	0	0	1	0	0	0	0	0	2	0
LYMd, G1, G2 (N=0;0;3;0;0;0;0;0;2;0)	0	0	1	0	0	0	0	0	0	0
LYMd, G2, G1 (N=0;0;0;0;1;0;0;0;0;0)	0	0	0	0	1	0	0	0	0	0
NEUd, UNK, G0 (N=1;1;3;1;1;1;1;2;5;2)	0	1	2	0	1	0	1	1	2	1
NEUd, UNK, G1 (N=1;1;3;1;1;1;1;2;5;2)	1	0	1	1	0	1	0	0	1	0
NEUd, UNK, G2 (N=1;1;3;1;1;1;1;2;5;2)	0	0	0	0	0	0	0	1	1	1
NEUd, UNK, G3 (N=1;1;3;1;1;1;1;2;5;2)	0	0	0	0	0	0	0	0	1	0
NEUd, G0, UNK (N=41;41;41;44;41;44;43;41;39;41)	0	0	0	0	0	0	1	0	0	0
NEUd, G0, G0 (N=41;41;41;44;41;44;43;41;39;41)	35	34	37	35	36	36	34	35	34	34
NEUd, G0, G1 (N=41;41;41;44;41;44;43;41;39;41)	5	4	2	5	3	6	5	4	4	6
NEUd, G0, G2 (N=41;41;41;44;41;44;43;41;39;41)	1	2	2	2	1	2	3	1	1	1
NEUd, G0, G3 (N=41;41;41;44;41;44;43;41;39;41)	0	1	0	2	1	0	0	1	0	0
NEUd, G1, G0 (N=2;4;0;1;2;1;1;2;1;1)	1	2	0	0	0	1	0	0	0	0
NEUd, G1, G1 (N=2;4;0;1;2;1;1;2;1;1)	0	2	0	0	1	0	0	1	0	1
NEUd, G1, G2 (N=2;4;0;1;2;1;1;2;1;1)	1	0	0	1	1	0	1	1	1	0
NEUd, G2, G0 (N=0;0;1;0;1;0;0;2;1;2)	0	0	1	0	0	0	0	0	0	1
NEUd, G2, G1 (N=0;0;1;0;1;0;0;2;1;2)	0	0	0	0	0	0	0	2	0	0
NEUd, G2, G2 (N=0;0;1;0;1;0;0;2;1;2)	0	0	0	0	1	0	0	0	1	1
NEUd, G3, G1 (N=0;0;0;0;1;0;0;0;0;0)	0	0	0	0	1	0	0	0	0	0
PLTCd, UNK, G0 (N=0;1;0;0;0;0;1;0;1;1)	0	1	0	0	0	0	1	0	1	1
PLTCd, G0, UNK (N=44;45;45;44;46;46;44;46;44;45)	0	0	0	0	0	0	1	0	0	0
PLTCd, G0, G0 (N=44;45;45;44;46;46;44;46;44;45)	42	45	44	43	46	44	43	45	44	45
PLTCd, G0, G1 (N=44;45;45;44;46;46;44;46;44;45)	2	0	0	0	0	1	0	1	0	0
PLTCd, G0, G2 (N=44;45;45;44;46;46;44;46;44;45)	0	0	1	1	0	1	0	0	0	0
PLTCd, G1, G0 (N=0;0;0;2;0;0;0;1;0;0)	0	0	0	1	0	0	0	1	0	0
PLTCd, G1, G3 (N=0;0;0;2;0;0;0;1;0;0)	0	0	0	1	0	0	0	0	0	0
PLTCd, G2, G2 (N=0;0;0;0;0;0;0;0;1;0)	0	0	0	0	0	0	0	0	1	0
WBCd, UNK, G0 (N=0;1;0;0;0;0;1;0;2;1)	0	1	0	0	0	0	1	0	1	0
WBCd, UNK, G1 (N=0;1;0;0;0;0;1;0;2;1)	0	0	0	0	0	0	0	0	1	1
WBCd, G0, UNK (N=43;45;44;46;44;46;44;44;42;45)	0	0	0	0	0	0	1	0	0	0
WBCd, G0, G0 (N=43;45;44;46;44;46;44;44;42;45)	39	42	41	40	41	46	42	41	38	41
WBCd, G0, G1 (N=43;45;44;46;44;46;44;44;42;45)	4	3	3	6	2	0	1	3	4	4
WBCd, G0, G2 (N=43;45;44;46;44;46;44;44;42;45)	0	0	0	0	1	0	0	0	0	0
WBCd, G1, G0 (N=1;0;1;0;1;0;0;3;2;0)	0	0	1	0	1	0	0	2	1	0
WBCd, G1, G1 (N=1;0;1;0;1;0;0;3;2;0)	1	0	0	0	0	0	0	1	1	0
WBCd, G2, G1 (N=0;0;0;0;1;0;0;0;0;0)	0	0	0	0	1	0	0	0	0	0
WBCi, UNK, G0 (N=0;1;0;0;0;0;1;0;2;1)	0	1	0	0	0	0	1	0	2	1
WBCi, G0, UNK (N=42;43;44;44;45;46;42;44;40;44)	0	0	0	0	0	0	1	0	0	0
WBCi, G0, G0 (N=42;43;44;44;45;46;42;44;40;44)	37	38	40	37	43	43	35	37	36	36
WBCi, G0, G1 (N=42;43;44;44;45;46;42;44;40;44)	5	5	4	6	2	3	5	6	3	7
WBCi, G0, G2 (N=42;43;44;44;45;46;42;44;40;44)	0	0	0	1	0	0	1	1	0	1
WBCi, G0, G3 (N=42;43;44;44;45;46;42;44;40;44)	0	0	0	0	0	0	0	0	1	0
WBCi, G1, G0 (N=2;2;1;2;1;0;2;3;3;1)	0	0	0	1	1	0	0	1	1	0
WBCi, G1, G1 (N=2;2;1;2;1;0;2;3;3;1)	1	2	1	1	0	0	2	2	1	1
WBCi, G1, G2 (N=2;2;1;2;1;0;2;3;3;1)	1	0	0	0	0	0	0	0	1	0
WBCi, G2, G1 (N=0;0;0;0;0;0;0;0;1;0)	0	0	0	0	0	0	0	0	1	0

No statistical analyses for this end point

Primary: Number of subjects with any medically-attended adverse events (MAEs)

Top of page

End point title

Number of subjects with any medically-attended adverse events (MAEs) ^[13]

End point description

MAEs are defined as events for which the subject receives medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any MAE(s) = Occurrence of any MAE(s) regardless of intensity grade or relation to vaccination.

End point type

Primary

End point timeframe

During the entire study period (from Day 1 up to Month 26)

Notes
[13] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: This outcome was descriptive; hence no statistical analyses were required.

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	45	46	47	47	48	47	47	48	46	47
Units: Participants	21	16	20	23	21	14	19	18	23	20

No statistical analyses for this end point

Primary: Number of subjects reporting any potential immune-mediated diseases (pIMDs)

Top of page

End point title

Number of subjects reporting any potential immune-mediated diseases (pIMDs) ^[14]

End point description

pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.

End point type

Primary

End point timeframe

During the entire study period (from Day 1 up to Month 26)

Notes
[14] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: This outcome was descriptive; hence no statistical analyses were required.

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	45	46	47	47	48	47	47	48	46	47
Units: Participants	0	0	0	0	0	0	1	0	0	0

No statistical analyses for this end point

Primary: Number of subjects with serious adverse events (SAEs).

Top of page

End point title

Number of subjects with serious adverse events (SAEs). ^[15]

End point description

SAEs include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

End point type

Primary

End point timeframe

During the entire study period (from Day 1 up to Month 26)

Notes
[15] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: This outcome was descriptive; hence no statistical analyses were required.

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	45	46	47	47	48	47	47	48	46	47
Units: Participants	2	1	1	2	2	2	0	2	2	3

No statistical analyses for this end point

Primary: Number of seropositive subjects for anti-H1 stalk antibodies measured by enzyme-linked immunosorbent assay (ELISA)– Day 1

Top of page

End point title

Number of seropositive subjects for anti-H1 stalk antibodies measured by enzyme-linked immunosorbent assay (ELISA)– Day 1 ^[16]

End point description

Anti-H1 stalk immune response measured by ELISA. A seropositive subject is a subject whose concentration is greater than or equal to the cut-off value: ELISA cut-off = 66 ELISA.Unit per milliliter (EL.U/mL).

End point type

Primary

End point timeframe

At Day 1

Notes
[16] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: This outcome was descriptive; hence no statistical analyses were required.

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	45	46	47	47	48	47	47	46	44	45
Units: Participants	45	46	47	47	48	47	47	46	44	45

No statistical analyses for this end point

Primary: Number of seropositive subjects for anti-H1 stalk antibodies measured by ELISA– Day 29

Top of page

End point title

Number of seropositive subjects for anti-H1 stalk antibodies measured by ELISA– Day 29 ^[17]

End point description

Anti-H1 stalk immune response measured by ELISA. A seropositive subject is a subject whose concentration is greater than or equal to the cut-off value: ELISA cut-off = 66 EL.U/mL.

End point type

Primary

End point timeframe

At Day 29

Notes
[17] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: This outcome was descriptive; hence no statistical analyses were required.

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	43	40	41	40	42	42	37	41	39	40
Units: Participants	43	40	41	40	42	42	37	41	39	40

No statistical analyses for this end point

Primary: Number of seropositive subjects for anti-H1 stalk antibodies measured by ELISA– Day 85

Top of page

End point title

Number of seropositive subjects for anti-H1 stalk antibodies measured by ELISA– Day 85 ^[18]

End point description

Anti-H1 stalk immune response measured by ELISA. A seropositive subject is a subject whose concentration is greater than or equal to the cut-off value: ELISA cut-off = 66 EL.U/mL.

End point type

Primary

End point timeframe

At Day 85

Notes
[18] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: This outcome was descriptive; hence no statistical analyses were required.

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	39	36	34	35	39	35	34	34	35	38
Units: Participants	39	36	34	35	39	35	34	34	35	38

No statistical analyses for this end point

Primary: Concentrations of serum H1 stalk antibodies measured by ELISA– Day 1

Top of page

End point title

Concentrations of serum H1 stalk antibodies measured by ELISA– Day 1 ^[19]

End point description

Concentrations are presented as Geometric Mean Concentrations (GMCs) and measured by ELISA. ELISA cut-off = 66 EL.U/mL.

End point type

Primary

End point timeframe

At Day 1

Notes
[19] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: This outcome was descriptive; hence no statistical analyses were required.

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	45	46	47	47	48	47	47	46	44	45
Units: EL.U/mL
geometric mean (confidence interval 95%)	8887.9 (7004.9 to 11277.1)	8719.3 (6547.0 to 11612.3)	9691 (7593.7 to 12367.7)	9121 (7180.0 to 11586.6)	9948.6 (8106.2 to 12209.8)	8555.5 (6980.1 to 10486.4)	9019.6 (7263.5 to 11200.2)	9278.2 (7430.7 to 11585.1)	9039.3 (6930.7 to 11789.5)	9160 (7225.7 to 11612.2)

No statistical analyses for this end point

Primary: Concentrations of serum H1 stalk antibodies measured by ELISA– Day 29

Top of page

End point title

Concentrations of serum H1 stalk antibodies measured by ELISA– Day 29 ^[20]

End point description

Concentrations are presented as GMCs and measured by ELISA. ELISA cut-off = 66 EL.U/mL.

End point type

Primary

End point timeframe

At Day 29

Notes
[20] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: This outcome was descriptive; hence no statistical analyses were required.

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	43	40	41	40	42	42	37	41	39	40
Units: EL.U/mL
geometric mean (confidence interval 95%)	112973.2 (90888.2 to 140424.5)	45645 (35289.4 to 59039.5)	116596.8 (93869.6 to 144826.6)	61634.2 (49810.3 to 76264.7)	46596.2 (38306.7 to 56679.5)	67114.6 (54649.7 to 82422.6)	35580.2 (24654.2 to 51348.2)	20398.6 (16362.4 to 25430.5)	36426.2 (29124.8 to 45558.0)	21938.1 (18037.8 to 26681.8)

No statistical analyses for this end point

Primary: Concentrations of serum H1 stalk antibodies measured by ELISA– Day 85

Top of page

End point title

Concentrations of serum H1 stalk antibodies measured by ELISA– Day 85 ^[21]

End point description

Concentrations are presented as GMCs and measured by ELISA. ELISA cut-off = 66 EL.U/mL.

End point type

Primary

End point timeframe

At Day 85

Notes
[21] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: This outcome was descriptive; hence no statistical analyses were required.

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	39	36	34	35	39	35	34	34	35	38
Units: EL.U/mL
geometric mean (confidence interval 95%)	45351.6 (36766.7 to 55941.1)	28437.5 (21623.4 to 37398.9)	74639.7 (59986.3 to 92872.6)	30419.3 (23619.9 to 39176.0)	25718.6 (20748.8 to 31878.8)	48775.9 (40697.7 to 58457.7)	28617.8 (19448.1 to 42110.9)	15105.9 (12007.7 to 19003.6)	37911.4 (30149.4 to 47671.7)	16749.9 (13471.8 to 20825.8)

No statistical analyses for this end point

Primary: Number of seropositive subjects for anti-H1 stalk antibodies measured by microneutralization (MN) assay – Day 1

Top of page

End point title

Number of seropositive subjects for anti-H1 stalk antibodies measured by microneutralization (MN) assay – Day 1 ^[22]

End point description

Anti-H1 stalk immune response measured by MN are expressed in 1/DILUTION (DIL). The functionality of the stalk-reactive antibodies is evaluated by MN assays developed using chimeric viruses. A seropositive subject is a subject whose titer is greater than or equal to the cut-off value: MN cut-off = 20 1/DIL.

End point type

Primary

End point timeframe

At Day 1

Notes
[22] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: This outcome was descriptive; hence no statistical analyses were required.

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	44	44	45	46	44	46	45	43	42	41
Units: Participants	32	34	35	36	33	40	37	34	31	33

No statistical analyses for this end point

Primary: Number of seropositive subjects for anti-H1 stalk antibodies measured by MN assay – Day 29

Top of page

End point title

Number of seropositive subjects for anti-H1 stalk antibodies measured by MN assay – Day 29 ^[23]

End point description

Anti-H1 stalk immune response measured by MN are expressed in 1/DIL. The functionality of the stalk-reactive antibodies is evaluated by MN assays developed using chimeric viruses. A seropositive subject is a subject whose titer is greater than or equal to the cut-off value: MN cut-off = 20 1/DIL.

End point type

Primary

End point timeframe

At Day 29

Notes
[23] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: This outcome was descriptive; hence no statistical analyses were required.

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	43	40	40	40	41	42	37	41	39	40
Units: Participants	43	40	40	40	41	41	36	41	37	40

No statistical analyses for this end point

Primary: Number of seropositive subjects for anti-H1 stalk antibodies measured by MN assay – Day 85

Top of page

End point title

Number of seropositive subjects for anti-H1 stalk antibodies measured by MN assay – Day 85 ^[24]

End point description

End point type

Primary

End point timeframe

At Day 85

Notes
[24] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: This outcome was descriptive; hence no statistical analyses were required.

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	38	36	34	33	39	35	34	34	35	38
Units: Participants	36	35	34	31	38	35	30	32	35	37

No statistical analyses for this end point

Primary: Titers for serum H1 stalk antibodies measured by MN assay – Day 1

Top of page

End point title

Titers for serum H1 stalk antibodies measured by MN assay – Day 1 ^[25]

End point description

Titers are presented as GMTs and measured by MN assay. MN cut-off = 20 1/DIL.

End point type

Primary

End point timeframe

At Day 1

Notes
[25] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: This outcome was descriptive; hence no statistical analyses were required.

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	44	44	45	46	44	46	45	43	42	41
Units: Titer
geometric mean (confidence interval 95%)	40.6 (29.4 to 56.1)	45.4 (33.4 to 61.6)	45.9 (34.2 to 61.8)	45.8 (34.5 to 60.8)	41.9 (30.7 to 57.3)	45.1 (35.0 to 58.2)	44.6 (34.4 to 57.7)	43.4 (32.4 to 58.0)	42.7 (31.2 to 58.6)	38 (28.8 to 50.2)

No statistical analyses for this end point

Primary: Titers for serum H1 stalk antibodies measured by MN assay – Day 29

Top of page

End point title

Titers for serum H1 stalk antibodies measured by MN assay – Day 29 ^[26]

End point description

Titers are presented as GMTs and measured by MN assay. MN cut-off = 20 1/DIL.

End point type

Primary

End point timeframe

At Day 29

Notes
[26] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: This outcome was descriptive; hence no statistical analyses were required.

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	43	40	40	40	41	42	37	41	39	40
Units: Titer
geometric mean (confidence interval 95%)	100.3 (88.1 to 114.1)	109.3 (94.0 to 127.0)	113.1 (96.5 to 132.6)	105.6 (91.0 to 122.5)	96.4 (83.2 to 111.6)	89.8 (73.0 to 110.5)	86.2 (69.9 to 106.3)	80 (66.6 to 96.1)	74.5 (59.6 to 93.2)	87.2 (75.6 to 100.7)

No statistical analyses for this end point

Primary: Titers for serum H1 stalk antibodies measured by MN assay – Day 85

Top of page

End point title

Titers for serum H1 stalk antibodies measured by MN assay – Day 85 ^[27]

End point description

Titers are presented as GMTs and measured by MN assay. MN cut-off = 20 1/DIL.

End point type

Primary

End point timeframe

At Day 85

Notes
[27] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: This outcome was descriptive; hence no statistical analyses were required.

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	38	36	34	33	39	35	34	34	35	38
Units: Titer
geometric mean (confidence interval 95%)	73 (58.3 to 91.5)	98.9 (81.5 to 119.9)	122.7 (108.9 to 138.3)	59.6 (45.9 to 77.4)	87.4 (71.1 to 107.6)	109.8 (93.0 to 129.8)	55.4 (41.3 to 74.3)	75.3 (56.4 to 100.4)	88.3 (74.2 to 105.2)	86.1 (70.2 to 105.5)

No statistical analyses for this end point

Primary: Percentage of subjects with a ≥ 4-fold increase of anti-H1 stalk antibody concentration measured by ELISA – Day 29

Top of page

End point title

Percentage of subjects with a ≥ 4-fold increase of anti-H1 stalk antibody concentration measured by ELISA – Day 29 ^[28]

End point description

Percentage of subjects with an equal or greater than (≥) 4-fold increase of anti-H1 stalk antibody concentration, from Day 1, is calculated with exact 95% CI by ELISA.

End point type

Primary

End point timeframe

At Day 29, compared to pre-vaccination at Day 1

Notes
[28] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: This outcome was descriptive; hence no statistical analyses were required.

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	43	40	41	40	42	42	37	41	39	40
Units: Percentage of subjects
number (confidence interval 95%)	88.4 (74.9 to 96.1)	60 (43.3 to 75.1)	87.8 (73.8 to 95.9)	70 (53.5 to 83.4)	52.4 (36.4 to 68.0)	83.3 (68.6 to 93.0)	35.1 (20.2 to 52.5)	24.4 (12.4 to 40.3)	38.5 (23.4 to 55.4)	15 (5.7 to 29.8)

No statistical analyses for this end point

Primary: Percentage of subjects with a ≥ 4-fold increase of anti-H1 stalk antibody concentration measured by ELISA – Day 85

Top of page

End point title

Percentage of subjects with a ≥ 4-fold increase of anti-H1 stalk antibody concentration measured by ELISA – Day 85 ^[29]

End point description

Percentage of subjects with a ≥ 4-fold increase of anti-H1 stalk antibody concentration, from Day 1, is calculated with exact 95% CI by ELISA.

End point type

Primary

End point timeframe

At Day 85, compared to pre-vaccination at Day 1

Notes
[29] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: This outcome was descriptive; hence no statistical analyses were required.

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	39	36	34	35	39	35	34	34	35	38
Units: Percentage of subjects
number (confidence interval 95%)	51.3 (34.8 to 67.6)	44.4 (27.9 to 61.9)	79.4 (62.1 to 91.3)	37.1 (21.5 to 55.1)	20.5 (9.3 to 36.5)	80 (63.1 to 91.6)	29.4 (15.1 to 47.5)	8.8 (1.9 to 23.7)	37.1 (21.5 to 55.1)	7.9 (1.7 to 21.4)

No statistical analyses for this end point

Primary: Percentage of subjects with a ≥ 4-fold increase of anti-H1 stalk titer measured by MN assay – Day 29

Top of page

End point title

Percentage of subjects with a ≥ 4-fold increase of anti-H1 stalk titer measured by MN assay – Day 29 ^[30]

End point description

Percentage of subjects with a ≥ 4-fold increase of anti-H1 stalk antibody titer from Day 1, is calculated with exact 95% CI by MN assay.

End point type

Primary

End point timeframe

At Day 29, compared to pre-vaccination at Day 1

Notes
[30] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: This outcome was descriptive; hence no statistical analyses were required.

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	42	38	38	39	38	41	35	38	37	36
Units: Percentage of subjects
number (confidence interval 95%)	40.5 (25.6 to 56.7)	39.5 (24.0 to 56.6)	31.6 (17.5 to 48.7)	41 (25.6 to 57.9)	36.8 (21.8 to 54.0)	31.7 (18.1 to 48.1)	34.3 (19.1 to 52.2)	26.3 (13.4 to 43.1)	29.7 (15.9 to 47.0)	36.1 (20.8 to 53.8)

No statistical analyses for this end point

Primary: Percentage of subjects with a ≥ 4-fold increase of anti-H1 stalk titer measured by MN assay – Day 85

Top of page

End point title

Percentage of subjects with a ≥ 4-fold increase of anti-H1 stalk titer measured by MN assay – Day 85 ^[31]

End point description

Percentage of subjects with a ≥ 4-fold increase of anti-H1 stalk antibody titer from Day 1, is calculated with exact 95% CI by MN assay.

End point type

Primary

End point timeframe

At Day 85, compared to pre-vaccination at Day 1

Notes
[31] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: This outcome was descriptive; hence no statistical analyses were required.

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	37	34	32	33	35	34	33	32	33	34
Units: Percentage of subjects
number (confidence interval 95%)	29.7 (15.9 to 47.0)	38.2 (22.2 to 56.4)	34.4 (18.6 to 53.2)	15.2 (5.1 to 31.9)	31.4 (16.9 to 49.3)	41.2 (24.6 to 59.3)	21.2 (9.0 to 38.9)	18.8 (7.2 to 36.4)	33.3 (18.0 to 51.8)	41.2 (24.6 to 59.3)

No statistical analyses for this end point

Primary: Percentage of subjects with a ≥ 10-fold increase of anti-H1 stalk antibody concentration measured by ELISA – Day 29

Top of page

End point title

Percentage of subjects with a ≥ 10-fold increase of anti-H1 stalk antibody concentration measured by ELISA – Day 29 ^[32]

End point description

Percentage of subjects with a ≥ 10-fold increase of anti-H1 stalk antibody concentration, from Day 1, is calculated with exact 95% CI by ELISA.

End point type

Primary

End point timeframe

At Day 29, compared to pre-vaccination at Day 1

Notes
[32] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: This outcome was descriptive; hence no statistical analyses were required.

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	43	40	41	40	42	42	37	41	39	40
Units: Percentage of subjects
number (confidence interval 95%)	58.1 (42.1 to 73.0)	35 (20.6 to 51.7)	61 (44.5 to 75.8)	30 (16.6 to 46.5)	21.4 (10.3 to 36.8)	42.9 (27.7 to 59.0)	13.5 (4.5 to 28.8)	2.4 (0.1 to 12.9)	15.4 (5.9 to 30.5)	2.5 (0.1 to 13.2)

No statistical analyses for this end point

Primary: Percentage of subjects with a ≥ 10-fold increase of anti-H1 stalk antibody concentration measured by ELISA – Day 85

Top of page

End point title

Percentage of subjects with a ≥ 10-fold increase of anti-H1 stalk antibody concentration measured by ELISA – Day 85 ^[33]

End point description

Percentage of subjects with a ≥ 10-fold increase of anti-H1 stalk antibody concentration, from Day 1, is calculated with exact 95% CI by ELISA.

End point type

Primary

End point timeframe

At Day 85, compared to pre-vaccination at Day 1

Notes
[33] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: This outcome was descriptive; hence no statistical analyses were required.

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	39	36	34	35	39	35	34	34	35	38
Units: Percentage of subjects
number (confidence interval 95%)	12.8 (4.3 to 27.4)	5.6 (0.7 to 18.7)	47.1 (29.8 to 64.9)	17.1 (6.6 to 33.6)	5.1 (0.6 to 17.3)	25.7 (12.5 to 43.3)	17.6 (6.8 to 34.5)	2.9 (0.1 to 15.3)	14.3 (4.8 to 30.3)	5.3 (0.6 to 17.7)

No statistical analyses for this end point

Primary: Percentage of subjects with a ≥ 10-fold increase of anti-H1 stalk titer measured by MN assay – Day 29

Top of page

End point title

Percentage of subjects with a ≥ 10-fold increase of anti-H1 stalk titer measured by MN assay – Day 29 ^[34]

End point description

Percentage of subjects with a ≥ 10-fold increase of anti-H1 stalk antibody titer from Day 1, is calculated with exact 95% CI by MN assay.

End point type

Primary

End point timeframe

At Day 29, compared to pre-vaccination at Day 1

Notes
[34] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: This outcome was descriptive; hence no statistical analyses were required.

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	42	38	38	39	38	41	35	38	37	36
Units: Percentage of subjects
number (confidence interval 95%)	7.1 (1.5 to 19.5)	7.9 (1.7 to 21.4)	10.5 (2.9 to 24.8)	5.1 (0.6 to 17.3)	7.9 (1.7 to 21.4)	4.9 (0.6 to 16.5)	8.6 (1.8 to 23.1)	2.6 (0.1 to 13.8)	2.7 (0.1 to 14.2)	2.8 (0.1 to 14.5)

No statistical analyses for this end point

Primary: Percentage of subjects with a ≥ 10-fold increase of anti-H1 stalk titer measured by MN assay – Day 85

Top of page

End point title

Percentage of subjects with a ≥ 10-fold increase of anti-H1 stalk titer measured by MN assay – Day 85 ^[35]

End point description

Percentage of subjects with a ≥ 10-fold increase of anti-H1 stalk antibody titer from Day 1, is calculated with exact 95% CI by MN assay.

End point type

Primary

End point timeframe

At Day 85, compared to pre-vaccination at Day 1

Notes
[35] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: This outcome was descriptive; hence no statistical analyses were required.

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	37	34	32	33	35	34	33	32	33	34
Units: Percentage of subjects
number (confidence interval 95%)	2.7 (0.1 to 14.2)	8.8 (1.9 to 23.7)	15.6 (5.3 to 32.8)	3 (0.1 to 15.8)	8.6 (1.8 to 23.1)	8.8 (1.9 to 23.7)	0 (0.0 to 10.6)	6.3 (0.8 to 20.8)	3 (0.1 to 15.8)	2.9 (0.1 to 15.3)

No statistical analyses for this end point

Primary: Mean Geometric Increase (MGI) for anti-H1 stalk antibody concentration measured by ELISA – Day 29

Top of page

End point title

Mean Geometric Increase (MGI) for anti-H1 stalk antibody concentration measured by ELISA – Day 29 ^[36]

End point description

MGI is defined as the geometric mean of the fold increase in serum HI concentration post-vaccination compared to Day 1

End point type

Primary

End point timeframe

At Day 29, compared to pre-vaccination at Day 1

Notes
[36] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: This outcome was descriptive; hence no statistical analyses were required.

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	43	40	41	40	42	42	37	41	39	40
Units: Ratio
geometric mean (confidence interval 95%)	12.4 (9.2 to 16.7)	5.9 (4.4 to 8.0)	12.6 (9.2 to 17.1)	6.8 (4.9 to 9.5)	4.7 (3.6 to 6.2)	8.1 (6.2 to 10.5)	4.2 (2.9 to 6.2)	2.3 (1.8 to 3.0)	3.9 (2.8 to 5.4)	2.4 (1.9 to 2.9)

No statistical analyses for this end point

Primary: MGI for anti-H1 stalk antibody concentration measured by ELISA – Day 85

Top of page

End point title

MGI for anti-H1 stalk antibody concentration measured by ELISA – Day 85 ^[37]

End point description

MGI is defined as the geometric mean of the fold increase in serum HI concentration post-vaccination compared to Day 1

End point type

Primary

End point timeframe

At Day 85, compared to pre-vaccination at Day 1

Notes
[37] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: This outcome was descriptive; hence no statistical analyses were required.

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	39	36	34	35	39	35	34	34	35	38
Units: Ratio
geometric mean (confidence interval 95%)	5 (3.9 to 6.5)	3.4 (2.6 to 4.5)	8.1 (6.1 to 10.8)	3.4 (2.4 to 4.9)	2.6 (2.1 to 3.2)	6.3 (5.0 to 7.9)	3.4 (2.3 to 5.0)	1.7 (1.4 to 2.1)	3.8 (2.7 to 5.5)	1.8 (1.5 to 2.3)

No statistical analyses for this end point

Primary: MGI for anti-H1 stalk antibody titer measured by MN assay – Day 29

Top of page

End point title

MGI for anti-H1 stalk antibody titer measured by MN assay – Day 29 ^[38]

End point description

MGI is defined as the geometric mean of the fold increase in serum HI titer post-vaccination compared to Day 1

End point type

Primary

End point timeframe

At Day 29, compared to pre-vaccination at Day 1

Notes
[38] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: This outcome was descriptive; hence no statistical analyses were required.

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	42	38	38	39	38	41	35	38	37	36
Units: Ratio
geometric mean (confidence interval 95%)	2.4 (1.7 to 3.3)	2.6 (1.9 to 3.6)	2.4 (1.8 to 3.3)	2.3 (1.7 to 3.2)	2.3 (1.7 to 3.2)	2 (1.5 to 2.7)	2.3 (1.7 to 3.2)	1.9 (1.4 to 2.5)	1.7 (1.2 to 2.4)	2.2 (1.6 to 3.1)

No statistical analyses for this end point

Primary: MGI for anti-H1 stalk antibody titer measured by MN assay – Day 85

Top of page

End point title

MGI for anti-H1 stalk antibody titer measured by MN assay – Day 85 ^[39]

End point description

MGI is defined as the geometric mean of the fold increase in serum HI titer post-vaccination compared to Day 1

End point type

Primary

End point timeframe

At Day 85, compared to pre-vaccination at Day 1

Notes
[39] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: This outcome was descriptive; hence no statistical analyses were required.

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	37	34	32	33	35	34	33	32	33	34
Units: Ratio
geometric mean (confidence interval 95%)	1.6 (1.2 to 2.2)	2.2 (1.5 to 3.2)	2.5 (1.7 to 3.7)	1.1 (0.8 to 1.6)	2 (1.5 to 2.8)	2.5 (1.7 to 3.5)	1.2 (0.9 to 1.7)	1.6 (1.1 to 2.2)	2 (1.4 to 2.8)	2.4 (1.7 to 3.3)

No statistical analyses for this end point

Secondary: Adjusted GMCs for anti-H1 HA stalk antibody measured by ELISA

Top of page

End point title

Adjusted GMCs for anti-H1 HA stalk antibody measured by ELISA

End point description

The adjusted GMCs are presented to evaluate the adjuvant effect post-dose 1 and post-dose 2.

End point type

Secondary

End point timeframe

28 days post priming dose(s) i.e. at Day 29 for 1 priming dose groups and at Day 85 for 2 priming doses groups

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	43	40	34	40	42	35	37	41	35	40
Units: EL.U/mL
geometric mean (confidence interval 95%)	112206.4 (91362.2 to 137806.3)	47432.6 (38317.4 to 58716.2)	73945.6 (58686.6 to 93172.2)	61356.7 (49582.3 to 75927)	45346.6 (36827 to 55837.2)	50602.8 (40283.4 to 63565.8)	36159.3 (28972.3 to 45129)	20403.5 (16531.4 to 25182.7)	36826.9 (29320 to 46255.8)	21675.2 (17515.2 to 26823.1)

AS03 adjuvant effect for anti-H1 stalk

Statistical analysis description

To evaluate the adjuvant effect of AS03 (Pooling of results at Day 29 of D-SUIV Adjuvant Group 1, at Day 29 of D-SUIV Adjuvant Group 2 and Day 85 of D-SUIV Adjuvant Group 3) on the humoral immune response for anti-H1 stalk antibody by ELISA at Day 29 and Day 85 (i.e. 28 days post-vaccination) when compared to the non-adjuvanted formulations (Pooling of results at Day 29 of D-SUIV Unadjuvanted Group 1, at Day 29 of D-SUIV Unadjuvanted Group 2 and Day 85 of D-SUIV Unadjuvanted Group 3).

Comparison groups

D-SUIV Adjuvanted Group 1 v D-SUIV Unadjuvanted Group 1

Number of subjects included in analysis

Analysis specification

Pre-specified

Analysis type

^[40]

Method

Dunnett’s t test

Parameter type

GMC ratio

Point estimate

2.47

Confidence interval

level

94.46%

sides

2-sided

lower limit

2.06

upper limit

2.95

Notes
[40] - The use of the adjuvant (AS03) is to be considered justified if the lower limit of the 94.46% CI of the GMC ratio (adjuvanted vs non-adjuvanted) is > 1.50

AS01 Adjuvant effect for Anti-H1 stalk

Statistical analysis description

To evaluate the adjuvant effect of AS01 (Pooling of results at Day 29 of D-SUIV Adjuvant Group 4, at Day 29 of D-SUIV Adjuvant Group 5 and Day 85 of D-SUIV Adjuvant Group 6) on the humoral immune response for anti-H1 stalk antibody by ELISA at Day 29 and Day 85 (i.e. 28 days post-vaccination) when compared to the non-adjuvanted formulations (Pooling of results at Day 29 of D-SUIV Unadjuvanted Group 1, at Day 29 of D-SUIV Unadjuvanted Group 2 and Day 85 of D-SUIV Unadjuvanted Group 3).

Comparison groups

D-SUIV Adjuvanted Group 4 v D-SUIV Unadjuvanted Group 1

Number of subjects included in analysis

Analysis specification

Pre-specified

Analysis type

^[41]

Method

Dunnett’s t test

Parameter type

GMC ratio

Point estimate

1.75

Confidence interval

level

94.46%

sides

2-sided

lower limit

1.46

upper limit

2.1

Notes
[41] - The use of the adjuvant (AS01) is to be considered justified if the lower limit of the 94.46% CI of the GMC ratio (adjuvanted vs non-adjuvanted) is > 1.50

Secondary: Concentrations of serum H1 stalk antibodies measured by ELISA– Month 8 to 26

Top of page

End point title

Concentrations of serum H1 stalk antibodies measured by ELISA– Month 8 to 26

End point description

Concentrations are presented as GMCs and measured by ELISA. ELISA cut-off = 66 EL.U/mL.

End point type

Secondary

End point timeframe

At Month 8, Month 14, Month 14 + 28 days, Month 20 and Month 26.

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	39	34	30	27	36	33	30	34	33	34
Units: EL.U/mL
geometric mean (confidence interval 95%)
M8 (N=39;34;30;27;36;33;30;34;33;34)	27068.3 (21884.3 to 33480.4)	17155.9 (13158.7 to 22367.4)	41759.7 (32814.0 to 53144.1)	18915.3 (15026.4 to 23810.7)	15092.4 (12226.1 to 18630.8)	25279.1 (20711.4 to 30854.2)	19028.4 (13706.8 to 26416.0)	11024.8 (8751.5 to 13888.6)	22359.8 (18089.1 to 27638.8)	13142.1 (10306.0 to 16758.7)
M14 (N=35;32;26;26;31;31;25;30;30;31)	22687.1 (18078.5 to 28470.4)	17662.4 (14339.6 to 21755.1)	37282.2 (29437.7 to 47216.9)	20146.8 (15305.9 to 26518.8)	16645.4 (12389.7 to 22362.8)	24615 (19677.5 to 30791.4)	16969.8 (11848.5 to 24304.6)	10820.3 (8524.9 to 13733.9)	22791.5 (17767.3 to 29236.4)	12458.4 (9721.6 to 15965.7)
M14+28 days (N=28;31;23;25;29;29;22;26;27;29)	49594 (39888.4 to 61661.1)	92885.6 (73985.7 to 116613.7)	73078 (62288.9 to 85736.0)	36709.7 (30186.1 to 44643.2)	75155.7 (56729.2 to 99567.4)	52026.4 (42254.7 to 64057.8)	22653.6 (16071.5 to 31931.4)	29508.2 (21062.2 to 41341.1)	38364 (30403.9 to 48408.1)	17593.3 (13932.1 to 22216.6)
M20 (N=29;30;24;24;31;27;20;27;27;25)	27648.6 (22712.3 to 33657.7)	36133.6 (29063.7 to 44923.2)	38120.3 (30433.7 to 47748.2)	21916.1 (17219.1 to 27894.4)	31396.4 (24953.9 to 39502.2)	29988.8 (24033.9 to 37419.1)	18408.1 (12608.3 to 26875.7)	16632.9 (12484.8 to 22159.2)	23145.3 (18447.2 to 29039.9)	12635.2 (9489.2 to 16824.1)
M26 (N=29;29;22;21;25;25;20;25;25;23)	22850.2 (18790.0 to 27787.8)	29027.2 (23343.2 to 36095.3)	32635.4 (26013.9 to 40942.3)	18266 (14093.9 to 23673.1)	27491.3 (20448.3 to 36960.2)	25059.4 (19893.4 to 31567.0)	18220.9 (12067.9 to 27511.0)	14269 (10104.9 to 20149.0)	21673.7 (17482.9 to 26869.2)	12050.6 (8943.4 to 16237.5)

No statistical analyses for this end point

Secondary: Number of seropositive subjects for anti-H1 stalk antibodies measured by ELISA– Month 8 to 26

Top of page

End point title

Number of seropositive subjects for anti-H1 stalk antibodies measured by ELISA– Month 8 to 26

End point description

Anti-H1 stalk immune response measured by ELISA. A seropositive subject is a subject whose concentration is greater than or equal to the cut-off value: ELISA cut-off = 66 EL.U/mL.

End point type

Secondary

End point timeframe

At Month 8, Month 14, Month 14 + 28 days, Month 20 and Month 26.

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	39	34	30	27	36	33	30	34	33	34
Units: Participants
M8 (N=39;34;30;27;36;33;30;34;33;34)	39	34	30	27	36	33	30	34	33	34
M14 (N=35;32;26;26;31;31;25;30;30;31)	35	32	26	26	31	31	25	30	30	31
M14+28 days (N=28;31;23;25;29;29;22;26;27;29)	28	31	23	25	29	29	22	26	27	29
M20 (N=29;30;24;24;31;27;20;27;27;25)	29	30	24	24	31	27	20	27	27	25
M26 (N=29;29;22;21;25;25;20;25;25;23)	29	29	22	21	25	25	20	25	25	23

No statistical analyses for this end point

Secondary: Percentage of subjects with a ≥ 4-fold increase of anti-H1 stalk antibody concentration, measured by ELISA – Month 8 to 26.

Top of page

End point title

Percentage of subjects with a ≥ 4-fold increase of anti-H1 stalk antibody concentration, measured by ELISA – Month 8 to 26.

End point description

Percentage of subjects with a ≥ 4-fold increase of anti-H1 stalk antibody concentration, from Day 1, is calculated with exact 95% CI by ELISA.

End point type

Secondary

End point timeframe

At Month 8, Month 14, Month 14 + 28 days, Month 20 and Month 26, compared to Day 1

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	39	34	30	27	36	33	30	34	33	34
Units: Percentage of subjects
number (confidence interval 95%)
M8 (N=39;34;30;27;36;33;30;34;33;34)	23.1 (11.1 to 39.3)	23.5 (10.7 to 41.2)	53.3 (34.3 to 71.7)	14.8 (4.2 to 33.7)	5.6 (0.7 to 18.7)	39.4 (22.9 to 57.9)	23.3 (9.9 to 42.3)	8.8 (1.9 to 23.7)	21.2 (9.0 to 38.9)	0 (0.0 to 10.3)
M14 (N=35;32;26;26;31;31;25;30;30;31)	20 (8.4 to 36.9)	25 (11.5 to 43.4)	50 (29.9 to 70.1)	30.8 (14.3 to 51.8)	9.7 (2.0 to 25.8)	38.7 (21.8 to 57.8)	12 (2.5 to 31.2)	3.3 (0.1 to 17.2)	13.3 (3.8 to 30.7)	0 (0.0 to 11.2)
M14+28 days (N=28;31;23;25;29;29;22;26;27;29)	46.4 (27.5 to 66.1)	83.9 (66.3 to 94.5)	82.6 (61.2 to 95.0)	44 (24.4 to 65.1)	69 (49.2 to 84.7)	75.9 (56.5 to 89.7)	22.7 (7.8 to 45.4)	38.5 (20.2 to 59.4)	33.3 (16.5 to 54.0)	10.3 (2.2 to 27.4)
M20 (N=29;30;24;24;31;27;20;27;27;25)	27.6 (12.7 to 47.2)	60 (40.6 to 77.3)	50 (29.1 to 70.9)	33.3 (15.6 to 55.3)	38.7 (21.8 to 57.8)	48.1 (28.7 to 68.1)	20 (5.7 to 43.7)	11.1 (2.4 to 29.2)	25.9 (11.1 to 46.3)	0 (0.0 to 13.7)
M26 (N=29;29;22;21;25;25;20;25;25;23)	20.7 (8.0 to 39.7)	41.4 (23.5 to 61.1)	36.4 (17.2 to 59.3)	28.6 (11.3 to 52.2)	32 (14.9 to 53.5)	36 (18.0 to 57.5)	15 (3.2 to 37.9)	8 (1.0 to 26.0)	24 (9.4 to 45.1)	0 (0.0 to 14.8)

No statistical analyses for this end point

Secondary: Percentage of subjects with a ≥ 10-fold increase of anti-H1 stalk antibody concentration, measured by ELISA – Month 8 to 26.

Top of page

End point title

Percentage of subjects with a ≥ 10-fold increase of anti-H1 stalk antibody concentration, measured by ELISA – Month 8 to 26.

End point description

Percentage of subjects with a ≥ 10-fold increase of anti-H1 stalk antibody concentration, from Day 1, is calculated with exact 95% CI by ELISA.

End point type

Secondary

End point timeframe

At Month 8, Month 14, Month 14 + 28 days, Month 20 and Month 26, compared to Day 1

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	39	34	30	27	36	33	30	34	33	34
Units: Percentage of subjects
number (confidence interval 95%)
M8 (N=39;34;30;27;36;33;30;34;33;34)	7.7 (1.6 to 20.9)	0 (0.0 to 10.3)	23.3 (9.9 to 42.3)	7.4 (0.9 to 24.3)	0 (0.0 to 9.7)	9.1 (1.9 to 24.3)	10 (2.1 to 26.5)	0 (0.0 to 10.3)	9.1 (1.9 to 24.3)	0 (0.0 to 10.3)
M14 (N=35;32;26;26;31;31;25;30;30;31)	5.7 (0.7 to 19.2)	3.1 (0.1 to 16.2)	30.8 (14.3 to 51.8)	3.8 (0.1 to 19.6)	3.2 (0.1 to 16.7)	3.2 (0.1 to 16.7)	4 (0.1 to 20.4)	0 (0.0 to 11.6)	10 (2.1 to 26.5)	0 (0.0 to 11.2)
M14+28 days (N=28;31;23;25;29;29;22;26;27;29)	17.9 (6.1 to 36.9)	58.1 (39.1 to 75.5)	52.2 (30.6 to 73.2)	24 (9.4 to 45.1)	37.9 (20.7 to 57.7)	34.5 (17.9 to 54.3)	4.5 (0.1 to 22.8)	11.5 (2.4 to 30.2)	18.5 (6.3 to 38.1)	0 (0.0 to 11.9)
M20 (N=29;30;24;24;31;27;20;27;27;25)	10.3 (2.2 to 27.4)	26.7 (12.3 to 45.9)	16.7 (4.7 to 37.4)	8.3 (1.0 to 27.0)	9.7 (2.0 to 25.8)	11.1 (2.4 to 29.2)	5 (0.1 to 24.9)	3.7 (0.1 to 19.0)	11.1 (2.4 to 29.2)	0 (0.0 to 13.7)
M26 (N=29;29;22;21;25;25;20;25;25;23)	3.4 (0.1 to 17.8)	13.8 (3.9 to 31.7)	4.5 (0.1 to 22.8)	4.8 (0.1 to 23.8)	4 (0.1 to 20.4)	12 (2.5 to 31.2)	10 (1.2 to 31.7)	4 (0.1 to 20.4)	12 (2.5 to 31.2)	0 (0.0 to 14.8)

No statistical analyses for this end point

Secondary: MGI for anti-H1 stalk antibody measured by ELISA – Month 8 to 26

Top of page

End point title

MGI for anti-H1 stalk antibody measured by ELISA – Month 8 to 26

End point description

MGI is defined as the geometric mean of the fold increase in serum HI concentration post-vaccination compared to Day 1

End point type

Secondary

End point timeframe

At Month 8, Month 14, Month 14 + 28 days, Month 20 and Month 26, compared to Day 1

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	39	34	30	27	36	33	30	34	33	34
Units: Ratio
geometric mean (confidence interval 95%)
M8 (N=39;34;30;27;36;33;30;34;33;34)	2.9 (2.2 to 3.7)	2.3 (1.8 to 2.9)	4.7 (3.5 to 6.3)	2 (1.4 to 2.8)	1.4 (1.2 to 1.8)	3.3 (2.6 to 4.3)	2.2 (1.5 to 3.1)	1.3 (1.1 to 1.7)	2.4 (1.7 to 3.3)	1.3 (1.1 to 1.5)
M14 (N=35;32;26;26;31;31;25;30;30;31)	2.5 (2.0 to 3.2)	2.4 (1.8 to 3.2)	4.7 (3.2 to 6.8)	2.3 (1.7 to 3.2)	1.6 (1.2 to 2.1)	3.2 (2.5 to 4.2)	2 (1.4 to 2.8)	1.2 (1.0 to 1.5)	2.1 (1.4 to 3.1)	1.2 (1.0 to 1.4)
M14+28 days (N=28;31;23;25;29;29;22;26;27;29)	5.3 (3.7 to 7.7)	12.6 (8.7 to 18.2)	9.5 (6.6 to 13.6)	4.3 (3.0 to 6.4)	7.3 (5.0 to 10.7)	7.1 (5.3 to 9.5)	2.7 (2.0 to 3.8)	3.4 (2.3 to 5.0)	4.1 (2.6 to 6.3)	1.7 (1.3 to 2.2)
M20 (N=29;30;24;24;31;27;20;27;27;25)	3 (2.3 to 3.8)	4.9 (3.5 to 6.8)	4.6 (3.3 to 6.3)	2.6 (1.8 to 3.8)	3.1 (2.3 to 4.1)	4 (3.0 to 5.3)	2.2 (1.5 to 3.2)	1.8 (1.4 to 2.3)	2.5 (1.7 to 3.6)	1.3 (1.1 to 1.6)
M26 (N=29;29;22;21;25;25;20;25;25;23)	2.7 (2.0 to 3.5)	3.7 (2.7 to 5.2)	3.7 (2.7 to 5.2)	2.3 (1.5 to 3.6)	2.6 (1.9 to 3.7)	3.3 (2.4 to 4.4)	2.1 (1.4 to 3.3)	1.5 (1.1 to 2.1)	2.2 (1.5 to 3.3)	1.3 (1.1 to 1.6)

No statistical analyses for this end point

Secondary: Concentrations of anti-H2 and anti-H18 antibodies measured by ELISA

Top of page

End point title

Concentrations of anti-H2 and anti-H18 antibodies measured by ELISA

End point description

Concentrations are presented as GMCs and measured by ELISA. ELISA cut-off = 22 EL.U/mL (H2) and 43 EL.U/mL (H18).

End point type

Secondary

End point timeframe

At Days 1, 29, 85, Month 8, Month 14, Month 14 + 28 days, Month 20 and Month 26

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	45	46	47	47	48	47	47	46	44	45
Units: EL.U/mL
geometric mean (confidence interval 95%)
Anti-H2, Day 1 (N=45;46;47;47;48;47;47;46;44;45)	5848.2 (4577.0 to 7472.5)	5975.5 (4615.6 to 7736.1)	6882.1 (5488.8 to 8629.2)	5968.7 (4723.0 to 7542.9)	6704 (5329.0 to 8433.8)	5513.6 (4551.7 to 6678.7)	6042.3 (4790.1 to 7622.0)	5917.2 (4681.7 to 7478.9)	6320.1 (4858.6 to 8221.2)	5512.2 (4373.1 to 6948.0)
Anti-H2, Day 29 (N=43;40;41;40;42;42;37;41;39;40)	111973.1 (90350.2 to 138770.8)	28538 (22181.5 to 36716.0)	115020.5 (93922.9 to 140857.1)	59190.1 (46420.7 to 75472.2)	30980 (25025.9 to 38350.8)	64182.7 (50875.4 to 80970.8)	30976.4 (20643.7 to 46481.0)	12700 (10182.5 to 15839.8)	33198.1 (25465.3 to 43279.1)	10941.3 (8962.2 to 13357.5)
Anti-H2, Day 85 (N=39;36;34;35;39;35;34;34;35;38)	42295.4 (34505.4 to 51844.2)	18172.7 (13948.3 to 23676.6)	60609.1 (47899.9 to 76690.5)	26581.4 (19839.5 to 35614.4)	16519.5 (13127.6 to 20787.9)	39576.4 (31245.9 to 50128.0)	23576.8 (15654.3 to 35508.7)	9640.8 (7382.5 to 12590.1)	29437.8 (22555.8 to 38419.7)	8939.2 (7063.2 to 11313.4)
Anti-H2, M8 (N=39;34;30;27;36;33;30;34;33;34)	29904.9 (24015.3 to 37238.9)	12923.2 (9816.8 to 17012.6)	38258.4 (29536.3 to 49556.3)	18259.9 (13789.8 to 24179.0)	12402.4 (9535.4 to 16131.4)	24555.6 (19235.1 to 31347.7)	19264.5 (13044.6 to 28450.1)	8229 (6456.6 to 10488.1)	22379.6 (17763.5 to 28195.2)	9409 (7202.0 to 12292.4)
Anti-H2, M14 (N=35;32;26;26;31;31;25;30;30;31)	21754.4 (17375.9 to 27236.2)	11417.4 (8969.1 to 14534.0)	30670.3 (23748.7 to 39609.2)	17100.4 (12454.3 to 23479.8)	10899.7 (8122.1 to 14627.2)	19573.6 (14935.3 to 25652.3)	15050.2 (9969.1 to 22721.0)	7717.7 (5839.8 to 10199.6)	21978.5 (17171.0 to 28132.1)	8582.5 (6443.9 to 11430.8)
Anti-H2, M14+28d(N=28;31;23;25;29;29;22;26;27;29)	36459.1 (29419.5 to 45183.3)	91778 (73053.9 to 115301.3)	76909.5 (63594.4 to 93012.4)	27256.3 (20573.9 to 36109.3)	81616.2 (64374.2 to 103476.4)	58542.1 (47219.6 to 72579.5)	19172.9 (12543.2 to 29306.6)	29940.3 (20765.3 to 43169.3)	41953 (34398.2 to 51167.0)	11753.1 (9023.9 to 15307.8)
Anti-H2, M20 (N=29;30;24;24;31;27;20;27;27;25)	24198.7 (19291.6 to 30353.9)	34266 (26622.0 to 44104.8)	36950 (29306.1 to 46587.6)	19456.7 (14167.4 to 26720.7)	32287.4 (25257.3 to 41274.2)	28818 (22130.7 to 37525.9)	14269 (9295.0 to 21905.0)	15780.8 (11287.6 to 22062.7)	25006.7 (19478.3 to 32104.2)	7961.8 (5712.7 to 11096.2)
Anti-H2, M26 (N=29;29;22;21;25;25;20;25;25;23)	20136.5 (16257.6 to 24940.8)	27000.7 (21059.5 to 34617.9)	29403.8 (22530.7 to 38373.5)	15358.6 (11070.7 to 21307.3)	27477.2 (20295.7 to 37199.7)	22917.6 (17205.8 to 30525.6)	14906.4 (9433.3 to 23554.9)	13186.7 (9162.6 to 18978.2)	23570.6 (18496.4 to 30036.9)	7708.3 (5593.3 to 10623.1)
Anti-H18, Day 1 (N=45;46;46;47;48;47;47;46;44;45)	4936.1 (3878.3 to 6282.3)	4845.1 (3641.3 to 6446.9)	5936.9 (4557.4 to 7734.1)	5299.3 (4197.0 to 6691.1)	5368.1 (4259.0 to 6766.0)	4651.7 (3734.8 to 5793.7)	4991.2 (4039.5 to 6167.0)	5543.3 (4394.6 to 6992.4)	5399.2 (4075.9 to 7152.3)	5681.1 (4327.4 to 7458.4)
Anti-H18, Day 29 (N=43;40;41;40;42;42;37;41;39;40)	26663.7 (21555.9 to 32981.8)	19762.5 (15199.9 to 25694.6)	30387.7 (25266.3 to 36547.2)	19951 (16410.4 to 24255.6)	21416.3 (17539.0 to 26150.8)	19348 (16009.2 to 23383.0)	13383.5 (9734.9 to 18399.5)	10899.9 (8829.7 to 13455.5)	14152.1 (11530.1 to 17370.3)	11675.5 (9209.8 to 14801.4)
Anti-H18, Day 85 (N=39;36;34;35;39;35;34;34;35;38)	13071 (10618.2 to 16090.3)	13472.1 (10474.3 to 17327.9)	27305.6 (22369.5 to 33330.8)	10270.7 (8541.1 to 12350.5)	12017.1 (9474.7 to 15241.8)	17205.7 (14796.1 to 20007.7)	10062.6 (7439.9 to 13610.1)	8762.3 (6910.2 to 11110.9)	15219.4 (12301.2 to 18829.9)	9136.2 (6966.1 to 11982.3)
Anti-H18, M8 (N=39;34;30;27;36;33;30;34;33;34)	11992.9 (9665.8 to 14880.2)	10240.6 (7932.7 to 13220.0)	18529.9 (15273.7 to 22480.4)	10260.8 (8094.5 to 13006.8)	9973.8 (7709.1 to 12903.9)	12753.8 (10434.4 to 15588.8)	9988.8 (7297.7 to 13672.3)	8182.1 (6517.6 to 10271.7)	12617.3 (10198.5 to 15609.8)	9590.3 (7160.5 to 12844.6)
Anti-H18, M14 (N=35;32;26;26;31;31;25;30;30;31)	9039.6 (7212.3 to 11329.9)	8610.3 (6938.0 to 10685.6)	14078.6 (11455.9 to 17301.7)	8820.4 (6959.4 to 11179.1)	8370.2 (6213.2 to 11276.0)	10216.5 (8035.8 to 12989.1)	8526.2 (6047.8 to 12020.2)	6955.8 (5553.1 to 8713.0)	11876.7 (9622.1 to 14659.6)	8178.4 (6007.8 to 11133.2)
Anti-H18, M14+28d(N=28;31;23;25;29;29;22;26;27;29)	19763.3 (15225.3 to 25653.9)	26567.6 (21331.9 to 33088.4)	20291 (17142.5 to 24017.8)	15768 (12672.2 to 19620.0)	24020.6 (19157.0 to 30118.9)	15872.3 (12888.2 to 19547.3)	11742.6 (8553.4 to 16120.9)	12543.5 (9593.4 to 16400.7)	14564 (12163.0 to 17439.0)	10758.1 (8190.4 to 14130.7)
Anti-H18, M20 (N=29;30;24;24;31;27;20;27;27;25)	12192 (9446.1 to 15736.1)	14228.2 (11276.5 to 17952.5)	13068.8 (10894.9 to 15676.5)	10503.1 (8169.3 to 13503.6)	12541.2 (9836.1 to 15990.2)	10695.2 (8464.7 to 13513.5)	9695.4 (6545.1 to 14362.2)	8934.7 (6832.5 to 11683.6)	12302.2 (9853.6 to 15359.2)	7764.5 (5518.3 to 10925.1)
Anti-H18, M26 (N=29;29;22;21;25;25;20;25;25;23)	10832.8 (8488.3 to 13825.0)	11823.4 (9575.2 to 14599.4)	12186.4 (9948.2 to 14928.2)	9767.9 (7407.6 to 12880.1)	11445.8 (8371.9 to 15648.3)	9308.8 (7285.1 to 11894.6)	10283.6 (6627.6 to 15956.4)	7937 (5903.9 to 10670.1)	11617.9 (8948.6 to 15083.3)	7646.4 (5326.5 to 10976.9)

No statistical analyses for this end point

Secondary: Number of seropositive subjects for anti-H2 and anti-H18 antibodies measured by ELISA

Top of page

End point title

Number of seropositive subjects for anti-H2 and anti-H18 antibodies measured by ELISA

End point description

Anti-H2 and anti-H18 immune response measured by ELISA. A seropositive subject is a subject whose concentration is greater than or equal to the cut-off value: ELISA cut-off = 22 EL.U/mL (H2) and 43 EL.U/mL (H18).

End point type

Secondary

End point timeframe

At Days 1, 29, 85, Month 8, Month 14, Month 14 + 28 days, Month 20 and Month 26

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	45	46	47	47	48	47	47	46	44	45
Units: Participants
Anti-H2, Day 1 (N=45;46;47;47;48;47;47;46;44;45)	45	46	47	47	48	47	47	46	44	45
Anti-H2, Day 29 (N=43;40;41;40;42;42;37;41;39;40)	43	40	41	40	42	42	37	41	39	40
Anti-H2, Day 85 (N=39;36;34;35;39;35;34;34;35;38)	39	36	34	35	39	35	34	34	35	38
Anti-H2, M8 (N=39;34;30;27;36;33;30;34;33;34)	39	34	30	27	36	33	30	34	33	34
Anti-H2, M14 (N=35;32;26;26;31;31;25;30;30;31)	35	32	26	26	31	31	25	30	30	31
Anti-H2, M14+28d(N=28;31;23;25;29;29;22;26;27;29)	28	31	23	25	29	29	22	26	27	29
Anti-H2, M20 (N=29;30;24;24;31;27;20;27;27;25)	29	30	24	24	31	27	20	27	27	25
Anti-H2, M26 (N=29;29;22;21;25;25;20;25;25;23)	29	29	22	21	25	25	20	25	25	23
Anti-H18, Day 1 (N=45;46;46;47;48;47;47;46;44;45)	45	46	46	47	48	47	47	46	44	45
Anti-H18, Day 29 (N=43;40;41;40;42;42;37;41;39;40)	43	40	41	40	42	42	37	41	39	40
Anti-H18, Day 85 (N=39;36;34;35;39;35;34;34;35;38)	39	36	34	35	39	35	34	34	35	38
Anti-H18, M8 (N=39;34;30;27;36;33;30;34;33;34)	39	34	30	27	36	33	30	34	33	34
Anti-H18, M14 (N=35;32;26;26;31;31;25;30;30;31)	35	32	26	26	31	31	25	30	30	31
Anti-H18, M14+28d(N=28;31;23;25;29;29;22;26;27;29)	28	31	23	25	29	29	22	26	27	29
Anti-H18, M20 (N=29;30;24;24;31;27;20;27;27;25)	29	30	24	24	31	27	20	27	27	25
Anti-H18, M26 (N=29;29;22;21;25;25;20;25;25;23)	29	29	22	21	25	25	20	25	25	23

No statistical analyses for this end point

Secondary: Percentage of subjects with a ≥ 4-fold increase of anti-H2 and anti-H18 antibody concentration measured by ELISA

Top of page

End point title

Percentage of subjects with a ≥ 4-fold increase of anti-H2 and anti-H18 antibody concentration measured by ELISA

End point description

Percentage of subjects with a ≥ 4-fold increase of anti-H2 and anti-H18 antibody concentration, from Day 1, is calculated with exact 95% CI by ELISA .

End point type

Secondary

End point timeframe

At Day 29, at Day 85, Month 8, Month 14, Month 14 + 28 days, Month 20 and Month 26, compared to Day 1

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	43	40	41	40	42	42	37	41	39	40
Units: Percentage of subjects
number (confidence interval 95%)
Anti-H2, Day 29 (N=43;40;41;40;42;42;37;41;39;40)	95.3 (84.2 to 99.4)	62.5 (45.8 to 77.3)	92.7 (80.1 to 98.5)	82.5 (67.2 to 92.7)	57.1 (41.0 to 72.3)	90.5 (77.4 to 97.3)	62.2 (44.8 to 77.5)	26.8 (14.2 to 42.9)	48.7 (32.4 to 65.2)	12.5 (4.2 to 26.8)
Anti-H2, Day 85 (N=39;36;34;35;39;35;34;34;35;38)	66.7 (49.8 to 80.9)	36.1 (20.8 to 53.8)	79.4 (62.1 to 91.3)	45.7 (28.8 to 63.4)	17.9 (7.5 to 33.5)	77.1 (59.9 to 89.6)	35.3 (19.7 to 53.5)	2.9 (0.1 to 15.3)	42.9 (26.3 to 60.6)	5.3 (0.6 to 17.7)
Anti-H2, M8 (N=39;34;30;27;36;33;30;34;33;34)	51.3 (34.8 to 67.6)	23.5 (10.7 to 41.2)	73.3 (54.1 to 87.7)	29.6 (13.8 to 50.2)	8.3 (1.8 to 22.5)	69.7 (51.3 to 84.4)	26.7 (12.3 to 45.9)	5.9 (0.7 to 19.7)	33.3 (18.0 to 51.8)	0 (0.0 to 10.3)
Anti-H2, M14 (N=35;32;26;26;31;31;25;30;30;31)	34.3 (19.1 to 52.2)	15.6 (5.3 to 32.8)	61.5 (40.6 to 79.8)	30.8 (14.3 to 51.8)	6.5 (0.8 to 21.4)	58.1 (39.1 to 75.5)	16 (4.5 to 36.1)	3.3 (0.1 to 17.2)	23.3 (9.9 to 42.3)	0 (0.0 to 11.2)
Anti-H2, M14+28d(N=28;31;23;25;29;29;22;26;27;29)	57.1 (37.2 to 75.5)	100 (88.8 to 100.0)	100 (85.2 to 100.0)	52 (31.3 to 72.2)	82.8 (64.2 to 94.2)	96.6 (82.2 to 99.9)	36.4 (17.2 to 59.3)	50 (29.9 to 70.1)	63 (42.4 to 80.6)	6.9 (0.8 to 22.8)
Anti-H2, M20 (N=29;30;24;24;31;27;20;27;27;25)	41.4 (23.5 to 61.1)	70 (50.6 to 85.3)	75 (53.3 to 90.2)	41.7 (22.1 to 63.4)	54.8 (36.0 to 72.7)	74.1 (53.7 to 88.9)	20 (5.7 to 43.7)	18.5 (6.3 to 38.1)	37 (19.4 to 57.6)	4 (0.1 to 20.4)
Anti-H2, M26 (N=29;29;22;21;25;25;20;25;25;23)	41.4 (23.5 to 61.1)	62.1 (42.3 to 79.3)	54.5 (32.2 to 75.6)	38.1 (18.1 to 61.6)	48 (27.8 to 68.7)	56 (34.9 to 75.6)	20 (5.7 to 43.7)	16 (4.5 to 36.1)	32 (14.9 to 53.5)	4.3 (0.1 to 21.9)
Anti-H18, Day 29 (N=43;40;40;40;42;42;37;41;39;40)	55.8 (39.9 to 70.9)	52.5 (36.1 to 68.5)	50 (33.8 to 66.2)	40 (24.9 to 56.7)	45.2 (29.8 to 61.3)	52.4 (36.4 to 68.0)	21.6 (9.8 to 38.2)	19.5 (8.8 to 34.9)	20.5 (9.3 to 36.5)	15 (5.7 to 29.8)
Anti-H18, Day 85 (N=39;36;33;35;39;35;34;34;35;38)	17.9 (7.5 to 33.5)	33.3 (18.6 to 51.0)	48.5 (30.8 to 66.5)	14.3 (4.8 to 30.3)	20.5 (9.3 to 36.5)	48.6 (31.4 to 66.0)	14.7 (5.0 to 31.1)	5.9 (0.7 to 19.7)	25.7 (12.5 to 43.3)	5.3 (0.6 to 17.7)
Anti-H18, M8 (N=39;34;29;27;36;33;30;34;33;34)	12.8 (4.3 to 27.4)	20.6 (8.7 to 37.9)	44.8 (26.4 to 64.3)	11.1 (2.4 to 29.2)	11.1 (3.1 to 26.1)	39.4 (22.9 to 57.9)	16.7 (5.6 to 34.7)	11.8 (3.3 to 27.5)	24.2 (11.1 to 42.3)	0 (0.0 to 10.3)
Anti-H18, M14 (N=35;32;25;26;31;31;25;30;30;31)	8.6 (1.8 to 23.1)	21.9 (9.3 to 40.0)	36 (18.0 to 57.5)	11.5 (2.4 to 30.2)	6.5 (0.8 to 21.4)	29 (14.2 to 48.0)	8 (1.0 to 26.0)	3.3 (0.1 to 17.2)	13.3 (3.8 to 30.7)	0 (0.0 to 11.2)
Anti-H18, M14+28d(N=28;31;22;25;29;29;22;26;27;29)	35.7 (18.6 to 55.9)	71 (52.0 to 85.8)	54.5 (32.2 to 75.6)	36 (18.0 to 57.5)	55.2 (35.7 to 73.6)	55.2 (35.7 to 73.6)	18.2 (5.2 to 40.3)	15.4 (4.4 to 34.9)	25.9 (11.1 to 46.3)	6.9 (0.8 to 22.8)
Anti-H18, M20 (N=29;30;23;24;31;27;20;27;27;25)	20.7 (8.0 to 39.7)	40 (22.7 to 59.4)	30.4 (13.2 to 52.9)	20.8 (7.1 to 42.2)	19.4 (7.5 to 37.5)	29.6 (13.8 to 50.2)	5 (0.1 to 24.9)	7.4 (0.9 to 24.3)	11.1 (2.4 to 29.2)	4 (0.1 to 20.4)
Anti-H18, M26 (N=29;29;21;21;25;25;20;25;25;23)	24.1 (10.3 to 43.5)	31 (15.3 to 50.8)	28.6 (11.3 to 52.2)	23.8 (8.2 to 47.2)	20 (6.8 to 40.7)	12 (2.5 to 31.2)	10 (1.2 to 31.7)	8 (1.0 to 26.0)	12 (2.5 to 31.2)	0 (0.0 to 14.8)

No statistical analyses for this end point

Secondary: Percentage of subjects with a ≥ 10-fold increase of anti-H2 and anti-H18 antibody concentration measured by ELISA

Top of page

End point title

Percentage of subjects with a ≥ 10-fold increase of anti-H2 and anti-H18 antibody concentration measured by ELISA

End point description

Percentage of subjects with a ≥ 10-fold increase of anti-H2 and anti-H18 antibody concentration, from Day 1, is calculated with exact 95% CI by ELISA .

End point type

Secondary

End point timeframe

At Day 29, at Day 85, Month 8, Month 14, Month 14 + 28 days, Month 20 and Month 26, compared to Day 1

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	43	40	41	40	42	42	37	41	39	40
Units: Percentage of subjects
number (confidence interval 95%)
Anti-H2, Day 29 (N=43;40;41;40;42;42;37;41;39;40)	67.4 (51.5 to 80.9)	15 (5.7 to 29.8)	68.3 (51.9 to 81.9)	42.5 (27.0 to 59.1)	16.7 (7.0 to 31.4)	61.9 (45.6 to 76.4)	18.9 (8.0 to 35.2)	2.4 (0.1 to 12.9)	20.5 (9.3 to 36.5)	2.5 (0.1 to 13.2)
Anti-H2, Day 85 (N=39;36;34;35;39;35;34;34;35;38)	25.6 (13.0 to 42.1)	5.6 (0.7 to 18.7)	55.9 (37.9 to 72.8)	22.9 (10.4 to 40.1)	2.6 (0.1 to 13.5)	48.6 (31.4 to 66.0)	20.6 (8.7 to 37.9)	2.9 (0.1 to 15.3)	17.1 (6.6 to 33.6)	5.3 (0.6 to 17.7)
Anti-H2, M8 (N=39;34;30;27;36;33;30;34;33;34)	15.4 (5.9 to 30.5)	0 (0.0 to 10.3)	26.7 (12.3 to 45.9)	11.1 (2.4 to 29.2)	0 (0.0 to 9.7)	12.1 (3.4 to 28.2)	16.7 (5.6 to 34.7)	0 (0.0 to 10.3)	15.2 (5.1 to 31.9)	0 (0.0 to 10.3)
Anti-H2, M14 (N=35;32;26;26;31;31;25;30;30;31)	14.3 (4.8 to 30.3)	0 (0.0 to 10.9)	23.1 (9.0 to 43.6)	11.5 (2.4 to 30.2)	0 (0.0 to 11.2)	6.5 (0.8 to 21.4)	8 (1.0 to 26.0)	0 (0.0 to 11.6)	10 (2.1 to 26.5)	0 (0.0 to 11.2)
Anti-H2, M14+28d(N=28;31;23;25;29;29;22;26;27;29)	25 (10.7 to 44.9)	71 (52.0 to 85.8)	65.2 (42.7 to 83.6)	24 (9.4 to 45.1)	48.3 (29.4 to 67.5)	65.5 (45.7 to 82.1)	9.1 (1.1 to 29.2)	15.4 (4.4 to 34.9)	22.2 (8.6 to 42.3)	3.4 (0.1 to 17.8)
Anti-H2, M20 (N=29;30;24;24;31;27;20;27;27;25)	13.8 (3.9 to 31.7)	23.3 (9.9 to 42.3)	25 (9.8 to 46.7)	20.8 (7.1 to 42.2)	25.8 (11.9 to 44.6)	22.2 (8.6 to 42.3)	5 (0.1 to 24.9)	7.4 (0.9 to 24.3)	11.1 (2.4 to 29.2)	0 (0.0 to 13.7)
Anti-H2, M26 (N=29;29;22;21;25;25;20;25;25;23)	13.8 (3.9 to 31.7)	13.8 (3.9 to 31.7)	18.2 (5.2 to 40.3)	9.5 (1.2 to 30.4)	24 (9.4 to 45.1)	12 (2.5 to 31.2)	10 (1.2 to 31.7)	8 (1.0 to 26.0)	12 (2.5 to 31.2)	0 (0.0 to 14.8)
Anti-H18, Day 29 (N=43;40;40;40;42;42;37;41;39;40)	23.3 (11.8 to 38.6)	15 (5.7 to 29.8)	25 (12.7 to 41.2)	12.5 (4.2 to 26.8)	16.7 (7.0 to 31.4)	16.7 (7.0 to 31.4)	8.1 (1.7 to 21.9)	2.4 (0.1 to 12.9)	7.7 (1.6 to 20.9)	2.5 (0.1 to 13.2)
Anti-H18, Day 85 (N=39;36;33;35;39;35;34;34;35;38)	7.7 (1.6 to 20.9)	2.8 (0.1 to 14.5)	24.2 (11.1 to 42.3)	5.7 (0.7 to 19.2)	2.6 (0.1 to 13.5)	5.7 (0.7 to 19.2)	2.9 (0.1 to 15.3)	2.9 (0.1 to 15.3)	11.4 (3.2 to 26.7)	5.3 (0.6 to 17.7)
Anti-H18, M8 (N=39;34;29;27;36;33;30;34;33;34)	2.6 (0.1 to 13.5)	0 (0.0 to 10.3)	6.9 (0.8 to 22.8)	3.7 (0.1 to 19.0)	0 (0.0 to 9.7)	3 (0.1 to 15.8)	6.7 (0.8 to 22.1)	2.9 (0.1 to 15.3)	9.1 (1.9 to 24.3)	0 (0.0 to 10.3)
Anti-H18, M14 (N=35;32;25;26;31;31;25;30;30;31)	0 (0.0 to 10.0)	0 (0.0 to 10.9)	12 (2.5 to 31.2)	3.8 (0.1 to 19.6)	0 (0.0 to 11.2)	0 (0.0 to 11.2)	4 (0.1 to 20.4)	0 (0.0 to 11.6)	10 (2.1 to 26.5)	0 (0.0 to 11.2)
Anti-H18, M14+28d(N=28;31;22;25;29;29;22;26;27;29)	17.9 (6.1 to 36.9)	25.8 (11.9 to 44.6)	18.2 (5.2 to 40.3)	12 (2.5 to 31.2)	17.2 (5.8 to 35.8)	3.4 (0.1 to 17.8)	4.5 (0.1 to 22.8)	7.7 (0.9 to 25.1)	11.1 (2.4 to 29.2)	0 (0.0 to 11.9)
Anti-H18, M20 (N=29;30;23;24;31;27;20;27;27;25)	6.9 (0.8 to 22.8)	13.3 (3.8 to 30.7)	4.3 (0.1 to 21.9)	4.2 (0.1 to 21.1)	6.5 (0.8 to 21.4)	0 (0.0 to 12.8)	5 (0.1 to 24.9)	3.7 (0.1 to 19.0)	11.1 (2.4 to 29.2)	0 (0.0 to 13.7)
Anti-H18, M26 (N=29;29;21;21;25;25;20;25;25;23)	6.9 (0.8 to 22.8)	10.3 (2.2 to 27.4)	4.8 (0.1 to 23.8)	4.8 (0.1 to 23.8)	8 (1.0 to 26.0)	0 (0.0 to 13.7)	10 (1.2 to 31.7)	0 (0.0 to 13.7)	8 (1.0 to 26.0)	0 (0.0 to 14.8)

No statistical analyses for this end point

Secondary: MGI for anti-H2 and anti-H18 antibodies concentrations measured by ELISA

Top of page

End point title

MGI for anti-H2 and anti-H18 antibodies concentrations measured by ELISA

End point description

MGI is defined as the geometric mean of the fold increase in serum HI concentration post-vaccination compared to Day 1.

End point type

Secondary

End point timeframe

At Day 29, at Day 85, Month 8, Month 14, Month 14 + 28 days, Month 20 and Month 26, compared to Day 1

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	43	40	41	40	42	42	37	41	39	40
Units: Ratio
geometric mean (confidence interval 95%)
Anti-H2, Day 29 (N=43;40;41;40;42;42;37;41;39;40)	18.4 (13.6 to 24.9)	5.3 (4.0 to 7.0)	17.3 (12.9 to 23.1)	9.9 (7.0 to 14.0)	4.7 (3.7 to 6.0)	12.3 (9.2 to 16.3)	5.6 (3.8 to 8.1)	2.3 (1.8 to 2.9)	5 (3.5 to 7.0)	1.9 (1.6 to 2.3)
Anti-H2, Day 85 (N=39;36;34;35;39;35;34;34;35;38)	7 (5.2 to 9.2)	3.2 (2.5 to 4.2)	9.5 (7.2 to 12.5)	4.4 (3.0 to 6.5)	2.4 (2.0 to 2.9)	8.2 (6.3 to 10.7)	4.1 (2.8 to 5.8)	1.7 (1.4 to 2.0)	4.2 (2.9 to 6.1)	1.6 (1.3 to 1.9)
Anti-H2, M8 (N=39;34;30;27;36;33;30;34;33;34)	4.8 (3.7 to 6.2)	2.4 (1.9 to 2.9)	6.2 (4.6 to 8.4)	3.1 (2.1 to 4.4)	1.8 (1.5 to 2.1)	5.2 (4.0 to 6.6)	3.3 (2.2 to 4.9)	1.5 (1.3 to 1.8)	3.3 (2.3 to 4.7)	1.5 (1.3 to 1.7)
Anti-H2, M14 (N=35;32;26;26;31;31;25;30;30;31)	3.6 (2.8 to 4.7)	2.2 (1.8 to 2.6)	5.6 (3.9 to 8.1)	3.1 (2.1 to 4.5)	1.6 (1.4 to 2.0)	4.1 (3.3 to 5.3)	2.5 (1.8 to 3.6)	1.4 (1.2 to 1.7)	2.8 (2.0 to 4.0)	1.4 (1.2 to 1.6)
Anti-H2, M14+28d(N=28;31;23;25;29;29;22;26;27;29)	6.1 (4.3 to 8.7)	17.2 (12.5 to 23.8)	14.7 (10.4 to 20.8)	5.1 (3.4 to 7.7)	12.1 (8.0 to 18.3)	12.6 (9.7 to 16.2)	3.3 (2.3 to 4.8)	5.6 (3.7 to 8.4)	6.1 (4.2 to 8.9)	1.9 (1.5 to 2.3)
Anti-H2, M20 (N=29;30;24;24;31;27;20;27;27;25)	3.9 (3.0 to 5.1)	6.4 (4.8 to 8.7)	6.5 (4.6 to 9.0)	3.6 (2.4 to 5.3)	4.8 (3.4 to 6.9)	6.2 (4.8 to 8.0)	2.5 (1.7 to 3.6)	2.7 (1.9 to 3.9)	3.7 (2.6 to 5.2)	1.3 (1.1 to 1.6)
Anti-H2, M26 (N=29;29;22;21;25;25;20;25;25;23)	3.5 (2.7 to 4.6)	5 (3.7 to 6.7)	5 (3.5 to 7.1)	3 (2.0 to 4.7)	4.2 (2.8 to 6.1)	4.9 (3.7 to 6.5)	2.6 (1.7 to 3.9)	2.3 (1.6 to 3.4)	3.2 (2.2 to 4.6)	1.4 (1.2 to 1.6)
Anti-H18, Day 29 (N=43;40;40;40;42;42;37;41;39;40)	5.2 (3.9 to 6.9)	4.6 (3.5 to 6.0)	5.3 (3.8 to 7.3)	3.7 (2.8 to 4.9)	4.1 (3.2 to 5.3)	4.3 (3.3 to 5.6)	2.7 (2.0 to 3.7)	2.1 (1.7 to 2.7)	2.5 (1.9 to 3.3)	2 (1.7 to 2.4)
Anti-H18, Day 85 (N=39;36;33;35;39;35;34;34;35;38)	2.6 (2.1 to 3.3)	2.9 (2.2 to 3.7)	4.9 (3.7 to 6.5)	2 (1.5 to 2.7)	2.2 (1.8 to 2.7)	4.3 (3.4 to 5.3)	2 (1.5 to 2.7)	1.6 (1.4 to 2.0)	2.6 (1.9 to 3.6)	1.6 (1.3 to 1.9)
Anti-H18, M8 (N=39;34;29;27;36;33;30;34;33;34)	2.4 (1.9 to 2.9)	2.4 (1.9 to 3.0)	3.5 (2.6 to 4.6)	1.8 (1.4 to 2.4)	1.8 (1.5 to 2.2)	3.2 (2.6 to 3.9)	2 (1.5 to 2.7)	1.6 (1.3 to 2.0)	2.3 (1.7 to 3.2)	1.5 (1.3 to 1.7)
Anti-H18, M14 (N=35;32;25;26;31;31;25;30;30;31)	1.9 (1.5 to 2.2)	2.1 (1.7 to 2.6)	3.1 (2.3 to 4.4)	1.8 (1.3 to 2.4)	1.6 (1.3 to 2.0)	2.6 (2.1 to 3.3)	1.7 (1.2 to 2.3)	1.3 (1.1 to 1.5)	1.9 (1.4 to 2.5)	1.3 (1.1 to 1.5)
Anti-H18, M14+28d(N=28;31;22;25;29;29;22;26;27;29)	4.1 (2.9 to 5.7)	6.4 (4.6 to 9.0)	4.6 (3.1 to 6.6)	3.3 (2.3 to 4.7)	4.4 (3.3 to 5.9)	4.3 (3.4 to 5.3)	2.4 (1.8 to 3.3)	2.4 (1.8 to 3.2)	2.6 (1.8 to 3.6)	1.7 (1.3 to 2.1)
Anti-H18, M20 (N=29;30;23;24;31;27;20;27;27;25)	2.5 (1.9 to 3.1)	3.5 (2.6 to 4.8)	2.7 (2.0 to 3.8)	2.2 (1.6 to 3.1)	2.4 (1.9 to 3.1)	2.8 (2.3 to 3.5)	2 (1.4 to 2.8)	1.6 (1.3 to 2.0)	2.1 (1.6 to 2.9)	1.3 (1.1 to 1.6)
Anti-H18, M26 (N=29;29;21;21;25;25;20;25;25;23)	2.4 (1.8 to 3.0)	2.9 (2.1 to 3.9)	2.4 (1.7 to 3.4)	2.1 (1.5 to 3.1)	2.2 (1.6 to 3.0)	2.5 (2.0 to 3.1)	2.1 (1.4 to 3.2)	1.4 (1.1 to 1.8)	1.9 (1.3 to 2.8)	1.4 (1.2 to 1.6)

No statistical analyses for this end point

Secondary: Titers for anti-H1N1 swine influenza and anti-IIV4-H1N1 anti-bodies measured by MN assay

Top of page

End point title

Titers for anti-H1N1 swine influenza and anti-IIV4-H1N1 anti-bodies measured by MN assay

End point description

Titers are presented as GMTs and measured by MN assay. MN cut-off = 20 1/DIL

End point type

Secondary

End point timeframe

At Days 1, 29 and 85

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	45	46	46	46	47	47	47	46	44	45
Units: Titer
geometric mean (confidence interval 95%)
Day 1 (N=45;46;46;46;47;47;47;46;44;45)	58.8 (45.6 to 75.7)	61 (47.8 to 77.8)	62.9 (50.8 to 77.8)	51.7 (39.5 to 67.6)	53.7 (42.6 to 67.7)	56.2 (44.5 to 70.8)	56.2 (45.6 to 69.1)	70.9 (57.3 to 87.8)	56.6 (45.2 to 70.8)	60.6 (48.9 to 75.2)
Day 29 (N=43;40;40;40;41;42;37;41;39;40)	84 (68.8 to 102.5)	93.5 (76.7 to 113.9)	87.2 (77.0 to 98.8)	84.3 (74.2 to 95.7)	93.1 (82.2 to 105.5)	80 (67.8 to 94.4)	71.5 (59.4 to 86.0)	78.7 (64.9 to 95.4)	69.4 (54.1 to 88.9)	103.7 (88.0 to 122.3)
Day 85 (N=39;36;34;35;38;35;34;34;35;38)	65.8 (49.6 to 87.2)	89.8 (73.7 to 109.5)	96.1 (83.8 to 110.2)	56 (45.3 to 69.2)	81.5 (68.1 to 97.5)	86.6 (73.7 to 101.7)	63.9 (51.7 to 79.1)	68 (52.8 to 87.5)	84.9 (72.6 to 99.3)	99.6 (78.5 to 126.3)

No statistical analyses for this end point

Secondary: Number of seropositive subjects for anti-H1N1 swine influenza and anti-IIV4-H1N1 antibodies measured by MN assay

Top of page

End point title

Number of seropositive subjects for anti-H1N1 swine influenza and anti-IIV4-H1N1 antibodies measured by MN assay

End point description

Anti-H1N1 swine influenza and anti-IIV4-H1N1 immune response measured by MN assay. A seropositive subject is a subject whose titer is greater than or equal to the cut-off value: cut-off = 20 1/DIL.

End point type

Secondary

End point timeframe

At Days 1, 29 and 85

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	45	46	46	46	47	47	47	46	44	45
Units: Participants
Day 1 (N=45;46;46;46;47;47;47;46;44;45)	40	41	43	38	42	42	44	43	42	43
Day 29 (N=43;40;40;40;41;42;37;41;39;40)	42	39	40	40	41	42	37	40	36	40
Day 85 (N=39;36;34;35;38;35;34;34;35;38)	36	35	34	34	38	35	34	32	35	37

No statistical analyses for this end point

Secondary: Percentage of subjects with a ≥ 4-fold increase of anti-H1N1 swine influenza and anti-IIV4-H1N1 antibody titers measured by MN assay

Top of page

End point title

Percentage of subjects with a ≥ 4-fold increase of anti-H1N1 swine influenza and anti-IIV4-H1N1 antibody titers measured by MN assay

End point description

Percentage of subjects with a ≥ 4-fold increase of anti-H1N1 swine influenza and anti-IIV4-H1N1 antibody titers, from Day 1, is calculated with exact 95% CI by MN assay.

End point type

Secondary

End point timeframe

At Day 29 and Day 85, compared to Day 1

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	43	40	39	39	41	42	37	41	39	40
Units: Percentage of subjects
number (confidence interval 95%)
Day 29 (N=43;40;39;39;41;42;37;41;39;40)	9.3 (2.6 to 22.1)	22.5 (10.8 to 38.5)	7.7 (1.6 to 20.9)	23.1 (11.1 to 39.3)	24.4 (12.4 to 40.3)	9.5 (2.7 to 22.6)	10.8 (3.0 to 25.4)	2.4 (0.1 to 12.9)	7.7 (1.6 to 20.9)	15 (5.7 to 29.8)
Day 85 (N=39;36;33;34;38;35;34;34;35;38)	5.1 (0.6 to 17.3)	16.7 (6.4 to 32.8)	18.2 (7.0 to 35.5)	5.9 (0.7 to 19.7)	21.1 (9.6 to 37.3)	14.3 (4.8 to 30.3)	5.9 (0.7 to 19.7)	0 (0.0 to 10.3)	8.6 (1.8 to 23.1)	15.8 (6.0 to 31.3)

No statistical analyses for this end point

Secondary: Percentage of subjects with a ≥ 10-fold increase of anti-H1N1 swine influenza and anti-IIV4-H1N1 antibody titers measured by MN assay

Top of page

End point title

Percentage of subjects with a ≥ 10-fold increase of anti-H1N1 swine influenza and anti-IIV4-H1N1 antibody titers measured by MN assay

End point description

Percentage of subjects with a ≥ 10-fold increase of anti-H1N1 swine influenza and anti-IIV4-H1N1 antibody titers, from Day 1, is calculated with exact 95% CI by MN assay.

End point type

Secondary

End point timeframe

At Day 29 and Day 85, compared to Day 1

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	43	40	39	39	41	42	37	41	39	40
Units: Percentage of subjects
number (confidence interval 95%)
Day 29 (N=43;40;39;39;41;42;37;41;39;40)	2.3 (0.1 to 12.3)	2.5 (0.1 to 13.2)	0 (0.0 to 9.0)	0 (0.0 to 9.0)	0 (0.0 to 8.6)	0 (0.0 to 8.4)	0 (0.0 to 9.5)	0 (0.0 to 8.6)	0 (0.0 to 9.0)	0 (0.0 to 8.8)
Day 85 (N=39;36;33;34;38;35;34;34;35;38)	0 (0.0 to 9.0)	2.8 (0.1 to 14.5)	3 (0.1 to 15.8)	0 (0.0 to 10.3)	0 (0.0 to 9.3)	2.9 (0.1 to 14.9)	0 (0.0 to 10.3)	0 (0.0 to 10.3)	0 (0.0 to 10.0)	0 (0.0 to 9.3)

No statistical analyses for this end point

Secondary: MGI for anti-H1N1 swine influenza and anti-IIV4-H1N1 antibodies titers measured by MN assay

Top of page

End point title

MGI for anti-H1N1 swine influenza and anti-IIV4-H1N1 antibodies titers measured by MN assay

End point description

MGI is defined as the geometric mean of the fold increase in serum HI titer post-vaccination compared to Day 1.

End point type

Secondary

End point timeframe

At Day 29 and at Day 85, compared to Day 1

End point values	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 1	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Number of subjects analysed	43	40	39	39	41	42	37	41	39	40
Units: Ratio
geometric mean (confidence interval 95%)
Day 29 (N=43;40;39;39;41;42;37;41;39;40)	1.4 (1.1 to 1.7)	1.7 (1.3 to 2.1)	1.4 (1.2 to 1.6)	1.7 (1.3 to 2.2)	1.7 (1.4 to 2.2)	1.4 (1.2 to 1.7)	1.3 (1.0 to 1.5)	1.1 (0.9 to 1.3)	1.2 (1.0 to 1.5)	1.7 (1.4 to 2.0)
Day 85 (N=39;36;33;34;38;35;34;34;35;38)	1.1 (0.9 to 1.3)	1.5 (1.1 to 2.0)	1.6 (1.2 to 2.1)	1 (0.9 to 1.3)	1.5 (1.2 to 1.9)	1.5 (1.2 to 1.9)	1.1 (0.9 to 1.3)	0.9 (0.8 to 1.1)	1.3 (1.1 to 1.6)	1.5 (1.3 to 1.9)

No statistical analyses for this end point

Adverse events

Top of page

Timeframe for reporting adverse events

Solicited AEs were collected during the 7-day follow-up period after each vaccination. Unsolicited AEs were collected during the 28-day follow-up period after any vaccination. SAEs were collected during the entire study period (from Day 1 up to Month 26).

Assessment type

Systematic

Dictionary name

MedDRA

Dictionary version

23.1

Reporting group title

D-SUIV Adjuvanted Group 1

Reporting group description

Reporting group title

D-SUIV Adjuvanted Group 2

Reporting group description

Reporting group title

D-SUIV Adjuvanted Group 3

Reporting group description

Reporting group title

D-SUIV Adjuvanted Group 4

Reporting group description

Reporting group title

D-SUIV Adjuvanted Group 5

Reporting group description

Reporting group title

D-SUIV Unadjuvanted Group 1

Reporting group description

Reporting group title

D-SUIV Adjuvanted Group 6

Reporting group description

Reporting group title

D-SUIV Unadjuvanted Group 2

Reporting group description

Reporting group title

D-SUIV Unadjuvanted Group 3

Reporting group description

Reporting group title

IIV4 Group

Reporting group description

Serious adverse events	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Unadjuvanted Group 1	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Total subjects affected by serious adverse events
subjects affected / exposed	2 / 45 (4.44%)	1 / 46 (2.17%)	1 / 47 (2.13%)	2 / 47 (4.26%)	2 / 48 (4.17%)	0 / 47 (0.00%)	2 / 47 (4.26%)	2 / 48 (4.17%)	2 / 46 (4.35%)	3 / 47 (6.38%)
number of deaths (all causes)	0	0	0	0	0	0	1	0	0	0
number of deaths resulting from adverse events	0	0	0	0	0	0	0	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant melanoma stage II
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	1 / 46 (2.17%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications
Overdose
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	1 / 47 (2.13%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 1	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders
Ankyloglossia congenital
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	1 / 47 (2.13%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
Pregnancy, puerperium and perinatal conditions
Ectopic pregnancy
subjects affected / exposed	1 / 45 (2.22%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
Hyperemesis gravidarum
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	1 / 48 (2.08%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
Pre-eclampsia
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	1 / 48 (2.08%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 1	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
Immune system disorders
Drug hypersensitivity
subjects affected / exposed	1 / 45 (2.22%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders
Menometrorrhagia
subjects affected / exposed	0 / 45 (0.00%)	1 / 46 (2.17%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders
Cholecystitis
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	1 / 47 (2.13%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
Cholelithiasis
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	1 / 47 (2.13%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders
Asthma
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	1 / 47 (2.13%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 1	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
Sleep apnoea syndrome
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	1 / 47 (2.13%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
Psychiatric disorders
Suicide attempt
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	1 / 47 (2.13%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 1	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders
Rotator cuff syndrome
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	1 / 48 (2.08%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 1	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
Infections and infestations
Appendicitis
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	1 / 48 (2.08%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
Influenza
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	1 / 47 (2.13%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 1	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
Meningitis viral
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	1 / 46 (2.17%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
Pyelonephritis
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	1 / 47 (2.13%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	1 / 47 (2.13%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 1	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
Viral infection
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	1 / 47 (2.13%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 1	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
Wound infection
subjects affected / exposed	1 / 45 (2.22%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders
Obesity
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	1 / 47 (2.13%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 0%

Non-serious adverse events	D-SUIV Adjuvanted Group 1	D-SUIV Adjuvanted Group 2	D-SUIV Adjuvanted Group 3	D-SUIV Adjuvanted Group 4	D-SUIV Adjuvanted Group 5	D-SUIV Unadjuvanted Group 1	D-SUIV Adjuvanted Group 6	D-SUIV Unadjuvanted Group 2	D-SUIV Unadjuvanted Group 3	IIV4 Group
Total subjects affected by non serious adverse events
subjects affected / exposed	40 / 45 (88.89%)	43 / 46 (93.48%)	44 / 47 (93.62%)	44 / 47 (93.62%)	45 / 48 (93.75%)	34 / 47 (72.34%)	44 / 47 (93.62%)	38 / 48 (79.17%)	42 / 46 (91.30%)	44 / 47 (93.62%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Anogenital warts
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	1 / 46 (2.17%)	0 / 47 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	1	0
Melanocytic naevus
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	1 / 48 (2.08%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	0	0	1	0	0	0	0	0
Skin papilloma
subjects affected / exposed	0 / 45 (0.00%)	1 / 46 (2.17%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	1	0	0	0	0	0	0	0	0
Vascular disorders
Flushing
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	1 / 47 (2.13%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	0	0	0	0	1	0	0	0
Hypertension
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	1 / 48 (2.08%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	0	0	0	0	0	1	0	0
Phlebitis superficial
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	1 / 47 (2.13%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	0	0	0	1	0	0	0	0
General disorders and administration site conditions
Chest discomfort
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	1 / 48 (2.08%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	0	0	1	0	0	0	0	0
Chest pain
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	1 / 47 (2.13%)	0 / 48 (0.00%)	0 / 46 (0.00%)	1 / 47 (2.13%)
occurrences all number	0	0	0	0	0	0	1	0	0	1
Chills
subjects affected / exposed	9 / 45 (20.00%)	16 / 46 (34.78%)	15 / 47 (31.91%)	13 / 47 (27.66%)	20 / 48 (41.67%)	3 / 47 (6.38%)	17 / 47 (36.17%)	4 / 48 (8.33%)	5 / 46 (10.87%)	3 / 47 (6.38%)
occurrences all number	13	20	20	16	25	3	21	4	6	5
Cyst
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	1 / 47 (2.13%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	0	1	0	0	0	0	0	0
Energy increased
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	1 / 47 (2.13%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	1	0	0	0	0	0	0	0
Fatigue
subjects affected / exposed	25 / 45 (55.56%)	28 / 46 (60.87%)	28 / 47 (59.57%)	25 / 47 (53.19%)	25 / 48 (52.08%)	18 / 47 (38.30%)	26 / 47 (55.32%)	24 / 48 (50.00%)	18 / 46 (39.13%)	15 / 47 (31.91%)
occurrences all number	39	44	50	40	48	24	35	30	28	21
Influenza like illness
subjects affected / exposed	4 / 45 (8.89%)	3 / 46 (6.52%)	4 / 47 (8.51%)	2 / 47 (4.26%)	2 / 48 (4.17%)	2 / 47 (4.26%)	3 / 47 (6.38%)	4 / 48 (8.33%)	1 / 46 (2.17%)	1 / 47 (2.13%)
occurrences all number	5	5	7	2	3	3	4	4	1	1
Injection site bruising
subjects affected / exposed	1 / 45 (2.22%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	1 / 47 (2.13%)	1 / 48 (2.08%)	0 / 46 (0.00%)	1 / 47 (2.13%)
occurrences all number	1	0	0	0	0	0	1	1	0	1
Injection site erythema
subjects affected / exposed	2 / 45 (4.44%)	4 / 46 (8.70%)	3 / 47 (6.38%)	2 / 47 (4.26%)	2 / 48 (4.17%)	1 / 47 (2.13%)	4 / 47 (8.51%)	0 / 48 (0.00%)	1 / 46 (2.17%)	0 / 47 (0.00%)
occurrences all number	2	4	3	2	2	1	4	0	1	0
Injection site haematoma
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	1 / 47 (2.13%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	1	0	0	0	0	0	0	0
Injection site haemorrhage
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	1 / 47 (2.13%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	1	0	0	0	0	0	0	0
Injection site hypoaesthesia
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	1 / 48 (2.08%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	0	0	1	0	0	0	0	0
Injection site lymphadenopathy
subjects affected / exposed	0 / 45 (0.00%)	1 / 46 (2.17%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	1	0	0	0	0	0	0	0	0
Injection site mass
subjects affected / exposed	0 / 45 (0.00%)	1 / 46 (2.17%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	1	0	0	0	0	0	0	0	0
Injection site pain
subjects affected / exposed	37 / 45 (82.22%)	42 / 46 (91.30%)	41 / 47 (87.23%)	43 / 47 (91.49%)	42 / 48 (87.50%)	18 / 47 (38.30%)	44 / 47 (93.62%)	22 / 48 (45.83%)	23 / 46 (50.00%)	39 / 47 (82.98%)
occurrences all number	66	75	92	69	76	24	99	28	40	66
Injection site paraesthesia
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	1 / 48 (2.08%)	0 / 47 (0.00%)	0 / 47 (0.00%)	1 / 48 (2.08%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	0	0	1	0	0	1	0	0
Injection site pruritus
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	1 / 48 (2.08%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	0	0	1	0	0	0	0	0
Injection site reaction
subjects affected / exposed	1 / 45 (2.22%)	0 / 46 (0.00%)	3 / 47 (6.38%)	1 / 47 (2.13%)	1 / 48 (2.08%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	1 / 47 (2.13%)
occurrences all number	1	0	3	1	1	0	0	0	0	1
Injection site swelling
subjects affected / exposed	5 / 45 (11.11%)	4 / 46 (8.70%)	5 / 47 (10.64%)	5 / 47 (10.64%)	4 / 48 (8.33%)	0 / 47 (0.00%)	2 / 47 (4.26%)	0 / 48 (0.00%)	1 / 46 (2.17%)	0 / 47 (0.00%)
occurrences all number	6	4	6	5	4	0	5	0	1	0
Injection site warmth
subjects affected / exposed	1 / 45 (2.22%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	2	0	0	0	0	0	0	0	0	0
Malaise
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	1 / 47 (2.13%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	0	0	0	0	1	0	0	0
Pain
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	1 / 48 (2.08%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	0	0	2	0	0	0	0	0
Peripheral swelling
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	1 / 47 (2.13%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	0	0	0	0	1	0	0	0
Pyrexia
subjects affected / exposed	7 / 45 (15.56%)	11 / 46 (23.91%)	8 / 47 (17.02%)	9 / 47 (19.15%)	6 / 48 (12.50%)	5 / 47 (10.64%)	9 / 47 (19.15%)	4 / 48 (8.33%)	6 / 46 (13.04%)	6 / 47 (12.77%)
occurrences all number	7	17	8	10	9	6	11	5	6	7
Swelling
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	1 / 47 (2.13%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	1	0	0	0	0	0	0	0
Thirst
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	1 / 47 (2.13%)	1 / 48 (2.08%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	0	0	0	0	1	1	0	0
Vaccination site pain
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	1 / 47 (2.13%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	0	1	0	0	0	0	0	0
Immune system disorders
Seasonal allergy
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	1 / 47 (2.13%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	0	0	0	1	0	0	0	0
Reproductive system and breast disorders
Dysmenorrhoea
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	1 / 47 (2.13%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	0	0	0	1	0	0	0	0
Menorrhagia
subjects affected / exposed	1 / 45 (2.22%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	1	0	0	0	0	0	0	0	0	0
Respiratory, thoracic and mediastinal disorders
Cough
subjects affected / exposed	1 / 45 (2.22%)	1 / 46 (2.17%)	2 / 47 (4.26%)	3 / 47 (6.38%)	2 / 48 (4.17%)	1 / 47 (2.13%)	1 / 47 (2.13%)	4 / 48 (8.33%)	2 / 46 (4.35%)	1 / 47 (2.13%)
occurrences all number	1	1	3	3	2	1	1	4	2	1
Dysphonia
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	1 / 47 (2.13%)	1 / 47 (2.13%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	0	0	0	1	1	0	0	0
Dyspnoea
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	1 / 47 (2.13%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	0	1	0	0	0	0	0	0
Lower respiratory tract congestion
subjects affected / exposed	1 / 45 (2.22%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	2	0	0	0	0	0	0	0	0	0
Nasal congestion
subjects affected / exposed	2 / 45 (4.44%)	2 / 46 (4.35%)	2 / 47 (4.26%)	3 / 47 (6.38%)	1 / 48 (2.08%)	1 / 47 (2.13%)	1 / 47 (2.13%)	1 / 48 (2.08%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	2	2	2	3	2	1	2	1	0	0
Oropharyngeal pain
subjects affected / exposed	3 / 45 (6.67%)	6 / 46 (13.04%)	1 / 47 (2.13%)	5 / 47 (10.64%)	5 / 48 (10.42%)	5 / 47 (10.64%)	1 / 47 (2.13%)	4 / 48 (8.33%)	6 / 46 (13.04%)	1 / 47 (2.13%)
occurrences all number	3	6	1	7	5	5	1	4	6	2
Productive cough
subjects affected / exposed	1 / 45 (2.22%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	1	0	0	0	0	0	0	0	0	0
Respiratory disorder
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	1 / 46 (2.17%)	0 / 47 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	1	0
Respiratory tract congestion
subjects affected / exposed	0 / 45 (0.00%)	1 / 46 (2.17%)	1 / 47 (2.13%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	1	1	0	0	0	0	0	0	0
Rhinitis allergic
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	1 / 47 (2.13%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	0	1	0	0	0	0	0	0
Rhinorrhoea
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	1 / 47 (2.13%)	1 / 47 (2.13%)	0 / 48 (0.00%)	2 / 47 (4.26%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	1	1	0	2	0	0	0	0
Sinus congestion
subjects affected / exposed	1 / 45 (2.22%)	1 / 46 (2.17%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	1	1	0	0	0	0	0	0	0	0
Sneezing
subjects affected / exposed	0 / 45 (0.00%)	1 / 46 (2.17%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	1 / 47 (2.13%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	1	0	0	0	1	0	0	0	0
Psychiatric disorders
Abnormal dreams
subjects affected / exposed	1 / 45 (2.22%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	1	0	0	0	0	0	0	0	0	0
Anxiety
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	1 / 47 (2.13%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	0	1	0	0	0	0	0	0
Depression
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	1 / 47 (2.13%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	0	1	0	0	0	0	0	0
Insomnia
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	1 / 47 (2.13%)
occurrences all number	0	0	0	0	0	0	0	0	0	1
Obsessive-compulsive disorder
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	1 / 47 (2.13%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	0	0	0	0	1	0	0	0
Investigations
Alanine aminotransferase increased
subjects affected / exposed	1 / 45 (2.22%)	0 / 46 (0.00%)	0 / 47 (0.00%)	1 / 47 (2.13%)	0 / 48 (0.00%)	1 / 47 (2.13%)	1 / 47 (2.13%)	0 / 48 (0.00%)	2 / 46 (4.35%)	0 / 47 (0.00%)
occurrences all number	1	0	0	1	0	1	1	0	2	0
Aspartate aminotransferase increased
subjects affected / exposed	1 / 45 (2.22%)	1 / 46 (2.17%)	0 / 47 (0.00%)	1 / 47 (2.13%)	0 / 48 (0.00%)	1 / 47 (2.13%)	0 / 47 (0.00%)	0 / 48 (0.00%)	2 / 46 (4.35%)	0 / 47 (0.00%)
occurrences all number	1	1	0	1	0	2	0	0	2	0
Body temperature increased
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	1 / 47 (2.13%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	1	0	0	0	0	0	0	0
Haemoglobin decreased
subjects affected / exposed	3 / 45 (6.67%)	0 / 46 (0.00%)	0 / 47 (0.00%)	2 / 47 (4.26%)	0 / 48 (0.00%)	1 / 47 (2.13%)	0 / 47 (0.00%)	1 / 48 (2.08%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	3	0	0	2	0	1	0	1	0	0
Lymphocyte count decreased
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	1 / 47 (2.13%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	0	0	0	0	1	0	0	0
Lymphocyte count increased
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	1 / 47 (2.13%)	1 / 47 (2.13%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	1 / 46 (2.17%)	0 / 47 (0.00%)
occurrences all number	0	0	1	1	0	0	0	0	1	0
Lymphocyte percentage decreased
subjects affected / exposed	0 / 45 (0.00%)	1 / 46 (2.17%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	1 / 46 (2.17%)	0 / 47 (0.00%)
occurrences all number	0	1	0	0	0	0	0	0	1	0
Lymphocyte percentage increased
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	1 / 47 (2.13%)	1 / 47 (2.13%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	1	1	0	0	0	0	0	0
Monocyte count increased
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	1 / 47 (2.13%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	1 / 46 (2.17%)	0 / 47 (0.00%)
occurrences all number	0	0	0	1	0	0	0	0	1	0
Neutrophil count decreased
subjects affected / exposed	1 / 45 (2.22%)	0 / 46 (0.00%)	2 / 47 (4.26%)	3 / 47 (6.38%)	3 / 48 (6.25%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	1 / 46 (2.17%)	0 / 47 (0.00%)
occurrences all number	1	0	2	3	3	0	0	0	2	0
Neutrophil count increased
subjects affected / exposed	0 / 45 (0.00%)	1 / 46 (2.17%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	1 / 47 (2.13%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	1	0	0	0	0	1	0	0	0
Neutrophil percentage decreased
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	1 / 47 (2.13%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	0	1	0	0	0	0	0	0
White blood cell count decreased
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	1 / 47 (2.13%)	2 / 47 (4.26%)	1 / 48 (2.08%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	1 / 46 (2.17%)	0 / 47 (0.00%)
occurrences all number	0	0	1	2	1	0	0	0	1	0
White blood cell count increased
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	1 / 46 (2.17%)	0 / 47 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	1	0
Injury, poisoning and procedural complications
Contusion
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	1 / 46 (2.17%)	0 / 47 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	1	0
Eye contusion
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	1 / 46 (2.17%)	0 / 47 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	1	0
Foot fracture
subjects affected / exposed	0 / 45 (0.00%)	1 / 46 (2.17%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	1	0	0	0	0	0	0	0	0
Fractured sacrum
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	1 / 48 (2.08%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	0	0	1	0	0	0	0	0
Ligament sprain
subjects affected / exposed	0 / 45 (0.00%)	1 / 46 (2.17%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	1	0	0	0	0	0	0	0	0
Limb injury
subjects affected / exposed	1 / 45 (2.22%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	1 / 47 (2.13%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	1 / 47 (2.13%)
occurrences all number	1	0	0	0	0	1	0	0	0	1
Muscle strain
subjects affected / exposed	1 / 45 (2.22%)	1 / 46 (2.17%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	1 / 47 (2.13%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	1	1	0	0	0	1	0	0	0	0
Procedural pain
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	1 / 47 (2.13%)	1 / 48 (2.08%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	2 / 47 (4.26%)
occurrences all number	0	0	0	1	1	0	0	0	0	2
Nervous system disorders
Dizziness
subjects affected / exposed	0 / 45 (0.00%)	1 / 46 (2.17%)	0 / 47 (0.00%)	0 / 47 (0.00%)	1 / 48 (2.08%)	1 / 47 (2.13%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	1	0	0	2	1	0	0	0	0
Headache
subjects affected / exposed	25 / 45 (55.56%)	29 / 46 (63.04%)	30 / 47 (63.83%)	31 / 47 (65.96%)	25 / 48 (52.08%)	20 / 47 (42.55%)	34 / 47 (72.34%)	25 / 48 (52.08%)	20 / 46 (43.48%)	23 / 47 (48.94%)
occurrences all number	37	50	50	49	42	26	55	43	31	28
Hypoaesthesia
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	1 / 48 (2.08%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	0	0	1	0	0	0	0	0
Migraine
subjects affected / exposed	1 / 45 (2.22%)	1 / 46 (2.17%)	0 / 47 (0.00%)	1 / 47 (2.13%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	1 / 46 (2.17%)	0 / 47 (0.00%)
occurrences all number	1	1	0	1	0	0	0	0	1	0
Paraesthesia
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	1 / 48 (2.08%)	0 / 47 (0.00%)	2 / 47 (4.26%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	0	0	1	0	2	0	0	0
Parosmia
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	1 / 47 (2.13%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	0	0	0	0	1	0	0	0
Presyncope
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	1 / 47 (2.13%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	0	0	0	1	0	0	0	0
Taste disorder
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	1 / 47 (2.13%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	0	0	0	0	1	0	0	0
Blood and lymphatic system disorders
Anaemia
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	1 / 46 (2.17%)	0 / 47 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	1	0
Leukopenia
subjects affected / exposed	1 / 45 (2.22%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	1	0	0	0	0	0	0	0	0	0
Lymph node pain
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	1 / 48 (2.08%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	0	0	1	0	0	0	0	0
Lymphadenopathy
subjects affected / exposed	1 / 45 (2.22%)	0 / 46 (0.00%)	2 / 47 (4.26%)	1 / 47 (2.13%)	2 / 48 (4.17%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	1	0	2	1	3	0	0	0	0	0
Ear and labyrinth disorders
Ear discomfort
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	1 / 48 (2.08%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	0	0	1	0	0	0	0	0
Ear pain
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	3 / 48 (6.25%)	1 / 47 (2.13%)	0 / 47 (0.00%)	1 / 48 (2.08%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	0	0	3	1	0	1	0	0
Tympanic membrane perforation
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	1 / 48 (2.08%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	0	0	1	0	0	0	0	0
Vertigo
subjects affected / exposed	0 / 45 (0.00%)	1 / 46 (2.17%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	1 / 46 (2.17%)	0 / 47 (0.00%)
occurrences all number	0	1	0	0	0	0	0	0	2	0
Eye disorders
Blepharospasm
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	1 / 46 (2.17%)	0 / 47 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	1	0
Dry eye
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	1 / 46 (2.17%)	0 / 47 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	1	0
Eye pain
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	1 / 46 (2.17%)	0 / 47 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	1	0
Myopia
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	1 / 46 (2.17%)	0 / 47 (0.00%)
occurrences all number	0	0	0	0	0	0	0	0	1	0
Photophobia
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	1 / 48 (2.08%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	0	0	1	0	0	0	0	0
Vision blurred
subjects affected / exposed	0 / 45 (0.00%)	1 / 46 (2.17%)	0 / 47 (0.00%)	0 / 47 (0.00%)	1 / 48 (2.08%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	1	0	0	1	0	0	0	0	0
Gastrointestinal disorders
Abdominal distension
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	1 / 47 (2.13%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	1	0	0	0	0	0	0	0
Abdominal pain
subjects affected / exposed	0 / 45 (0.00%)	2 / 46 (4.35%)	1 / 47 (2.13%)	0 / 47 (0.00%)	1 / 48 (2.08%)	1 / 47 (2.13%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	2	1	0	1	1	0	0	0	0
Abdominal pain upper
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	1 / 47 (2.13%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	1 / 47 (2.13%)
occurrences all number	0	0	0	1	0	0	0	0	0	1
Diarrhoea
subjects affected / exposed	0 / 45 (0.00%)	1 / 46 (2.17%)	1 / 47 (2.13%)	0 / 47 (0.00%)	2 / 48 (4.17%)	0 / 47 (0.00%)	2 / 47 (4.26%)	1 / 48 (2.08%)	0 / 46 (0.00%)	1 / 47 (2.13%)
occurrences all number	0	1	1	0	3	0	2	2	0	2
Dry mouth
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	1 / 47 (2.13%)	1 / 48 (2.08%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	0	0	0	0	1	1	0	0
Gastritis
subjects affected / exposed	0 / 45 (0.00%)	1 / 46 (2.17%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	1	0	0	0	0	0	0	0	0
Gastrointestinal disorder
subjects affected / exposed	10 / 45 (22.22%)	15 / 46 (32.61%)	14 / 47 (29.79%)	11 / 47 (23.40%)	12 / 48 (25.00%)	8 / 47 (17.02%)	15 / 47 (31.91%)	10 / 48 (20.83%)	12 / 46 (26.09%)	9 / 47 (19.15%)
occurrences all number	12	19	22	14	17	8	19	14	16	10
Gastrointestinal pain
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	1 / 47 (2.13%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	0	1	0	0	0	0	0	0
Gastrooesophageal reflux disease
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	1 / 47 (2.13%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	0	0	0	1	0	0	0	0
Nausea
subjects affected / exposed	1 / 45 (2.22%)	1 / 46 (2.17%)	1 / 47 (2.13%)	0 / 47 (0.00%)	0 / 48 (0.00%)	1 / 47 (2.13%)	2 / 47 (4.26%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	1	1	1	0	0	1	2	0	0	0
Toothache
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	1 / 47 (2.13%)
occurrences all number	0	0	0	0	0	0	0	0	0	1
Vomiting
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	1 / 47 (2.13%)	2 / 47 (4.26%)	0 / 48 (0.00%)	0 / 46 (0.00%)	2 / 47 (4.26%)
occurrences all number	0	0	0	0	0	1	2	0	0	2
Skin and subcutaneous tissue disorders
Dermatitis
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	1 / 47 (2.13%)
occurrences all number	0	0	0	0	0	0	0	0	0	1
Erythema
subjects affected / exposed	1 / 45 (2.22%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	1 / 47 (2.13%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	1	0	0	0	0	0	1	0	0	0
Hyperhidrosis
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	1 / 47 (2.13%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	1	0	0	0	0	0	0	0
Night sweats
subjects affected / exposed	1 / 45 (2.22%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	1 / 47 (2.13%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	1	0	0	0	0	0	1	0	0	0
Pruritus
subjects affected / exposed	0 / 45 (0.00%)	1 / 46 (2.17%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	2 / 47 (4.26%)	1 / 47 (2.13%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	1	0	0	0	2	1	0	0	0
Rash
subjects affected / exposed	0 / 45 (0.00%)	1 / 46 (2.17%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	1 / 48 (2.08%)	0 / 46 (0.00%)	1 / 47 (2.13%)
occurrences all number	0	1	0	0	0	0	0	1	0	1
Musculoskeletal and connective tissue disorders
Arthralgia
subjects affected / exposed	12 / 45 (26.67%)	13 / 46 (28.26%)	13 / 47 (27.66%)	6 / 47 (12.77%)	13 / 48 (27.08%)	7 / 47 (14.89%)	13 / 47 (27.66%)	6 / 48 (12.50%)	5 / 46 (10.87%)	5 / 47 (10.64%)
occurrences all number	13	19	17	6	17	8	18	6	6	8
Back pain
subjects affected / exposed	1 / 45 (2.22%)	1 / 46 (2.17%)	2 / 47 (4.26%)	0 / 47 (0.00%)	1 / 48 (2.08%)	1 / 47 (2.13%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	1	1	2	0	1	1	0	0	0	0
Coccydynia
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	1 / 47 (2.13%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	0	0	0	0	1	0	0	0
Flank pain
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	1 / 47 (2.13%)
occurrences all number	0	0	0	0	0	0	0	0	0	1
Joint swelling
subjects affected / exposed	0 / 45 (0.00%)	1 / 46 (2.17%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	1	0	0	0	0	0	0	0	0
Muscle spasms
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	1 / 47 (2.13%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	0	1	0	0	0	0	0	0
Musculoskeletal chest pain
subjects affected / exposed	1 / 45 (2.22%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	1	0	0	0	0	0	0	0	0	0
Musculoskeletal stiffness
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	1 / 47 (2.13%)	1 / 48 (2.08%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	0	1	1	0	0	0	0	0
Myalgia
subjects affected / exposed	24 / 45 (53.33%)	23 / 46 (50.00%)	30 / 47 (63.83%)	27 / 47 (57.45%)	26 / 48 (54.17%)	10 / 47 (21.28%)	28 / 47 (59.57%)	14 / 48 (29.17%)	15 / 46 (32.61%)	12 / 47 (25.53%)
occurrences all number	37	36	47	33	36	12	44	15	19	17
Neck pain
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	1 / 47 (2.13%)	0 / 47 (0.00%)	0 / 48 (0.00%)	1 / 47 (2.13%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	1	0	0	1	0	0	0	0
Pain in extremity
subjects affected / exposed	1 / 45 (2.22%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	2 / 48 (4.17%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	1 / 46 (2.17%)	0 / 47 (0.00%)
occurrences all number	1	0	0	0	2	0	0	0	1	0
Pain in jaw
subjects affected / exposed	0 / 45 (0.00%)	1 / 46 (2.17%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	1	0	0	0	0	0	0	0	0
Periostitis
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	1 / 48 (2.08%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	0	0	1	0	0	0	0	0
Polyarthritis
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	1 / 47 (2.13%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	0	0	0	1	0	0	0	0
Rotator cuff syndrome
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	1 / 47 (2.13%)
occurrences all number	0	0	0	0	0	0	0	0	0	1
Tendonitis
subjects affected / exposed	1 / 45 (2.22%)	1 / 46 (2.17%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	1 / 48 (2.08%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	1	1	0	0	0	0	0	1	0	0
Torticollis
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	1 / 48 (2.08%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	0	0	1	0	0	0	0	0
Infections and infestations
Abscess limb
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	1 / 47 (2.13%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	1	0	0	0	0	0	0	0
Bacterial vaginosis
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	1 / 47 (2.13%)	1 / 48 (2.08%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	0	0	0	0	1	1	0	0
Bronchitis
subjects affected / exposed	1 / 45 (2.22%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	1 / 47 (2.13%)	0 / 47 (0.00%)	0 / 48 (0.00%)	1 / 46 (2.17%)	1 / 47 (2.13%)
occurrences all number	1	0	0	0	0	1	0	0	1	1
Diarrhoea infectious
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	1 / 48 (2.08%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	0	0	1	0	0	0	0	0
Ear infection
subjects affected / exposed	0 / 45 (0.00%)	1 / 46 (2.17%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	1	0	0	0	0	0	0	0	0
Eye infection
subjects affected / exposed	0 / 45 (0.00%)	1 / 46 (2.17%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	1	0	0	0	0	0	0	0	0
Gastroenteritis
subjects affected / exposed	0 / 45 (0.00%)	1 / 46 (2.17%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	1 / 47 (2.13%)	0 / 47 (0.00%)	2 / 48 (4.17%)	0 / 46 (0.00%)	2 / 47 (4.26%)
occurrences all number	0	1	0	0	0	1	0	2	0	2
Gastroenteritis viral
subjects affected / exposed	1 / 45 (2.22%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	1 / 48 (2.08%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	1	0	0	0	0	0	0	1	0	0
Nasopharyngitis
subjects affected / exposed	3 / 45 (6.67%)	4 / 46 (8.70%)	2 / 47 (4.26%)	2 / 47 (4.26%)	1 / 48 (2.08%)	1 / 47 (2.13%)	1 / 47 (2.13%)	2 / 48 (4.17%)	3 / 46 (6.52%)	1 / 47 (2.13%)
occurrences all number	4	4	3	3	1	1	1	2	3	1
Oral herpes
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	1 / 47 (2.13%)	0 / 48 (0.00%)	0 / 47 (0.00%)	1 / 47 (2.13%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	0	1	0	0	1	0	0	0
Otitis media
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	2 / 48 (4.17%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	0	0	2	0	0	0	0	0
Pharyngitis
subjects affected / exposed	1 / 45 (2.22%)	0 / 46 (0.00%)	2 / 47 (4.26%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	1 / 47 (2.13%)	0 / 48 (0.00%)	1 / 46 (2.17%)	0 / 47 (0.00%)
occurrences all number	1	0	2	0	0	0	1	0	1	0
Pneumonia
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	1 / 47 (2.13%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	1	0	0	0	0	0	0	0
Rhinitis
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	1 / 47 (2.13%)	0 / 47 (0.00%)	0 / 48 (0.00%)	1 / 47 (2.13%)	0 / 47 (0.00%)	1 / 48 (2.08%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	1	0	0	1	0	1	0	0
Sinusitis
subjects affected / exposed	4 / 45 (8.89%)	2 / 46 (4.35%)	2 / 47 (4.26%)	1 / 47 (2.13%)	1 / 48 (2.08%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	1 / 46 (2.17%)	0 / 47 (0.00%)
occurrences all number	4	2	2	1	1	0	0	0	1	0
Tinea pedis
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	1 / 48 (2.08%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	0	0	0	0	0	1	0	0
Tonsillitis
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	1 / 47 (2.13%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	1 / 48 (2.08%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	1	0	0	0	0	1	0	0
Tooth infection
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	1 / 47 (2.13%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	1 / 47 (2.13%)
occurrences all number	0	0	0	1	0	0	0	0	0	1
Upper respiratory tract infection
subjects affected / exposed	2 / 45 (4.44%)	7 / 46 (15.22%)	5 / 47 (10.64%)	4 / 47 (8.51%)	3 / 48 (6.25%)	5 / 47 (10.64%)	4 / 47 (8.51%)	9 / 48 (18.75%)	7 / 46 (15.22%)	4 / 47 (8.51%)
occurrences all number	2	7	5	6	3	6	4	9	7	5
Urinary tract infection
subjects affected / exposed	1 / 45 (2.22%)	0 / 46 (0.00%)	1 / 47 (2.13%)	1 / 47 (2.13%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	1 / 47 (2.13%)
occurrences all number	1	0	1	1	0	0	0	0	0	1
Viral infection
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	1 / 47 (2.13%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	1	0	0	0	0	0	0	0
Viral upper respiratory tract infection
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	1 / 47 (2.13%)	0 / 47 (0.00%)	1 / 48 (2.08%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	1	0	1	0	0	0	0	0
Vulvovaginal candidiasis
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	1 / 48 (2.08%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	0	0	1	0	0	0	0	0
Vulvovaginal mycotic infection
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	1 / 47 (2.13%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	0	0	0	1	0	0	0	0
Metabolism and nutrition disorders
Dehydration
subjects affected / exposed	0 / 45 (0.00%)	0 / 46 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	0 / 48 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)	1 / 48 (2.08%)	0 / 46 (0.00%)	0 / 47 (0.00%)
occurrences all number	0	0	0	0	0	0	0	1	0	0

More information

Top of page

Were there any global substantial amendments to the protocol? Yes

11 Jul 2019

• The cell-mediated immune response was not assessed at Month 14 and later timepoints. The blood sampling for cell-mediated immunity at Visit 12 (Month 26) has been removed. • The hemagglutination inhibition assay (HI) was not performed on the inactivated influenza quadrivalent vaccine H1N1 component, cH11/1N1, cH6/1N5, H5N8 and H1N1 swine flu strains. For cH5/1N1 and cH8/1N1, the HI assay was only performed until Visit 6 (Day 85). • The micro-neutralisation (MN) assay was only performed for cH6/1N5 and H1N1 until Visit 6 (Day 85). MN assay was not performed for H5N8. • The anti-group 2 hemagglutinin (HA) stalk response by ELISA was not performed. • The immune response in terms of anti-neuraminidase antibodies was not assessed. • The passive transfer experiment in mice was not performed for the Month 14 and Month 26 time points. The blood collection at Month 26 for passive transfer has been removed. • The anti-H9 full length HA ELISA was not performed. • Anti-stalk antibody functionality was not further investigated, except for the antibody-dependent cell-mediated cytotoxicity until the interim analysis at Day 85. • Occurrence of RT-PCR-confirmed influenza cases endpoint was removed.

Were there any global interruptions to the trial? No

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

None reported

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA

Clinical trials

Trial information

Trial information

Subject disposition

Subject disposition

Baseline characteristics

Baseline characteristics

End points

End points

Primary: Number of subjects with solicited local adverse events (AEs) after first dose administration

Primary: Number of subjects with solicited local adverse events (AEs) after first dose administration

Primary: Number of subjects with solicited local AEs after second dose administration

Primary: Number of subjects with solicited local AEs after second dose administration

Primary: Number of subjects with solicited local AEs after booster dose administration

Primary: Number of subjects with solicited local AEs after booster dose administration

Primary: Number of subjects with solicited general AEs after first dose administration

Primary: Number of subjects with solicited general AEs after first dose administration

Primary: Number of subjects with solicited general AEs after second dose administration

Primary: Number of subjects with solicited general AEs after second dose administration

Primary: Number of subjects with solicited general AEs after booster dose administration

Primary: Number of subjects with solicited general AEs after booster dose administration

Primary: Number of subjects with any unsolicited AEs post-vaccination period

Primary: Number of subjects with any unsolicited AEs post-vaccination period

Primary: Number of subjects with change from baseline in hematological and biochemical laboratory results at Day 8 by toxicity grading

Primary: Number of subjects with change from baseline in hematological and biochemical laboratory results at Day 8 by toxicity grading

Primary: Number of subjects with change in hematological and biochemical laboratory results from Day 8 to Day 29 versus baseline by toxicity grading

Primary: Number of subjects with change in hematological and biochemical laboratory results from Day 8 to Day 29 versus baseline by toxicity grading

Primary: Number of subjects with change in hematological and biochemical laboratory results from Day 8 to Day 85 versus baseline by toxicity grading

Primary: Number of subjects with change in hematological and biochemical laboratory results from Day 8 to Day 85 versus baseline by toxicity grading

Primary: Number of subjects with change in hematological and biochemical laboratory results from Day 8 to Month 14+28 days versus baseline by toxicity grading

Primary: Number of subjects with change in hematological and biochemical laboratory results from Day 8 to Month 14+28 days versus baseline by toxicity grading

Primary: Number of subjects with change in hematological and biochemical laboratory results from Day 8 to Month 26 versus baseline by toxicity grading

Primary: Number of subjects with change in hematological and biochemical laboratory results from Day 8 to Month 26 versus baseline by toxicity grading

Primary: Number of subjects with any medically-attended adverse events (MAEs)

Primary: Number of subjects with any medically-attended adverse events (MAEs)

Primary: Number of subjects reporting any potential immune-mediated diseases (pIMDs)

Primary: Number of subjects reporting any potential immune-mediated diseases (pIMDs)

Primary: Number of subjects with serious adverse events (SAEs).

Primary: Number of subjects with serious adverse events (SAEs).

Primary: Number of seropositive subjects for anti-H1 stalk antibodies measured by enzyme-linked immunosorbent assay (ELISA)– Day 1

Primary: Number of seropositive subjects for anti-H1 stalk antibodies measured by enzyme-linked immunosorbent assay (ELISA)– Day 1

Primary: Number of seropositive subjects for anti-H1 stalk antibodies measured by ELISA– Day 29

Primary: Number of seropositive subjects for anti-H1 stalk antibodies measured by ELISA– Day 29

Primary: Number of seropositive subjects for anti-H1 stalk antibodies measured by ELISA– Day 85

Primary: Number of seropositive subjects for anti-H1 stalk antibodies measured by ELISA– Day 85

Primary: Concentrations of serum H1 stalk antibodies measured by ELISA– Day 1

Primary: Concentrations of serum H1 stalk antibodies measured by ELISA– Day 1

Primary: Concentrations of serum H1 stalk antibodies measured by ELISA– Day 29

Primary: Concentrations of serum H1 stalk antibodies measured by ELISA– Day 29

Primary: Concentrations of serum H1 stalk antibodies measured by ELISA– Day 85

Primary: Concentrations of serum H1 stalk antibodies measured by ELISA– Day 85

Primary: Number of seropositive subjects for anti-H1 stalk antibodies measured by microneutralization (MN) assay – Day 1

Primary: Number of seropositive subjects for anti-H1 stalk antibodies measured by microneutralization (MN) assay – Day 1

Primary: Number of seropositive subjects for anti-H1 stalk antibodies measured by MN assay – Day 29

Primary: Number of seropositive subjects for anti-H1 stalk antibodies measured by MN assay – Day 29

Primary: Number of seropositive subjects for anti-H1 stalk antibodies measured by MN assay – Day 85

Primary: Number of seropositive subjects for anti-H1 stalk antibodies measured by MN assay – Day 85

Primary: Titers for serum H1 stalk antibodies measured by MN assay – Day 1

Primary: Titers for serum H1 stalk antibodies measured by MN assay – Day 1

Primary: Titers for serum H1 stalk antibodies measured by MN assay – Day 29

Primary: Titers for serum H1 stalk antibodies measured by MN assay – Day 29

Primary: Titers for serum H1 stalk antibodies measured by MN assay – Day 85

Primary: Titers for serum H1 stalk antibodies measured by MN assay – Day 85

Primary: Percentage of subjects with a ≥ 4-fold increase of anti-H1 stalk antibody concentration measured by ELISA – Day 29

Primary: Percentage of subjects with a ≥ 4-fold increase of anti-H1 stalk antibody concentration measured by ELISA – Day 29

Primary: Percentage of subjects with a ≥ 4-fold increase of anti-H1 stalk antibody concentration measured by ELISA – Day 85

Primary: Percentage of subjects with a ≥ 4-fold increase of anti-H1 stalk antibody concentration measured by ELISA – Day 85

Primary: Percentage of subjects with a ≥ 4-fold increase of anti-H1 stalk titer measured by MN assay – Day 29

Primary: Percentage of subjects with a ≥ 4-fold increase of anti-H1 stalk titer measured by MN assay – Day 29

Primary: Percentage of subjects with a ≥ 4-fold increase of anti-H1 stalk titer measured by MN assay – Day 85

Primary: Percentage of subjects with a ≥ 4-fold increase of anti-H1 stalk titer measured by MN assay – Day 85

Primary: Percentage of subjects with a ≥ 10-fold increase of anti-H1 stalk antibody concentration measured by ELISA – Day 29

Primary: Percentage of subjects with a ≥ 10-fold increase of anti-H1 stalk antibody concentration measured by ELISA – Day 29

Primary: Percentage of subjects with a ≥ 10-fold increase of anti-H1 stalk antibody concentration measured by ELISA – Day 85

Primary: Percentage of subjects with a ≥ 10-fold increase of anti-H1 stalk antibody concentration measured by ELISA – Day 85

Primary: Percentage of subjects with a ≥ 10-fold increase of anti-H1 stalk titer measured by MN assay – Day 29

Primary: Percentage of subjects with a ≥ 10-fold increase of anti-H1 stalk titer measured by MN assay – Day 29

Primary: Percentage of subjects with a ≥ 10-fold increase of anti-H1 stalk titer measured by MN assay – Day 85

Primary: Percentage of subjects with a ≥ 10-fold increase of anti-H1 stalk titer measured by MN assay – Day 85

Primary: Mean Geometric Increase (MGI) for anti-H1 stalk antibody concentration measured by ELISA – Day 29